Alexander GC, Budnitz D, Hughes C, Maas R, Mair A, McDonald EG, Meid AD, Payne R, Seidling HM, Shakir S, Suissa S, Tannenbaum C, Schneeweiss S, Dreischulte T. Proceedings of the international ambulatory drug safety symposium: Munich, Germany, June 2023. Drug Saf 2024; 47:103-11.

Bajraktari-Sylejmani G, Oster JS, Burhenne B, Haefeli WE, Sauter M*, Weiss J*. In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases. Arch Toxicol 2024;98:807-20. * joint last authorship

Falconnier-Williams OC, Taeschner W, Hille A, Falconnier AD, Haefeli WE. Untapped options to reduce waste from blister packaging for tablets and capsules. Eur J Clin Pharmacol 2024;80:151-61.

Longuespée R, Kunz J, Fresnais M, Foerster KI, Burhenne J, Thomas M, Kazdal D, Stenzinger A, Christopoulos P, Haefeli WE. Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: a case report. Br J Clin Pharmacol 2024;90:344-9.

Phondeth L*, Kamaraj R*, Nilles J, Weiss J, Haefeli WE, Pávek P, Theile D. Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site. Arch Toxicol 2024;98:223-31. * equal contribution

Stoll F, Blank A, Mikus G, Czock D, Weiss J, Meyer-Tönnies MJ, Gümüs KS, Tzvetkov M, Burhenne J, Haefeli WE. Evaluation of hydroxychloroquine as a perpetrator on cytochrome P450 (CYP) 3A and CYP2D6 activity with microdosed probe drugs in healthy volunteers. Eur J Drug Metab Pharmacokinet 2024;49:101-9.

Wintermark P, Lapointe A, Steinhorn R, Rampakakis E, Burhenne J, Meid AD, Bajraktari-Sylejmani G, Khairy M, Altit G, Adamo MT, Poccia A, Gilbert G, Saint-Martin C, Toffoli D, Vachon J, Hailu E, Colin P, Haefeli WE. Feasibility and safety of sildenafil to repair brain injury secondary to birth asphyxia (SANE-01): A randomized, double-blind, placebo-controlled phase Ib clinical trial. J Pediatr 2024;266:113879.

Zülke AE, Pabst A, Luppa M, Roehr S, Seidling H, Oey A, Cardona MI, Blotenberg I, Bauer A, Weise S, Zöllinger I, Sanftenberg L, Brettschneider C, Döhring J, Lunden L, Czock D, Haefeli WE, Wiese B, Hoffmann W, Frese T, Gensichen J, König HH, Kaduszkiewicz H, Thyrian JR, Riedel-Heller SG. A multidomain intervention against cognitive decline in an at-risk-population in Germany – Results from the cluster-randomized AgeWell.de-trial. Alzheimers Dement 2024;20:615-28.

 

Buchbeiträge/Book contributions:

 

Publikationen im Druck/Publications in Press:

Arnet I, Sahm LJ, Gregório J, Tuula A, Krüger M, Wurmbach VS, Hoti K, Schulz M, Eickhoff C. Development and validation of the 15-STARS - A novel self-report pharmacy-based questionnaire to screen for medication non-adherence. Res Social Adm Pharm, in press

Krohmer E, Rohr BS, Stoll F, Gümüs KS, Bergamino M, Mikus G, Sauter M, Burhenne J, Weiss J, Meid AD, Czock D, Blank A, Haefeli WE. Influence of a short course of ritonavir as used as booster in antiviral therapies against SARS-CoV-2 on the exposure of atorvastatin and rosuvastatin. Cardiovasc Drugs Ther, in press

Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Mikus G, Meid AD, Haefeli WE, Blank A. Effect of clarithromycin, a strong CYP3A and P-glycoprotein inhibitor, on the pharmacokinetics of edoxaban in healthy volunteers and the evaluation of the drug interaction with other oral factor Xa inhibitors by a microdose cocktail approach. Cardiovasc Drugs Ther, in press

Mc Laughlin AM, Helland T, Klima F, Koolen SLW , van Schaik R, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar H-J, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Mellgren G, Thomas F, Kloft C, Hertz DL. Nonlinear mixed-effects model of Z-endoxifen concentrations in tamoxifen treated patients from the CEPAM cohort. Clin Pharmacol Ther, in press

Morath B, Meid AD, Zaradzki M, Geßele C, Nüse S, Chiriac U, Hoppe-Tichy T, Karck M, Soethoff J. Analysing and improving pre-operative medication management in cardiac surgery. Br J Clin Pharmacol, in press.

Nilles J, Weiss J, Masin M, Tuffs C, Strowitzki M, Haefeli WE, Rues S, Theile D. The differences in drug disposition gene induction by rifampicin and rifabutin are unlikely due to different effects on important pregnane X receptor (NR1I2) splice variants. Naunyn-Schmiedebergs Arch Pharmacol, in press

Rohr BS, Krohmer E, Foerster KI, Burhenne J, Schulz M, Blank A, Mikus G, Haefeli WE. Time course of the interaction between oral short-term ritonavir therapy with three factor Xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers. Clin Pharmcokinet, in press

Stoll F, Blank A, Mikus G, Czock D, Weiss J, Meyer-Tönnies MJ, Gümüs KS, Tzvetkov M, Burhenne J, Haefeli WE. Evaluation of hydroxychloroquine as a perpetrator on CYP3A and CYP2D6 activity with microdosed probe drugs in healthy volunteers. Eur J Drug Metab Pharmacokinet, in press

Terstegen T, Niestroj C, Stangl J, Scherkl C, Morath B, Haefeli WE, Seidling HM. Approaches to medication history taking in different hospital settings: a scoping review. Am J Health Syst Pharm, in press

 

 

Bay C, Bajraktari-Sylejmani G, Haefeli WE, Burhenne J, Weiss J, Sauter M. Correction: Bay et al. Functional characterization of the solute carrier LAT-1 (SLC7A5/SLC3A2) in human brain capillary endothelial cells with rapid UPLC-MS/MS quantification of intracellular isotopically labelled L-leucine. Int J Mol Sci 2023;24:5029.

Boettcher M, Duengen H-D, Corcea V, Donath F, Fuhr R, Gal P, Mikus G, Trenk D, Werner N, Pires PV, Maschke C, Aliprantis AO, Besche N, Becker C. Vericiguat: A randomized, phase Ib, placebo-controlled, double-blind, QTc interval study in patients with stable chronic coronary syndromes. Am J Cardiovasc Drugs 2023;23:145-55.

Breithaupt MH, Krohmer E, Taylor L, Körner E, Hoppe-Tichy T, Burhenne J, Foerster KI, Dachtler M, Huber G, Venkatesh R, Eggenreich K, Czock D, Mikus G, Blank A, Haefeli WE. Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers. Br J Clin Pharmacol 2023;89:2458-64.

Bucci-Muñoz M, Gola AM, Rigalli JP, Ceballos MP, Ruiz ML. Extracellular vesicles and cancer multidrug resistance: undesirable intercellular messengers? Life (Basel) 2023;13:1633.

Carotti V, van Megen WH, Rigalli JP, Barros ER, Sommers V, Rutten L, Sommerdijk N, Peters DJM, van Asbeck-van der Wijst J, Hoenderop JGJ. Extracellular vesicles contribute to early cyst development in autosomal dominant polycystic kidney disease by cell-to-cell communication. FASEB J 2023;37:e23006.

Dinh TS, Meid AD, Rudolf H, Brueckle M-S, González-González AI, Bencheva V, Gogolin M, Snell KIE, Elders PJM, Thuermann PA, Donner-Banzhoff N, Blom JW, van den Akker M, Gerlach FM, Harder S, Thiem U, Glasziou PP, Haefeli WE, Muth C. Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model. PLoS One 2023;18:e0280907.

Djaelani YA, Giese T, Sommerer C, Czock D. Pharmacodynamic monitoring of ciclosporin and tacrolimus: Insights from nuclear factor of activated T-cell-regulated gene expression in healthy volunteers. Ther Drug Monit 2023;45:87-94.

Eidam A, Marji J, Benzinger P, Foerster KI, Burhenne J, Czock D, Stoll F, Blank A, Mikus G, Haefeli WE, Bauer JM. Frailty as a marker for the plasma concentrations of direct oral anticoagulants in older patients: results of an exploratory study. Drugs Aging 2023;40:153-64.

Fresnais M, Jung I, Klein UB, Miller AK, Turcan S, Haefeli WE, Burhenne J, Longuespée R. Important requirements for desorption/ionization mass spectrometric measurements of temozolomide-induced 2´deoxyguanosine methylations in DNA. Cancers 2023;15:716.

Fresnais M, Jung I, Klein UB, Theile D, Liang S, Haefeli WE, Burhenne J, Longuespée R. Quantification of biologically-active DNA alkylation in temozolomide-exposed glioblastoma cell lines by ultra-performance liquid chromatography-tandem mass spectrometry: method development and recommendations for validation. ACS Omega 2023;8: 23695–705.

Fresnais M, Liang S, Seven D, Prodanovic N, Sundheimer J, Haefeli WE, Burhenne J, Longuespée R. Desorption kinetics evaluation for the development of validated desorption electrospray ionization-mass spectrometric assays for drug quantification in tissue sections. Int J Mol Sci 2023;24:8469

Gagliardi A, Bajraktari-Sylejmani G, Barocelli E, Weiss J, Rigalli JP. Extracellular vesicles as surrogates for drug metabolism and clearance: promise vs reality. Life 2023;13:1745.

Hermann SA, Mikus G, Chobanyan-Jürgens K, Gorenflo M, Ziesenitz VC. Pharmacokinetics of a microdosed cocktail of three direct oral anticoagulants in children with congenital heart defects: study protocol for a single-centre clinical trial (DOAC-Child). BMJ Paediatr Open 2023;7:e001662.

Hohmann N, Schröder F, Moreira B, Teng H, Burhenne J, Bruckner T, Mueller S, Haefeli WE*, Seitz HK*. Effect of clomethiazole vs. clorazepate on hepatic fat and serum transaminase activities in alcohol-associated liver disease: results from a randomized, controlled phase II clinical trial. Alcohol Alcohol 2023;58:134-41. *equal contribution

Hohmann N, Sprick MR, Pohl M, Ahmed A, Burhenne J, Kirchner M, Le Cornet L, Kratzmann M, Hajda J, Stenzinger A, Steindorf K, Delorme S, Schlemmer HP, Riethdorf S, van Schaik R, Pantel K, Siveke J, Seufferlein T, Jäger D, Haefeli WE, Trumpp A, Springfeld C. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy. Clin Transl Sci 2023;16:2483-93. 

Jungreithmayr V, Haefeli WE, Seidling HM, Implementation Team. Workflow, time requirement, and quality of medication documentation with or without a computerized physician order entry system—a simulation-based lab study. Methods Inf Med 2023;62:40-8.

Kluwe F, Michelet R, Huisinga W, Zeitlinger M, Mikus G, Kloft C. Towards model-informed precision dosing of voriconazole: Challenging published voriconazole nonlinear mixed-effects models with real-world clinical data. Clin Pharmacokinet 2023;62:1461-77.

Kühn T, Speer C, Morath C, Bartenschlager M, Kim H, Beimler J, Buylaert M, Nusshag C, Kälble F, Reineke M, Töllner M, Klein K, Blank A, Parthé S, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Tran TH, Schaier M, Benning L. Immune response to COVID-19 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid one- and three-months after an additional vaccine dose. ransplantation 2023;107:1139-50.

Longuespée R, Theile D, Zörnig I, Hassel JC, Lindner JR, Haefeli WE, Fresnais M. Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigations. Int J Cancer 2023;153:252-64.

Marok FZ, Wojtyniak J-G, Fuhr LM, Selzer D, Schwab M, Weiss J, Haefeli WE, Lehr T. A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug-drug interaction perpetrators. Pharmaceutics 2023;15:679.

Meid AD, Wirbka L, Moecker R, Ruff C, Weissenborn M, Haefeli WE, Seidling HM, ARMIN-Studienteam. Mortalität und Hospitalisierungen von Patienten mit interprofessionellem Medikationsmanagement: Resultate der Arzneimittelinitiative Sachsen-Thüringen (ARMIN). Dtsch Arztebl Int. 2023;120:253-60.

Morath B, Meid AD, Zaradzki M, Geßele C, Nüse S, Chiriac U, Hoppe-Tichy T, Karck M, Soethoff J. Analysing and improving pre-operative medication management in cardiac surgery. Br J Clin Pharmacol 2023;89:1349-59.

Morath C, Schaier M, Ibrahim E, Wang L, Kleist C, Opelz G, Süsal C, Ponath G, Aly M, Alvarez C, Kälble F, Speer C, Benning L, Nusshag C, da Silva LP, Sommerer C, Hückelhoven-Krauss A, Czock D, Mehrabi A, Schwab C, Waldherr R, Schnitzler P, Merle U, Tran TH, Scherer S, Boehmig G, Müller-Tidow C, Reiser J, Schmitt A, Zeier M, Schmitt M, Terness P, Daniel V. Induction of long-lasting regulatory B lymphocytes by modified immune cells in kidney transplant recipients. J Am Soc Nephrol 2023;34:160-74.

Muhareb A, Blank A, Meid AD, Foerster KI, Stoll F, Burhenne J, Haefeli WE, Mikus G. CYP3A and CYP2C19 activity determined by microdosed probe drugs accurately predict voriconazole clearance in healthy adults. Clin Pharmacokin 2023;62:1305-14.

Nilles J, Weiss J, Sauter M, Haefeli WE, Ruez S, Theile D. Comprehensive in vitro analysis evaluating the variable drug-drug interaction risk of rifampicin compared to rifabutin. Arch Toxicol 2023;97:2219-30.

Oliveira, C, Longuespee, R. MALDImID: Spatialomics R package and Shiny app for more specific identification of MALDI imaging proteolytic peaks using LC-MS/MS-based proteomic biomarker discovery data. Proteomics 2023;23:e2300005.

Rosenkranz M, Fürle K, Hibbert J, Ulmer A, Ali A, Giese T, Blank A, Haefeli WE, Böhnlein E, Lanzer M, Thomson-Luque R. Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine. NPJ Vaccines 2023;8:112.

Sauter M, Haag J, Bay C, Leuschner F, Haefeli WE, Kuhn TC, Burhenne J. Bioanalysis of the ex vivo labile PACE4 inhibitory peptide Ac-[d-Leu]LLLRVK-amba in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry quantification. Pharmaceutics 2023;15:2745.

Schaier M, Morath C, Wang L, Kleist C, Opelz G, Tran TH, Scherer S, Pham L, Ekpoom N, Süsal C, Ponath G, Kälble F, Speer C, Benning L, Nusshag C, Mahler CF, Pego Da Silva L, Sommerer C, Hückelhoven-Krauss A, Czock D, Mehrabi A, Schwab C, Waldherr R, Schnitzler P, Merle U, Schwenger V, Krautter M, Kemmner S, Fischereder M, Stangl M, Hauser IA, Böhmig G, Müller-Tidow C, Reiser J, Zeier MG, Schmitt M, Terness P, Schmitt A, Daniel V. Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation. Front Immunol 2023;14:1089664.

Sigaud R*, Rösch L*, Gatzweiler C*, Benzel J*, von Soosten L*, Peterziel H, Selt F, Najafi S, Ayhan S, Gerloff XF, Hofmann N, Büdenbender I, Schmitt L, Foerster KI, Burhenne J, Haefeli WE, Korshunov A, Sahm F, van Tilburg CM, Jones DTW, Pfister SM, Knoerzer D, Kreider BL, Sauter M*, Pajtler KW*, Zuckermann M*, Oehme I*, Witt O*, Milde T*. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Neuro-Oncology 2023;25:566-79.*equal contribution

Theile D, Nilles J, Meid AD. Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition. Br J Clin Pharmacol 2023;89:2329-31.

Uhl P, Bajraktari-Sylejmani B, Witzigmann D, Bay C, Zimmermann S, Burhenne J, Weiss J, Haefeli WE, Sauter M. A nanocarrier approach for oral peptide delivery: Evaluation of cell-penetrating peptide modified liposomal formulations in dogs. Adv Ther 2023;2300021.

van Leuven J, Evans S, Kichenadasse G, Steeghs N, Bonevski B, Mikus G, van Dyk M. Framework for implementing individualised dosing of anti-cancer drugs in routine care: overcoming the logistical challenges. Cancers 2023;15:3293.

Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Schulze zur Wiesch J, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. A multicentre, randomised, parallel-group, open-label phase 2 clinical trial (MYR202) to assess safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with HBV/HDV coinfection. Lancet Infect Dis 2023;23:117-129.

Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Wiesch JSZ, Zeuzem S, Ciesek S, Cornberg M, Lampertico P. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med 2023;389:22-32.

Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, Roessler S, Pfütze K, Schulz A, Wolf S, Hohmann N, Theile D, Sauter M, Burhenne J, Ei S, Heger U, Strobel O, Barry ST, Springfeld C, Tjaden C, Bergmann F, Büchler M, Hackert T, Fortunato F, Neoptolemos JP, Bailey P. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nat Cancer 2023;4:1362-81.

Zhu V, Burhenne J, Weiss J, Haag M, Hofmann U, Schwab M, Urban S, Mikus G, Czock D, Haefeli WE, Blank A. Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers. Front Pharmacol 2023;14:1128547.

Zöllinger I, Bauer A, Blotenberg I, Brettschneider C, Buchholz M, Czock D, Döhring J, Escales C, Fankhänel T, Frese T, Hoffmann W, Kaduszkiewicz H, König HH, Luppa M, Oey A, Pabst A, Sanftenberg L, Thyrian JR, Weiss J, Wendel F, Wiese B, Riedel-Heller S, Gensichen J. Associations of depressive symptoms with subjective cognitive decline in elderly persons – a cross-sectional analysis from the AgeWell.de-study. J Clin Med 2023;12:5205.

 

Buchbeiträge/Book contributions:

Blank A. Medikamente während Schwangerschaft und Stillzeit. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 329-31.

Czock D. Dosierung bei Leber- und Niereninsuffizienz. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 322-4.

Czock D. Gerinnungshemmung und Bridging. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 331-2.

Czock D, Haefeli WE. Kapitel 3.7 Medikamente und die Nebenwirkungen des Klimawandels. In C. Nikendei C, Bugaj TJ, Cranz A, Herrmann A, Tabatabai J, Nikendei F. Heidelberger Standards der Klimamedizin. Heidelberg: HeiCuMed; 2022, pp. 96-102.

Faller C. Neue Cannabis-Therapieverfahren. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 342-4.

Haefeli E. Häufige Arzneimittelinteraktionen  - ein Fokus auf Multikinase-Inhibitoren. In: Lehmann L, Bokemeyer C, Müller OL, Herausgeber. Kardioonkologie. Berlin/Boston: Walter de Gruyter GmbH; 2023; S. 367-380.

Haefeli WE, Seidling H. Polypharmazie und Interaktionen. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 321-2

Haefeli WE, Seidling H. Besonderheiten der Arzneimitteltherapie bei Betagten. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 327-9.

Haefeli WE, Seidling H. Unerwünschte Arzneimittelwirkungen. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 334-7.

Haefeli WE. Arzneimittelanamnese. In: Ärztekammer Nordrhein. Kommunikation im medizinischen Alltag. Ein Leitfaden für die Praxis. Düsseldorf: Ärztekammer Nordrhein; 2023, pp. 48-9.

Hohmann N, Mikus G. Medikamentöse Therapie neoplastischer Erkrankungen (Chemotherapie). In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 333-4.

Mikus G. Monitoring der Therapie inklusive therapeutisches Drug-Monitoring. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 334-5.

Seidling H. Besonderheiten der Arzneimitteltherapie bei Erwachsenen. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 326-7.

Seidling H. Selbstmedikation. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 338.

Seidling H, Faller C. Rezeptschreibung. In: Klimm HD, Peters-Klimm F, editors. Allgemeinmedizin. 7. Auflage Stuttgart: Georg Thieme Verlag; 2023. S. 319.

 

 

 

Alborzinia H, Flórez AF, Kreth S, Brückner LM, Yildiz U, Gartlgruber M, Odoni DI, Poschet G, Garbowicz K, Shao C, Klein C, Meier J, Zeisberger P, Nadler-Holly M, Ziehm M, Paul F, Burhenne J, Bell E, Shaikhkarami M, Würth R, Stainczyk SA, Wecht EM, Kreth J, Büttner M, Ishaque N, Schlesner M, Nicke B, Stresemann C, Llamazares-Prada M, Reiling JH, Fischer M, Amit I, Selbach M, Herrmann C, Wölfl S, Henrich KO, Höfer T, Trumpp A, Westermann F. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer 2022;3:471-485.

Alexovic M, Lindner JR, Bober P, Longuespée R, Sabo J, Davalieva K. Human peripheral blood mononuclear cells: A review of recent proteomic applications. Proteomics 2022, e2200026.

Amelung S, Czock D, Thalheimer M, Hoppe-Tichy T, Haefeli WE, Seidling HM. Shortcomings of administrative data to derive preventive strategies for inhospital drug-induced acute kidney failure – insights from patient record analysis. J Clin Med 2022;11:4285.

Bajraktari-Sylejmani G, Linde T, Burhenne J, Haefeli WE, Sauter M*, Weiss J*. Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides. Pharmaceutics 2022;14:1610. *equal contribution

Bay C*, Bajraktari-Sylejmani G*, Haefeli WE, Burhenne J, Weiss J, Sauter M. Functional characterization of the solute carrier LAT-1 (SLC7A5/SLC2A3) in human brain capillary endothelial cells with rapid UPLC-MS/MS quantification of intracellular isotopically labelled L-leucine. Int J Mol Sci 2022;23:3637. * equal contribution

Benning L, Morath C, Kühn T, Bartenschlager M, Kim H, Beimler J, Buylaert M, Nusshag C, Kälble F, Reineke M, Töllner M, Schaier M, Klein K, Blank A, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Tran TH and Speer C. Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid. Front Med 2022;9:958293.

Bittmann JA, Haefeli WE, Seidling HM. Modulators influencing medication alert acceptance: an explorative review. Appl Clin Inform 2022;13:468-485.

Blank A, Hohmann N, Dettmer M, Manka-Stuhlik A, Mikus G, Stoll F, Stützle-Schnetz M, Thomas D, Exner E, Schmitt-Bormann B, Schaller T, Laage R, Schönborn-Kellenberger O, Arndt M, Haefeli WE, Krauss J. First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers. Clin Transl Sci 2022;15:2366-2377.

Boettcher M, Duengen HD, Donath F, Mikus G, Werner N, Thuermann PA, Karakas M, Besche N, Koch T, Gurniak M, Becker C. Vericiguat in combination with short-acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study. Clin Pharmacol Ther 2022;111:1239-1247.

Boettcher M, Mikus G, Trenk D, Duengen HD, Donath F, Werner N, Karakas M, Besche N, Schulz-Burck D, Gerrits M, Hung J, Becker C. Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study. Clin Transl Sci 2022;15:1204-1214.

Breithaupt MH, Krohmer E, Taylor L, Koerner E, Hoppe-Tichy T, Burhenne J, Foerster KI, Dachtler M, Huber G, Venkatesh R, Eggenreich K, Czock D, Mikus G, Blank A, Haefeli WE. Oral bioavailability of microdoses and therapeutic doses of midazolam as a 2-dimensionally printed orodispersible film in healthy volunteers. Eur J Clin Pharmacol 2022;78:1965-1972.

Cardona MI, Weißenborn M, Zöllinger I, Kroeber ES, Bauer A, Luppa M, Pabst A, Czock D, König HH, Wiese B, Gensichen J, Frese T, Kaduszkiewicz H, Hoffmann W, Riedel-Heller SG, Thyrian JR. Physical activity determinants in older German adults at increased dementia risk with multimorbidity: baseline results of the AgeWell.de study. Int J Environ Res Public Health 2022;19:3164.

Carotti V*, Rigalli JP*, van Asbeck-van der Wijst J, Hoenderop JGJ. Interplay between purinergic signalling and extracellular vesicles in health and disease. Biochem Pharmacol 2022;203:115192. * equal contribution

Carotti V, van der Wijst J, Verschuren EHJ, Rutten L, Sommerdijk N, Kaffa C, Sommers V, Rigalli JP, Hoenderop JGJ. Involvement of ceramide biosynthesis in increased extracellular vesicle release in Pkd1 knock out cells. Front Endocrinol 2022;13:1005639.

Czock D, Keller F. Clinical pharmacokinetics and pharmacodynamics of roxadustat. Clin Pharmacokinet 2022;61:347-362.

Dreischulte T, Shahid F, Muth C, Schmiedl S, Haefeli WE. Verordnungskaskaden - entdecken, verhindern, bewusst einsetzen. Dtsch Arztebl Int 2022;119:745-752.

Eickhoff C, Müller U, Seidling HM, Lampert A, Botermann L, Strunz AK, Schulz M. Patients' perception on generating medication plans in an interprofessional medication management program: a mixed-methods study. J Interprof Care 2022;36:770-775.

Eidam A, Roth A, Frick E, Metzner M, Lampert A, Seidling HM, Haefeli WE, Bauer JM. Development of an electronic tool to assess patient preferences in geriatric polypharmacy (PolyPref). Patient Prefer Adherence 2022;16:1733-1747.

Elbe A, Foerster KI, Blank A, Rose P, Burhenne J, Haefeli WE, Mikus G. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol 2022;78:975-987.

Fresnais M, Karabulut S, Zeed YA, Ungermann J, Benzel J, Pajtler KW, Pfister SM, Haefeli WE, Burhenne J, Longuespée R. Important requirements for the selection of internal standards during the development of desorption/ionization assays for drug quantification in biological matrices - A practical example. Molecules 2022;27:690.

Fresnais M, Turcan S, Theile D, Ungermann J, Zeed YA, Lindner JR, Breitkopf M, Burhenne J, Haefeli WE, Longuespée R. Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastoma. Biomedicines 2022;10:1.

Fresnais M, Liang S, Breitkopf M, Lindner JR, Claude E, Pringle S, Levkin PA, Demir K, Benzel J, Sundheimer J, Statz B, Pajtler KW, Pfister SM, Haefeli WE, Burhenne J, Longuespée R. Analytical performance evaluation of new DESI enhancements for targeted drug quantification in tissue sections. Pharmaceuticals 2022;15:694.

Gerharz A*, Ruff C*, Wirbka L, Stoll F, Haefeli WE, Groll A, Meid AD. Predicting hospital readmissions from health insurance claims data: a modeling study targeting potentially inappropriate prescribing. Meth Inf Med 2022;61:55-60. * equal contribution

Gillot L, Lebeau A, Baudin L, Pottier C, Louis T, Durre T, Longuespée R, Mazzucchelli G, Nizet C, Blacher S, Kridelka F, Noel A. Periostin in lymph node pre-metastatic niches governs lymphatic endothelial cell functions and metastatic colonization. Cell Mol Life Sci 2022;79:295.

Haefeli WE. Orale Pharmakotherapie bei COVID-19. Wechselwirkungsmanagement beim Einsatz von Nirmatrelvir/Ritonavir. Schlusswort. Dtsch Arztebl Int. 2022;119:761-762.

Hohmann N, Schröder F, Moreira B, Teng H, Burhenne J, Bruckner T, Mueller S, Haefeli WE, Seitz HK. Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease. Gut 2022;71:842-844.

Hoiem TS, Andersen MK, Martin-Lorenzo M, Longuespée R, Claes BSR, Nordborg A, Dewez F, Balluff B, Giampà M, Sharma A, Hagen L, Heeren RMA, Bathen TF, Giskeodegard GF, Krossa S, Tessem MB. An optimized MALDI MSI protocol for spatial detection of tryptic peptides in fresh frozen prostate tissue. Proteomics 2022; e2100223.

Jost F, Theile D. Wechselwirkung zwischen Protonenpumpeninhibitoren und Checkpoint-Inhibitoren. MMP 2022;45:344-350.

Kama K, La Rosée P, Czock D, Ships JB, Illerhaus G. Hemophagocytic syndrome-associated intravascular large B-cell lymphoma with dialysis-dependent end-stage renal disease treated with autologous stem cell transplantation using a modified TEAM regimen. Cureus 2022.e25885.

Kraft M, Foerster KI, Wiedmann F, Sauter M, Paasche A, Blochberger PL, Yesilgöz B, L’hoste Y, Frey N, Haefeli WE, Burhenne J, Schmidt C. Simultaneous quantification and pharmacokinetic characterization of doxapram and 2-ketodoxapram in porcine plasma and brain tissue. Pharmaceutics 2022;14:762.

Kuznia S, Czock D, Kopp-Schneider A, Caspari R, Fischer H, Laetsch DC, Slavic M, Brenner H, Schöttker B. Efficacy and safety of a personalized vitamin D3 loading dose followed by daily 2,000 IU in colorectal cancer patients with vitamin D insufficiency. Nutrients 2022;14:4546.

Meid A, Gerharz A, Groll A. Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility. CPT Pharmacometrics Syst Pharmacol 2022;11:257-261.

Meid AD, Wirbka L, ARMIN Study Group, Groll A, Haefeli WE. Can machine learning from real-world data support drug treatment decisions? A prediction modeling case for direct oral anticoagulants. Med Decis Making 2022;42:587-598.

Mikus G, Foerster KI, Terstegen T, Vogt C, Said A, Schulz M, Haefeli WE. Oral drugs against COVID-19 – Management of drug interactions with the use of nirmatrelvir/ritonavir. Dtsch Arztebl Int 2022;119:263-269.

Moecker R, Terstegen T, Haefeli WE, Seidling HM. Erratum to "The influence of intervention complexity on barriers and facilitators in the implementation of professional pharmacy services - A systematic review" [Res Soc Adm Pharm 17/10 (2021) 1651-1662]. Res Social Adm Pharm 2022;18:2909-2911.

Moecker R, Weissenborn M, Klingenberg A, Wirbka L, Fuchs A, Eickhoff C, Mueller U, Schulz M, Kaufmann-Kolle P, Haefeli WE, Seidling HM. Task sharing in an interprofessional medication management program - a survey of general practitioners and community pharmacists. BMC Health Serv Res 2022;22:1005.

Moecker R, Fuchs A, ARMIN Study Group, Haefeli WE, Weissenborn M*, Seidling HM*. Attitudes of non-participating general practitioners and community pharmacists towards interprofessional medication management in primary care – an interview study. Int J Clin Pharm 2022;44:1380-1393. *equal contribution

Morath B, Lampert A, Glaß FE, Metzner M, Study Team D, Haefeli WE, Seidling HM. Changing the medication documentation process for discharge: impact on clinical routine and documentation quality - a process analysis. Eur J Hosp Pharm 2022;29:33-39.

Morath C, Schmitt A, Schmitt M, Wang L, Kleist C, Opelz G, Süsal C, Tran TH, Scherer S, Schwenger V, Kemmner S, Fischereder M, Stangl M, Hauser IA, Sommerer C, Nusshag C, Kälble F, Speer C, Benning L, Bischofs C, Sauer S, Schubert ML, Kunz A, Hückelhoven-Krauss A, Neuber B, Mehrabi A, Schwab C, Waldherr R, Czock D, Böhmig GA, Reiser J, Roers A, Müller-Tidow C, Terness P, Zeier M, Daniel V, Schaier M. Individualized immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicenter, open-label, phase II, randomized controlled trial. BMJ Open 2022;12:e066128.

Nassar YM*, Hohmann N*, Michelet R, Gottwalt K, Meid AD, Burhenne J, Huisinga W, Haefeli WE, Mikus G**, Kloft C**. Quantification of the time course of CYP3A inhibition, activation, and induction using a population pharmacokinetic model of microdosed midazolam continuous infusion. Clin Pharmacokinet 2022;61:1595-1607. *and**equal contribution

Neuman MG, Seitz HK, Teschke R, Malnick S, Johnson-Davis KL, Cohen LB, German A, Hohmann N, Moreira B, Moussa G, Opris M. Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury. Curr Issues Mol Biol 2022;44:1294-1315.

Nielsen PB, Melgaard L, Overvad TF, Jensen M, Larsen TB, Lip GYH. Risk of cerebrovascular events in intracerebral hemorrhage survivors with atrial fibrillation: a nationwide cohort study. Stroke 2022;53:2559-2568.

Nilles J, Weiss J, Haefeli WE, Ruez S, Theile D. How to avoid misinterpretation of dual reporter gene assay data affected by cell damage. Arch Toxicol 2022;96:2501-10.

Nilles J, Weiss J. Theile D. Crystal violet staining is a reliable alternative to bicinchoninic acid assay-based normalization. Biotechniques 2022;73:131-135.

Rizos T*, Meid AD*, Huppertz A*, Dumschat C, Purrucker J, Foerster KI, Burhenne J, Czock D, Jenetzky E, Ringleb PA, Haefeli WE. Low exposure to direct oral anticoagulants is associated with ischemic stroke and its severity. J Stroke 2022;24:88-97. * equal contribution

Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, Mikus G. Perpetrator characteristics of azole antifungal drugs on three oral factor Xa inhibitors administered as microdosed cocktail. Clin Pharmacokinet 2022;61:97-109.

Schulz J, Thomas A, Saleh A, Michelet R, Mikus G, Kloft C. Towards the elucidation of voriconazole pharmacokinetics: a quantitative characterization of its metabolism. Pharmaceutics 2022;14:477.

Schulz J, Michelet R, Joseph JF, Zeitlinger M, Schumacher F, Mikus G, Kloft C. A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications. J Pharm Biomed Anal 2022;210:114551.

Schulz J, Michelet R, Zeitlinger M, Mikus G, Kloft C. Microdialysis of drug and drug metabolite: a comprehensive in vitro analysis for voriconazole and voriconazole N-oxide. Pharm Res 2022;39:2991-3003.

Stoll F, Blank A, Mikus G, Czock D, Foerster KI, Hermann S, Gümüs K, Muhareb A, Hummler S, Sauter M, Weiss J, Burhenne J, Haefeli WE. Effect of pantoprazole on the absorption of hydroxychloroquine – a randomized drug-drug interaction trial in healthy adults. Clin Pharmacol Drug Dev 2022;11:285-290.

Stoll F, Eidam A, Michael L, Bauer JM, Haefeli WE. Drug treatment of hypercholesterolemia in older adults: focus on newer agents. Drugs Aging 2022;39:251-256.

Stoll F, Seidel-Glätzer A, Burghaus I, Göring O, Sauter M, Rose P, Daniel V, Haag M, Schwab M, Riffel J, Andre F, Taylor L, Weiss J, Burhenne J, Cleeves V, Haefeli WE, Blank A. Metabolic effect of blocking sodium-taurocholate co-transporting polypeptide in hypercholesterolemic humans with a twelve-week course of bulevirtide – an exploratory phase I clinical trial. Int J Mol Sci 2022;23:15924.

van Dyk M, Boylan C, Michelet R, Mc Laughlin AM, Kichenadasse G, May N, Ziesenitz V, Van Den Anker JN, Groenland SL, Huitema ADR, Steeghs N, Mikus G, Kloft C, Tapp H. Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review. BMJ Open 2022;12:e053308

Weiss J, Foerster KI, Weber M, Burhenne J, Mikus G, Lehr T, Haefeli WE. Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interactions potential of the parent compound? Eur J Pharm Sci 2022;169:106076.

Wendel F, Bauer A, Blotenberg I, Brettschneider C, Buchholz M, Czock D, Döhring J, Escales C, Frese T, Hoffmann W, Kaduszkiewicz H, König HH, Löbner M, Luppa M, Schwenker R, Thyrian JR, Weißenborn M, Wiese B, Zöllinger I, Riedel-Heller S, Gensichen J. Social network and social participation in elderly primary care patients in Germany and associations with depressive symptoms – a cross sectional analysis from the AgeWell.de study. J Clin Med 2022;11:5940.

Wiedmann F, Beyersdorf C, Zhou X-B, Kraft M, Paasche A, Jávorszky N, Rinné S, Sutanto H, Büscher A, Foerster KI, Blank A, El-Battrawy I, Li X, Lang S, Tochtermann U, Kremer J, Arif R, Karck M, Decher N, van Loon G, Akin I, Borggrefe M, Kallenberger S, Heijman J, Haefeli WE, Katus HA, Schmidt C. Treatment of atrial fibrillation with doxapram: TASK 1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res 2022;118:1728-1741.

Wirbka L, Ruff C, Haefeli WE, Meid AD. A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation. J Manag Care Spec Pharm 2022;28:1161-1172.

Wurmbach VS, Schmidt SJ, Lampert A, Bernard S, Meid AD, Frick E, Metzner M, Wilm S, Mortsiefer A, Bücker B, Altiner A, Sparenberg L, Szecsenyi J, Peters-Klimm F, Kaufmann-Kolle P, Thürmann PA, Haefeli WE, Seidling HM. Prevalence and patient-rated relevance of complexity factors in medication regimens of community-dwelling patients with polypharmacy. Eur J Clin Pharmacol 2022;78:1127-1136.

Wurmbach VS, Schmidt SJ, Lampert A, Bernard S, Meid AD, Frick E, Metzner M, Wilm S, Mortsiefer A, Bücker B, Altiner A, Sparenberg L, Szecsenyi J, Peters-Klimm F, Kaufmann-Kolle P, Thürmann PA, Haefeli WE, Seidling HM. Correction to: Prevalence and patient-rated relevance of complexity factors in medication regimens of community-dwelling patients with polypharmacy. Eur J Clin Pharmacol 2022;78:1363.

Wurmbach VS, Schmidt SJ, Lampert A, Bernard S, Meid AD, Frick E, Metzner M, Wilm S, Mortsiefer A, Bücker B, Altiner A, Sparenberg L, Szecsenyi J, Peters-Klimm F, Kaufmann-Kolle P, Thürmann PA, Seidling HM, Haefeli WE. HIOPP-6 - a pilot study on the evaluation of an electronic tool to assess and reduce the complexity of drug treatment considering patients' views. BMC Prim Care 2022;23:164.

 

 

Aklillu E, Zumla A, Habtewold A, Amogne W, Makonnen E, Yimer G, Burhenne J, Diczfalusy U. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. Br J Pharmacol 2021;178:3294-3308.

Alexovic M, Sabo J, Longuespée R. Microproteomic sample preparation. Proteomics 2021:e2000318.

Alexovic M, Sabo J, Longuespée R. Automation of single-cell proteomic sample preparation. Proteomics 2021;e2100198.

Benzel J, Bajraktari-Sylejmani G, Uhl P, Davis A, Nair S, Pfister S, Haefeli WE, Weiss J, Burhenne J, Pajtler KW, Sauter M. Investigating the central nervous system disposition of actinomycin D: Implementation and evaluation of cerebral microdialysis and brain tissue measurements supported by UPLC-MS/MS quantification. Pharmaceutics 2021;13:1498.

Bieber M, Foerster KI, Haefeli WE, Pham M, Schuhmann MK, Kraft P. Treatment with edoxaban attenuates acute stroke severity in mice by reducing blood-brain barrier damage and inflammation. Int J Mol Sci 2021;22:9893.

Bittmann JA, Rein EK, Metzner M, Haefeli WE, Seidling HM. The acceptance of interruptive medication alerts in an electronic decision support system differs between different alert types. Methods Inf Med 2021;60:180-184.

Ceré LI, Sedlmeier MG, Semeniuk M, Luquita MG, Francés D, Ronco MT, Rigalli JP, Ruiz ML, Catania VA. Induction of P-glycoprotein expression and activity by prolactin in female rat liver. Life Sci 2021;287:119936.

Dinh TS, González-González AI, Meid AD, Snell KIE, Rudolf H, Brueckle M-S, Blom JW, Thiem U, Trampisch H-J, Elders PJM, Donner-Banzhoff N, Gerlach FM, Harder S, van den Akker M, Glasziou PP, Haefeli WE, Muth C. Are anticholinergic symptoms a risk factor for falls in older general practice patients with polypharmacy? Study protocol for the development and validation of a prognostic model. Front Pharmacol 2021;11:577747.

Dominguez CJ, Tocchetti GN, Rigalli JP, Mottino AD. Acute regulation of apical ABC transporters in the gut. Potential influence on drug bioavailability. Pharmacol Res 2021;163:105251.

Fresnais M, Yildirim E, Karabulut S, Jäger D, Zörnig I, Benzel J, Pajtler K, Pfister S, Burhenne J, Haefeli WE, Longuespée R. Rapid MALDI-MS assays for drug quantification in biological matrices: lessons learned, new developments, and future perspectives. Molecules 2021;26:1281.

Fresnais M, Burhenne J, Haefeli WE, Longuespée R. Desorption/ionization-MS methods for drug quantification in biological matrices and their validation following regulatory guidance. Anal Chem 2021;93:7152-7163.

González-González AI, Meid AD, Dinh TS, Blom JW, van den Akker M, Elders PJ, Thiem U, Küllenerg De Gaudry D, Swart KMA, Rudolf H, Bosch-Lenders D, Trampisch HJ, Meerpohl JJ, Gerlach FM, Flaig B, Kom G, Snell KIE, Perera R, Haefeli WE, Glasziou PP, Muth C. A prognostic model predicted deterioration in health-related quality of life in older patients with multimorbidity and polypharmacy. J Clin Epidemiol 2021;130:1-12.

González-González AI, Dinh TS, Meid AD, Blom JW, van den Akker M, Elders PJM, Thiem U, Kuellenberg de Gaudry D, Snell KIE, Perera R, Swart KMA, Rudolf H, Bosch-Lenders D, Trampisch HJ, Meerpohl JJ, Flaig B, Kom G, Gerlach FM, Hafaeli WE, Glasziou PP, Muth C. Predicting negative health outcomes in older general practice patients with chronic illness: rationale and development of the PROPERmed harmonized individual participant data database. Mech Ageing Dev 2021;194:111436.

Grass J, Rose P, Burhenne J, Blank A, Haefeli WE, Mikus G. Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. J Clin Pharmacol 2021;61:472-479.

Halling T, Akkermann S, Löffler F, Groh A, Heitland I, Haefeli WE, Bauersachs J, Kahl KG, Westhoff-Bleck M. Factors that influence adherence to medication in adults with congenital heart disease (ACHD). Front Psychiatry 2021;12:788013.

Hein M, Chobanyan-Jürgens K, Tegtbur U, Engeli S, Jordan J, Haufe S. Effect of normobaric hypoxic exercise on blood pressure in old individuals. Eur J Appl Physiol 2021;121:817-825.

Hohmann N, Bozorgmehr F, Christopoulos P, Mikus G, Blank A, Burhenne J, Thomas M, Haefeli WE. Pharmacoenhancement of low crizotinib plasma concentrations in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer using the CYP3A inhibitor cobicistat. Clin Transl Sci 2021;14:487-491.

Huppertz A, Bollmann J, Behnisch R, Bruckner T, Zorn M, Burhenne J, Haefeli WE, Czock D. Differential effect of a continental breakfast on tacrolimus formulations with different release characteristics. Clin Pharmacol Drug Dev 2021;10:899-907.

Jungreithmayr V, Meid AD, Implementation Team, Haefeli WE, Seidling HM. The impact of a computerized physician order entry system implementation on 20 different criteria of medication documentation – a before-and-after study. BMC Med Inform Decis Mak 2021;21:279.

Kazdal D, Rempel E, Oliveira C, Allgauer M, Harms A, Singer K, Kohlwes E, Ormanns S, Fink L, Kriegsmann J, Leichsenring M, Kriegsmann K, Stogbauer, F, Tavernar L, Leichsenring J, Volckmar AL, Longuespee R, Winter H, Eichhorn M, Heussel CP, Herth F, Christopoulos P, Reck M, Muley T, Weichert W, Budczies J, Thomas M, Peters S, Warth A, Schirmacher P, Stenzinger A, Kriegsmann M. Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Transl Lung Cancer Res 2021;10:1666-1678.

Kluwe F, Michelet R, Mueller-Schoell A, Maier C, Klopp-Schulze L, van Dyk M, Mikus G, Huisinga W, Kloft C. Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. Clin Pharmacol Ther 2021;109:29.

Kraft M, Büscher A, Wiedmann F, L'hoste Y, Haefeli WE, Frey N, Katus HA, Schmidt C. Current drug treatment strategies for atrial fibrillation and TASK-1 inhibition as an emerging novel therapy option. Front Pharmacol 2021;12:638445.

Kulyyassov A, Fresnais M, Longuespée R. Targeted liquid chromatography-tandem mass spectrometry analysis of proteins: Basic principles, applications, and perspectives. Proteomics 2021;e2100153.

Kusch MKP, Haefeli WE, Seidling HM. Customization of information on adverse drug reactions according to patients’ needs – a qualitative study. Patient Educ Couns 2021;104:2351-2357.

Longuespée R, Theile D, Fresnais M, Burhenne J, Weiss J, Haefeli WE. Approaching sites of action of drugs in clinical pharmacology: new analytical options and their challenges. Br J Clin Pharmacol 2021;87:858-874.

Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E, Wery C, Collignon A, Longuespée R, Montero-Ruiz L, Dassoul I, Maloujahmoum N, Pottier C, Mazzucchelli G, Depauw E, Bellahcène A, Yoshida M, Noel A, Sounni NE. Tumor resistance to ferroptosis driven by stearoyl-CoA desaturase-1 (SCD1) in cancer cells and fatty acid binding protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol 2021;43:102006.

Mahmoudi M, Foerster KI, Burhenne J, Weiss J, Mikus G, Haefeli WE. Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity. J Clin Pharmacol 2021;61:789-798.

Meid AD, González-González AI, Dinh TS, Blom JW, van den Akker M, Elders PJM, Thiem U, Küllenberg de Gaudry D, Swart KMA, Rudolf H, Bosch-Lenders D, Trampisch HJ, Meerpohl JJ, Gerlach FM, Flaig B, Kom G, Snell KIE, Perera R, Haefeli WE, Glasziou PP, Muth C. Predicting hospital admissions from individual patient data (IPD): an applied example to explore key elements driving external validity. BMJ Open 2021;11:e045572.

Meid A. Teaching reproducible research for medical students and postgraduate pharmaceutical scientists. BMC Res Notes 2021;14:445.

Moecker R, Terstegen T, Haefeli WE, Seidling HM. The influence of intervention complexity on barriers and facilitators in the implementation of professional pharmacy services – a systematic review. Res Soc Admin Pharm 2021;17:1651-62.

Morath B*, Meid AD*, Rickmann J, Soethoff J, Verch M, Karck M, Zaradzki M. Renal Safety of Hydroxyethyl starch 130/0.42 After Cardiac Surgery: A Retrospective Cohort Analysis. Drug Saf 2021;44:1311-1321.

Mueller-Schoell A, Michelet R, Klopp-Schulze L, van Dyk M, Mürdter T, Schwab M, Joerger M, Huisinga W, Mikus G, Kloft C. Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups. Cancers 2021;13:2432.

Mueller-Schoell A, Michelet R, Weinelt F, Kloft C, Mikus G. CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications. Arch Toxicol 2021;95:2867-2870.

Rengelshausen J, Breithaupt-Groegler K, Donath F, Erb-Zohar K, Hardman T, Mikus G, Plassmann S, Wensing G, Sourgens H. How to interpret an investigator's brochure for meaningful risk assessment: results of an AGAH discussion forum. Ther Innov Regul Sci 2021;55:612-618.

Rigalli JP, Theile D, Nilles J, Weiss J. Regulation of PXR function by coactivator and corepressor proteins: ligand binding is just the beginning. Cells 2021;10:3137.

Röhr S, Zülke A, Luppa M, Brettschneider C, Weißenborn M, Kühne F, Zöllinger I, Samos FAZ, Bauer A, Döhring J, Krebs-Hein K, Oey A, Czock D, Frese T, Gensichen J, Haefeli WE, Hoffmann W, Kaduszkiewicz H, König HH, Thyrian JR, Wiese B, G. Riedel-Heller SG. Recruitment and baseline characteristics of participants in the AgeWell.de study – A pragmatic cluster-randomized controlled lifestyle trial against cognitive decline. Int J Environ Res Public Health 2021;18:408.

Ruff C, Gerharz A, Groll A, Stoll F, Wirbka L, Haefeli WE, Meid AD. Disease-dependent variations in the timing and causes of readmissions in Germany: a claims data analysis for six different conditions. PLoS ONE 2021;16:e0250298.

Sauter M, Uhl P, Burhenne J, Haefeli WE. Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides − Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS. J Pharm Biomed Anal 2021;194:113728.

Sauter M, Foerster KI, Benzel J, Pfister S, Pajtler KW, Haefeli WE, Burhenne J. Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. J Chromatogr B 2021;1176:122781.

Sauter M, Blank A, Stoll F, Lutz N, Haefeli WE, Burhenne J. Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. Anal Bioanal Chem 2021;413:5645-5654.

Schmulenson E, Zimmermann N, Mikus G, Joerger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol 2021;12:1407-1422.

Seidling HM, Wien K, Fabricius J, John C, Hauser J, Renner K, Schäfer P, Krisam J, Haefeli WE. Short and mid-term impact of community pharmacy-based medication reviews on medication- and patient-related outcomes in Germany. Int J Clin Pharmacol Ther 2021;59:188-197.

Semeniuk M, Ceré LI, Ciriaci N, Bucci Muñoz M, Quiroga AD, Luquita MG, Roma S, Catania VA, Mottino AD, Rigalli JP, Ruiz ML. Protective effect of genistein pre-treatment on paraquat hepatotoxicity in rats. Toxicol Appl Pharmacol 2021;426:115636.

Theile D, Wagner L, Haefeli WE, Weiss J. In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds. Eur J Pharm Sci 2021;162:105826.

Theile D, Wagner L, Bay C, Haefeli WE, Weiss J. Time-resolved effect of interferon-alpha 2a on activities of nuclear factor kappa B, pregnane X receptor, and on drug disposition genes. Pharmaceutics 2021;13:808.

Theile D, Wizgall P. Acquired ABC-transporter overexpression in cancer cells: Transcriptional induction or Darwinian selection? Naunyn Schmiedebergs Arch Pharmacol 2021;394:1621-1632.

Toenshoff B, Mueller B, Elling R, Renk H, Meissner P, Hengel H, Garbade S, Kieser M, Jeltsch K, Grulich-Henn J, Euler J, Stich M, Chobanyan-Jürgens K, Zernickel M, Janda A, Woelfle L, Stamminger T, Iftner T, Ganzenmueller T, Schmitt C, Görne T, Laketa V, Olberg S, Plaszczyca A, Cortese M, Pape C, Remme R, Huzly D, Panning M, Weigang S, Giese S, Ciminski K, Ankerhold J, Kochs G, Schwemmle M, Handgretinger R, Niemeyer C, Engel C, Kern W, Hoffmann G, Franz A, Henneke P, Debatin K-M, Kräusslich H-G. Prevalence of SARS-CoV-2 infection in children and their parents in southwest Germany. JAMA Pediatr 2021;175:586-593.

Uhl P, Sauter M, Hertlein T, Witzigmann D, Laffleur F, Hofhaus G, Fidelj V, Tursch A, Özbek S, Hopke E, Haberkorn U, Bernkop-Schnürch A, Ohlsen K, Fricker G, Mier W. Overcoming the Mucosal Barrier: Tetraether Lipid-Stabilized Liposomal Nanocarriers Decorated with Cell-Penetrating Peptides Enable Oral Delivery of Vancomycin. Adv Ther 2021;4:200247

von Linde T, Bajraktari-Sylejmani G, Haefeli WE, Burhenne J, Weiss J, Sauter M. Rapid and sensitive quantification of intracellular glycyl-sarcosine for semi high-throughput screening for inhibitors of PEPT-1. Pharmaceutics 2021;13:1019.

Wagner L, Haefeli WE, Merle U, Lorenz H-M, Hohmann N, Weiss J, Theile D. A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19. Cytokine 2021;138:155399

Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C. A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia 2021;35:701-711.

Weiss J, Bajraktari-Sylejmani G, Haefeli WE. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. Chem Biol Interact 2021;338:109428.

Wiebe ST, Huennemeyer A, Kadus W, Goettel M, Jambrecina A, Schultz A, Vinisko R, Schlieker L, Herich L, Mikus G. Midazolam microdosing applied in early clinical development for drug-drug interaction assessment. Br J Clin Pharmacol 2021;87:178-188.

Wiedmann F, Beyersdorf C, Zhou X-B, Kraft M, Foerster KI, El-Battrawy I, Lang S, Borggrefe M, Haefeli WE, Frey N, Schmidt C. The experimental TASK-1 potassium channel inhibitor A293 can be employed for rhythm control of persistent atrial fibrillation in a translational large animal model. Front Physiol 2021;11:629421.

Wild B, Wurmbach VS, Böhlen F, Kusch MK, Seidling HM, Reich P, Hartmann M, Haefeli WE, Friederich HC, Slaets J. Assessing the perspective of well-being of older patients with multiple morbidities by using the LAVA tool - a person-centered approach. BMC Geriatr 2021;21:427.

Wirbka L, ARMIN study group, Haefeli WE, Meid AD. Estimated thresholds of minimum necessary adherence for effective treatment with direct oral anticoagulants – a retrospective cohort study in health insurance claims data. Patient Prefer Adher 2021;15:2209-2220.

Wurmbach VS, Schmidt SJ, Lampert A, Bernard S, Faller CK, Thürmann PA, Haefeli WE, Seidling HM. Development and pilot-testing of key questions to identify patients’ difficulties in medication administration. Patient Prefer Adher 2021;15:2479-2488.

Zülke AE, Luppa M, Röhr S, Weißenborn M, Bauer A, Samos FAZ, Kühne F, Zöllinger F, Döhring J, Brettschneider C, Oey A, Czock D, Frese T, Gensichen J, Haefeli WE, Hoffmann W, Kaduszkiewicz H, König HH ,Thyrian JR, Wiese B, Riedel-Heller SG. Association of mental demands in the workplace with cognitive function in older adults at increased risk for dementia. BMC Geriatr 2021;21:688.

Buchbeiträge  

Czock D. Pharmakotherapie in der Niereninsuffizienz. In: Schwenger V (Hrsg.). Klinikleitfaden Nephrologie. München: Elsevier; 2021;625-636.

Seidling H, Haefeli WE. Arzneimitteltherapie bei älteren Patienten. In: Schäfer P. Allgemeinpharmazie. 2. Auflage; Stuttgart; Wissenschaftliche Verlagsgesellschaft Stuttgart; 2021: 425-436.

 

2020

 

Amelung S, Bender B, Meid A, Walk-Fritz S, Hoppe-Tichy T, Haefeli WE, Seidling HM. [How complete is the Germany-wide standardised medication list ("Bundeseinheitlicher Medikationsplan")? An analysis at hospital admission.] Dtsch Med Wochenschr 2020;145:e116-e122.

Arafah K, Kriegsmann M, Renner M, Lasitschka F, Fresnais M, Kriegsmann K, von Winterfeld M, Goeppert B, Kriegsmann J, Casadonte R, Kazdal D, Bulet P, Longuespée R. Microproteomics and immunohistochemistry reveal differences in aldo-keto reductase family 1 member C3 in tissue specimens of ulcerative colitis and Crohn's disease. Proteomics Clin Appl 2020;14:e1900110.

Bajraktari G & Weiss J. The aglycone diosmetin has the higher perpetrator drug-drug interaction potential compared to the parent flavone diosmin. J Funct Foods 2020;67:103842.

Bajraktari-Sylejmani G, Weiss J. Potential risk of food-drug interactions: Citrus polymethoxyflavones and flavanones as inhibitors of the organic anion transporting polypeptides (OATP) 1B1, 1B3, and 2B1. Eur J Drug Metab Pharmacokinet 2020;45:809-815.

Beck O, Paret C, Russo A, Burhenne J, Fresnais M, Steimel K, Seidmann L, Wagner DC, Vewinger N, Lehmann N, Sprang M, Backes N, Roth L, Neu MA, Wingerter A, Henninger N, Malki KE, Otto H, Alt F, Desuki A, Kindler T, Faber J. Safety and activity of the combination of ceritinib and dasatinib in osteosarcoma. Cancers 2020;12:793.

Blank A, Fürle K, Jäschke A, Mikus G, Lehmann M, Hüsing J, Heiss K, Giese T, Carter D, Böhnlein E, Lanzer M, Haefeli WE, Bujard H. Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial. NPJ Vaccines 2020;5:10.

Brinkmann F, Hanusch B, Ballmann M, Mayorandan S, Bollenbach A, Chobanyan-Jürgens K, Jansen K, Schmidt-Choudhury A, Derichs N, Tsikas D, Lücke L. Activated L-arginine/nitric oxide pathway in pediatric cystic fibrosis and its association with pancreatic insufficiency, liver involvement and nourishment: overview and new results. J Clin Med 2020;9:2012.

Czock D, Morath C. Dosierung von Antiinfektiva bei intensivpflichtigen Patienten mit akutem Nierenversagen und Nierenersatztherapie. Der Nephrologe 2020;15:225-232.

Czock D, Morath C. Arzneimittel-Wechselwirkungen mit Immunsuppressiva. Nieren- und Hochdruckkrankheiten 2020;49:395-400. Eidam A, Roth A, Lacroix A, Goisser S, Seidling HM, Haefeli WE, Bauer JM. Methods to assess patient preferences in old age pharmacotherapy – a systematic review. Patient Prefer Adherence 2020;14:467-497.

Engels A, Reber KC, Lindlbauer I, Rapp K, Büchele G, Klenk J, Meid A, Becker C, König HH. Osteoporotic hip fracture prediction from risk factors available in administrative claims data - A machine learning approach. PLoS One 2020;15:e0232969.

Foerster KI, Burhenne J. Microdosing drugs: a versatile technique to detect and assess drug-drug interactions. Expert Opin Drug Metab Toxicol 2020;16:447-8.

Foerster KI, Hermann S, Mikus G, Haefeli WE: Drug-drug interactions with direct oral anticoagulants. Clin Pharmacokinet 2020;59:967-80.

Fresnais M, Haefeli WE, Burhenne J, Longuespée R. Rapid drug detection in whole blood droplets using a DESI static profiling approach - a proof of concept. Rapid Commun Mass Spectrom 2020;34:e8614.

Fresnais M, Muck A, Majewsky M, Statz B, Krausert S, Benzel J, Castel D, Le Dret L, Pfister S, Haefeli WE, Burhenne J, Longuespée R. Rapid and sensitive drug quantification in tissue sections using matrix assisted laser desorption ionization-ion mobility-mass spectrometry (MALDI-IM-MS) profiling. J Am Soc Mass Spectrom 2020;31:742-751.

 Fresnais M, Haefeli WE, Burhenne J, Longuespée R. Advances in clinical pharmacology: Rapid detection of small molecules in solid samples at atmospheric pressure using desorption electrospray ionization (DESI). Omics, A Journal of Integrative Biology 2020;24:53-4.

Fresnais M, Roth A, Foerster KI, Jäger D, Pfister S, Haefeli WE, Burhenne J, Longuespée R. Rapid and sensitive quantification of osimertinib in human plasma using a fully validated MALDI-IM-MS/MS assay. Cancers 2020; 12;1897.

Fresnais M, Longuespée R, Sauter M, Schaller T, Arndt M, Krauss J, Blank A, Haefeli WE, Burhenne J. Development and validation of a LC-MS-based quantification assay for new therapeutic antibodies: application to a novel therapy against herpes simplex virus. ACS Omega 2020;5:24329-24339.

Gade C, Sverrisdóttir E, Dalhoff K, Sonne J, Johansen MØ, Christensen HR, Burhenne J, Mikus G, Holm JC, Lund TM, Holst H. Midazolam pharmacokinetics in obese and non-obese children and adolescents. Clin Pharmacokinet 2020;59:643-654.

Hanke N, Türk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, Müller F, Stopfer P, Nock V, Lehr T. A Comprehensive whole-body physiologically based pharmacokinetic drug-drug-gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals. Clin Pharmacokinet 2020;59:1419-1431.

Hanusch B, Brinkmann F, Mayorandan S, Chobanyan-Jürgens K, Wiemers A, Jansen K, Ballmann M, Schmidt-Choudhury A, Bollenbach A, Derichs N, Tsikas D, Lücke T. Local and systemic alterations of the L-arginine/nitric oxide pathway in sputum, blood, and urine of pediatric cystic fibrosis patients and effects of antibiotic treatment. J Clin Med 2020;9:3802.

Hoffmann M, Vander Stichele R, Bates DW , Björklund J, Alexander A, Andersson ML, Auraaen A, Bennie M, Dahl ML , Eiermann B, Hackl W, Hammar T, Hjemdahl P, Koch S, Kunnamo I, Le Louët H, Panagiotis P, Rägo L, Spedding M, Seidling HM, Demner-Fushman D, Gustafsson LL. Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. Exp Rev Clin Pharmacol 2020;13:925-34.

Jedamzik J, Mühlbacher J, Fitschek F, Schwarz C, Burhenne J, Asenbaum U,  Kaczirek K, Mikus G: No alteration of CYP3A4 activity after major hepatectomy in early postoperative period – a prospective before-after study. Int J Surg 2020;79:131-5.

Konrad C, Lossnitzer N, Boehlen FH, Haefeli WE, Holleczek B, Brenner H, Schoettker B, Wild B. Coping resources of heart failure patients – a comparison with cancer patients and individuals having no chronic condition. Results from the ESTHER study. Heart Lung 2020;49:829-35.

Kusch MKP, Zien A, Hachenberg C, Haefeli WE, Seidling HM. Information on adverse drug reactions - Proof of principle for a structured database that allows customization of drug information. Int J Med Inform 2020;133:103970.

Lampert A, Haefeli WE, Seidling HM. Reasons for drug administration problems and perceived needs for assistance of patients, family caregivers, and nurses: a qualitative study. J Patient Saf 2020;16:149-54.

Li X, Frechen S, Moj D, Lehr T, Taubert M, Hsin CH, Mikus G, Neuvonen PJ, Olkkola KT, Saari TI, Fuhr U. A physiologically based pharmacokinetic model of voriconazole integrating mechanism-based inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions. Clin Pharmacokinet 2020;59:781-808.

Meid AD, Ruff C, Wirbka L, Stoll F, Seidling HM, Groll A, Haefeli WE. Using the causal inference framework to support individualized drug treatment decisions based on observational healthcare data. Clin Epidemiol 2020;12:1223-34.

Mikus G, Foerster KI, Schaumaeker M, Lehmann M-L, Burhenne J, Haefeli WE. Application of a microdosed cocktail of three oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. Br J Clin Pharmacol 2020; 32159869.

Morath C, Schmitt A, Kleist C, Daniel V, Opelz G, Süsal C, Ibrahim E, Kälble F, Speer C, Nusshag C, Pego da Silva L, Sommerer C, Wang L, Ni M, Hückelhoven-Krauss A, Czock D, Merle U, Mehrabi A, Sander A, Hackbusch M, Eckert C, Waldherr R, Schnitzler P, Müller-Tidow C, Hoheisel JD, Mustafa SA, Alhamdani MS, Bauer AS, Reiser J, Zeier M, Schmitt M, Schaier M, Terness P. Phase I trial of donor-derived modified immune cell infusion in kidney transplantation. J Clin Invest 2020;130:2364-76.

Mugusi S, Habtewold A, Ngaimisi E, Amogne W, Yimer G, Minzi O, Makonnen E, Sudfeld C, Burhenne J, Aklillu E. Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel prospective cohort study in two sub-Sahara African populations. Front Pharmacol 2020;11:26.

Mueller T, Kalxdorf M, Longuespée R, Kazdal DN, Stenzinger A, Krijgsveld J. Automated sample preparation with SP3 for low-input clinical proteomics. Mol Syst Biol 2020;16:e9111.

Muhlack DC, Hoppe LK, Saum K-U, Haefeli WE, Brenner H, Schöttker B. Investigation of a possible association of potentially inappropriate medication for older adults and frailty in a prospective cohort study from Germany. Age Ageing 2020;49:20-5.

N.,mnbvfdsaguyen TNM, Laetsch DC, Chen L-J, Haefeli WE, Meid AD, Brenner H, Schöttker B. Pain severity and analgesics use in the community-dwelling older population: A drug utilization study from Germany. Eur J Clin Pharmacol 2020;76:1695-707.

Peters-Klimm F, Czock D. Herzinsuffizienz - Arzneimittel evidenzbasiert und sicher einsetzen. KVH aktuell 2020;25:4-15.

Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R, Sounni NE. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers 2020;12:731.

Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, Weisel K, Winderlich M, Griese J, Härtle S, Weirather J, Jarutat T, Peschel C, Chatterjee M. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol 2020;7:e381-94.

Rohr BS, Mikus G: Proposal of a safe and effective design to study CYP3A mediated drug-drug interactions. J Clin Pharmacol 2020;60:1294-303.

Sadik A, Somarribas Patterson LF, Öztürk S, Mohapatra SR, Panitz V, Secker PF, Pfänder P, Loth S, Salem H, Prentzell MT, Berdel B, Iskar M, Faessler E, Reuter F, Kirst I, Kalter V, Foerster KI, Jäger E, Ramallo Guevara C, Sobeh M, Hielscher T, Poschet G, Reinhardt A, Hassel J, Zapatka M,  Hahn U, von Deimling A, Hopf C, Schlichting R, Escher B, Burhenne J, Haefeli WE, Ishaque N, Böhme A, Schäuble S, Thedieck K, Trump S, Seiffert M, Opitz CA. The L-amino acid oxidase IL4I1 is the key enzyme of a tryptophan catabolizing pathway and elicits tumor-promoting outcomes through the AHR. Cell 2020;182:1252-1270.e34.

Santos JR, Merino A, Haefeli WE, Miranda C, Prats M, Bancu IE, Bailón L, Moltó J. Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis. A case report. BMC Nephrol 2020;21:24.

 Sauter M, Strieker M, Kleist C, Wischnjow A, Daniel V, Altmann A, Haberkorn U, Mier W. Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. J Control Release 2020;322:200-208.

Sauter M, Uhl P, Burhenne J, Haefeli WE. Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. J Pharm Biomed Anal 2020;186:113276.

Sauter M, Uhl P, Burhenne J, Haefeli WE. Post-extraction disulfide bond cleavage for MS/MS quantification of collision-induced dissociation-resistant cystine-cyclized peptides and its application to the ultra-sensitive UPLC-MS/MS bioanalysis of octreotide in plasma. Anal Chim Acta 2020;1114:42-9.

Sauter M, Uhl P, Meid AD, Mikus G, Burhenne J, Haefeli WE. New insights into the pharmacokinetics of vancomycin after oral and intravenous administration: An investigation in beagle dogs. J Pharm Sci 2020;109:2090-2094.

Sauter M, Uhl P, Burhenne J, Haefeli WE. Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS. J Pharm Anal 2020;10:233-9.

Sauter M, Burhenne J, Haefeli WE, Uhl P. An underestimated factor: The extent of cross-reactions modifying APIs in surface-modified liposomal preparations caused by comprised activated lipids. Molecules 2020;25:4436.

Schmidt S, Wurmbach VS, Lampert A, Bernard S, HIOPP-6 Consortium, Haefeli WE, Seidling HM, Thürmann PE. Individual factors increasing complexity of drug treatment—a narrative review. Eur J Clin Pharmacol 2020;76:745-54.

Schöttker B, Kuznia S, Laetsch DC, Czock D, Kopp-Schneider A, Caspari R, Brenner H. Protocol of the VICTORIA study: personalized vitamin D supplementation for reducing or preventing fatigue and enhancing quality of life of patients with colorectal tumor - randomized intervention trial. BMC Cancer 2020;20:739.

Schuster L, Sauter M, Uhl P, Meid A, Haefeli WE, Weiss J, Theile D. Reporter cell assay-based functional quantification of TNF-α-antagonists in serum -- a proof-of-principle study for adalimumab . Anal Biochem 2020;596:113646.

Seiberth S, Terstegen T, Strobach D, Czock D. Accuracy of freely available online GFR calculators using the CKD-EPI equation. Eur J Clin Pharmacol 2020;76:1465-70.

Seidling HM, Mahler C, Strauß B, Weis A, Stützle M, Krisam J, Szecsenyi J, Haefeli WE. An electronic medication module to improve health literacy in patients with type 2 diabetes mellitus: pilot randomized controlled trial. JMIR Form Res 2020;4:e13746.

Semeniuk M, Cere LI, Bucci Muñoz M, Villanueva SS, Mottino AD, Catania VA, Rigalli JP, Ruiz ML. Regulation of hepatic P-gp expression and activity by genistein in rats. Arch Toxicol 2020;94:1625-35.

Stoll F, Blank A, Mikus G, Czock D, Foerster KI, Hermann S, Haeussler K, Muhareb A, Hummler S, Weiss J, Burhenne J, Haefeli WE. Structured summary of the study protocol for the randomised controlled trial “Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19). Trials 2020;21:584.

Straßner C, Mahler C, Strauß B, Wehrmann U, Krug K, Szecsenyi J, Haefeli WE, Seidling H. Medication beliefs and use of medication lists – is there a connection? Results from a before-and-after study in Germany. BMC Geriatr 2020;20:116.

Tocchetti GN, Dominguez CJ, Zecchinati F, Arana MR, Rigalli JP, Ruiz ML, Villanueva SSM, Mottino AD.  Intraluminal nutrients acutely strengthen rat intestinal MRP2 barrier function by a glucagon-like-peptide-2-mediated mechanism. Acta Physiol (Oxf) 2020;e13514.

Uhl P, Grundmann C, Sauter M, Storck P, Tursch A, Özbek S, Leotta K, Roth R, Witzigmann D, Kulkarni JA, Fidelj V, Kleist C, Cullis PR, Fricker G, Mier W. Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide. Nanomedicine: Nanotechnology, Biology, and Medicine 2020;24:102132.

Vaughns JD, Ziesenitz VC, Williams EF, Nadler EP, Mikus G, van den Anker JN. Prophylactic use of enoxaparin in adolescents during bariatric surgery – a prospective clinical study. Obesity Surg 2020;30:63-68.

Vay M, Meyer MJ, Blank A, Skopp G, Rose P, Tzvetkov MV, Mikus G. Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed sequence phase 1 trial. Clin Pharmacokinet 2020;59:927-39.

Weiss J, Gattuso G, Barreca D, Haefeli WE. Nobiletin, sinensetin, and tangeretin are the main perpetrators in clementines provoking food-drug interactions in vitro. Food Chem 2020;319:126578.

Weiss J, Bajraktari-Sylejmani G, Haefeli WE. Interaction of hydroxychloroquine with pharmacokinetically important drug transporters. Pharmaceutics 2020;12:919.

Weissenborn M, Krass I, Van C, Dähne A, Ritter CA, Haefeli WE, Seidling HM. Process of translation and cross-cultural adaptation of two Australian instruments to evaluate the physician-pharmacist collaboration in Germany. Res Social Adm Pharm 2020;16:74-83.

Wiebe ST, Meid AD, Mikus G. Composite midazolam and 1’-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity. J Pharmacokin Pharmacodyn 2020;47:527-42.

Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, Gansser D, Ishiguro N, Taub ME, Sharma A, Ebner T, Mikus G, Fromm MF, Müller F, Stopfer P. Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil and cimetidine. Clin Pharmacokinet 2020;59:1627-39.

Wirbka L, Haefeli WE, Meid AD. A framework to build similarity-based cohorts for personalized treatment advice - a standardized, but flexible workflow with the R package SimBaCo. PLoS One 2020;15:e0233686.

Wurmbach VS, Schmidt SJ, Lampert A, Frick E, Metzner M, Bernard S, Thürmann PA, Wilm S, Mortsiefer A, Altiner A, Sparenberg L, Szecsenyi J, Peters-Klimm F, Kaufmann-Kolle P, Haefeli WE, Seidling HM. Development of an algorithm to detect and reduce complexity of drug treatment and its technical realisation. BMC Med Inform Decis Mak 2020;20:154.

Buchbeiträge 

Czock D. Pharmacokinetic equations. In: Keller F. Classical pharmacokinetics and concise pharmacodynamics for clinicians. München, Dustri-Verlag 2020, 1. Auflage, S. 438-50

Czock D, Sommerer C. Pharmakokinetik von Tumortherapeutika bei normaler und eingeschränkter Nierenfunktion. In: Jäger D, Zeier M, Hrsg. Onko-Nephrologie. 1. Auflage Berlin: Springer; 2020. S. 221-41.

2019

 

Amelung S, Meid AD, Nafe M, Thalheimer M, Hoppe-Tichy T, Haefeli WE, Seidling HM. Association of preventable adverse drug events with inpatients' length of stay - A propensity-matched cohort study. Int J Clin Pract 2019;71:e12990.

Becker C, Herrmann A, Haefeli WE, Rapp K, Lindemann U. New approaches in preventing health risks and excess-mortality of older persons during extreme heat. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019;62:565-70.

Boehlen FH*, Freigofas J*, Herzog W, Meid AD, Fujs A, Saum KU, Schoettker B, Brenner H, Haefeli WE, Wild B. Evidence for underuse and overuse of antidepressants in older adults - results of a large population-based sample. Int J Geriatr Psychiatry 2019;34:539-47.

Brefka S, Dallmeier D, Mühlbauer V, von Arnim CAF, Bollig C, Onder G, Petrovic M, Schönfeldt-Lecuona C, Seibert M, Torbahn G, Voigt-Radloff S, Haefeli WE, Bauer JM, Denkinger MD. A Proposal for the retrospective identification and categorization of older people with functional impairments in scientific studies-recommendations of the medication and quality of life in frail older persons (MedQoL) Research Group. J Am Med Dir Assoc 2019;20:138-46.

Brenner H, Calderazzo S, Seufferlein T, Ludwig L, Dikopoulos N, Mangold J, Böck W, Stolz T, Eisenbach T, Block T, Kopp-Schneider A, Czock D*, Tikk K*. Effect of a single aspirin dose prior to fecal immunochemical testing on test sensitivity for detecting advanced colorectal neoplasms: a randomized clinical trial. JAMA 2019;321:1686-92.

Brings A, Lehmann ML, Foerster KI, Burhenne J, Weiss J, Haefeli WE, Czock D. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. Br J Clin Pharmacol 2019;85:1528-37.

Ceballos MP, Rigalli JP, Cere LI, Semeniuk M, Catania VA, Ruiz ML. ABC transporters: Regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem 2019;26:1-26.

Chobanyan-Jürgens K, Scheibe RJ, Potthast AB, Hein M, Smith A, Freund R, Tegtbur U, Das AM, Engeli S, Jordan J, Haufe S. Influences of hypoxia exercise on whole body insulin sensitivity and oxidative metabolism in older individuals. J Clin Endocrinol Metab 2019;104:5238-48.

Czock D. Pharmacokinetics of gadolinium-based contrast agents. Radiologe 2019;59:408-12.

Eickhoff C, Müller U, Strunz AK, Seidling HM, Lampert A, Felberg M, Breiholz S, Klintworth D, Schulz M. [The PRIMA Project - Electronically-supported physician-pharmacist cooperation to generate and update medication plans in Germany]. Dtsch Med Wochenschr 2019;144:e114-20.

Flechsig P, Lindner T, Loktev A,  Roesch S, Mier W, Sauter M, Meister M, Herold-Mende C, Haberkorn U, Altmann A. PET/CT Imaging of NSCLC with a αvβ6 Integrin-Targeting Peptide. Mol Imaging Biol 2019.;5:973-83.

Foerster K, Theile D. Given the data of hommers and co-workers, valproic acid is not an unequivocal inducer of clozapine metabolism. J Clin Psychopharmacol 2019;39:419-20.

Gade C, Dalhoff K, Petersen T, Riis T, Schmeltz C, Chabanova E, Christensen H, Mikus G, Burhenne J, Holm JC, Holst H. Obesity induced CYP2E1 activity in children with obesity. Br J Clin Pharmacol 2019;85:458-9.

Gade C, Sverrisdóttir E, Dalhoff K, Sonne J, Johansen MØ, Christensen HR, Burhenne J, Mikus G, Holm JC, Lund TM, Holst H. Midazolam pharmacokinetics in obese and non-obese children and adolescents. Clin Pharmacokin 2019;doi:10.1007/s40262-019-00838-1.

Geist MJP, Bardenheuer HJ, Burhenne J, Mikus G. Alteration of drug metabolizing enzyme activity in palliative care patients: microdosed assessment of CYP3A. Pall Med 2019;33:850-5.

Geist MJP, Egerer G, Mikus G, Blank A, Hohmann N, Heinz W, Carls A. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions. Basic Clin Pharmacol Toxicol 2019; 124: 56-61.

Geist MJP, Siller N, Egerer G, Bardenheuer H, Burhenne J, Mikus G. Decreased CYP3A activity in palliative patients with hematological diseases: potential impact on supportive drug therapies. Basic Clin Pharmacol Toxicol 2019;125:117-22.

Geist MJP, Ziesenitz VC, Bardenheuer HJ, Burhenne J, Skopp G, Mikus G. Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. Sci Reports 2019;9:14635.

Greenblatt DJ, Mikus G. Ketoconazole and Liver Injury: A Five-Year Update. Clin Pharmacol Drug Dev 2019; 8:6-8.

Grüning E, Haefeli WE. Plasma drug concentrations in children receiving pulmonary arterial hypertension combination treatment. Respiration 2019;97:92 (letter)

Herrmann A, Haefeli WE, Lindemann U, Rapp K, Roigk P, Becker C. [Epidemiology and prevention of heat-related adverse health effects on elderly people]. Z Gerontol Geriatr 2019;52:487-502.

Hohls JK, Wild B, Heider D, Brenner H, Böhlen F, Saum KU, Schöttker B, Matschinger H, Haefeli WE, König HH, Hajek A. Association of generalized anxiety symptoms and panic with health care costs in older age - results from the ESTHER cohort study. J Affect Disord 2019;245:978-86.

Hohls JK, König HH, Heider D, Brenner H, Böhlen F, Matschinger H, Saum KU, Schöttker B, Haefeli WE, Hajek A, Wild B. Longitudinal association between panic disorder and health care costs in older adults. Depress Anxiety 2019;36:1135-42.

Hohmann N, Mikus G, Haefeli WE, Schwenger V, Gattuso G, Barreca D, Weiss J. Two single case experiments show no effect on CYP3A-dependent midazolam clearance. Eur J Pharm Sci 2019;133:54-8.

Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE. Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. Br J Clin Pharmacol 2019;85:2310-20.

Huppertz A*, Ott C*, Bruckner T, Foerster KI, Burhenne J, Weiss J, Zorn M, Haefeli WE*, Czock D*. Prolonged-release tacrolimus is less susceptible to interaction with the strong CYP3A inhibitor voriconazole in healthy volunteers. Clin Pharmacol Ther 2019;106:1290-8.

Huppertz A, Grond-Ginsbach C, Dumschat C, Foerster KI, Burhenne J, Weiss J, Czock D, Purrucker JC, Rizos T, Haefeli WE. Unexpected excessive apixaban exposure: Case report of a patient with polymorphisms of multiple apixaban elimination pathways. BMC Pharmacol Toxicol 2019;doi.org/10.1186/s40360-019-0331-9.

Kazdal D, Longuespée R, Dietz S, Casadonte R, Schwamborn K, Volckmar AL, Kriegsmann J, Kriegsmann K, Fresnais M, Stenzinger A, Sültmann H, Warth A, Kriegsmann M. Digital PCR after MALDI mass spectrometry imaging to combine proteomic mapping and identification of activating mutations in pulmonary adenocarcinoma. Proteomics Clin Appl 2019;13:e1800034.

Kiene K, Hayasi N, Burhenne J, Uchitomi R, Sünderhauf C, Schmid Y, Haschke M, Haefeli WE, Krähenbühl S, Mikus G, Inada H, Huwyler J. Microdosed midazolam for the determination of cytochrome P450 3A activity: development and clinical evaluation of a buccal film. Eur J Pharm Sci 2019;135:77-82.

Kirbs C, Kluwe FI, Drescher F, Lackner E, Matzneller P, Weiss J, Zeitlinger M, Kloft C. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. Eur J Pharm Sci 2019;131:218-29.

Kriegsmann K, Longuespée R, Hundemer M, Zgorzelski C, Casadonte R, Schwamborn K, Weichert W, Schirmacher P, Harms A, Kazdal D, Leichsenring J, Stenzinger A, Warth A, Fresnais M, Kriegsmann J, Kriegsmann M. Combined immunohistochemistry after mass spectrometry imaging for superior spatial information. Proteomics Clin Appl 2019;13:e1800035.

Kusch MKP, Zien A, Hachenberg C, Haefeli WE, Seidling HM. Information on adverse drug reactions-proof of principle for a structured database that allows customization of drug information. International Journal of Medical Informatics 2019;doi:10.1016/103970.

Lampert A, Haefeli WE, Seidling HM. Information gaps in package inserts cause insufficient patient information on correct handling of transdermal patches. Dtsch Med Wochenschr 2019;144:e36-e41.

Lampert A, Bruckner T, Haefeli WE, Seidling HM. Improving eye-drop administration skills of patients - A multicenter parallel-group cluster-randomized controlled trial. PLoS One 2019;14:e0212007.

Longuespée R, Ly A, Casadonte R, Schwamborn K, Kazdal D, Zgorzelski C, Bollwein C, Kriegsmann K, Weichert W, Kriegsmann J, Schirmacher P, Fresnais M, Oliveira C, Kriegsmann M. Identification of MALDI imaging proteolytic peptides using LC-MS/MS-based biomarker discovery data: A proof of concept. Proteomics Clin Appl. 2019;13:e1800158.

Longuespée R, Kriegsmann K, Cremer M, Zgorzelski C, Casadonte R, Kazdal D, Kriegsmann J, Weichert W, Schwamborn K, Fresnais M, Schirmacher P, Kriegsmann M. - In MALDI mass spectrometry imaging on formalin-fixed paraffin-embedded tissue specimen 0section thickness significantly influences m/z peak intensity. Proteomics Clin Appl 2019;13:e1800074.

Mahmoudi M, Haefeli WE. Medikamenteninteraktion bei oralen Kontrazeptiva. Gynäkologe 2019;52:117-25.

Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE. Microdosed cocktail of three oral factor Xa inhibitors to evaluate drug-drug interactions with potential perpetrator drugs. Clin Pharmacokinet 2019;58:1155-63.

Mikus G. Probes and cocktails for DDI evaluation: the future is microdosing? Clin Pharmacol Ther 2019;105:1335-7.

Morath B, Wien K, Hoppe-Tichy T, Haefeli WE, Seidling HM. Structure and content of drug monitoring advices included in discharge letters at interfaces of care: exploratory analysis preceding database development. JMIR Med Inform 2019;7:e10832.

Müller M, Altmann A, Sauter M, Lindner T, Jäger D, Rathke H, Herold-Mende C, Marmé F, Babich J, Mier W, Haberkorn U. Preclinical evaluation of peptide-based radiotracers for integrin αvβ6-positive pancreatic carcinoma. Nuklearmedizin 2019;58:309-18.

Muhlack DC, Hoppe LK, Saum KU, Haefeli WE, Brenner H, Schöttker B. Investigation of a possible association of potentially inappropriate medication for older adults and frailty in a prospective cohort study from Germany. Age Ageing 2019;49:20-5.

Pottier C, Kriegsmann M, Alberts D, Smargiasso N, Baiwir D, Mazzucchelli G, Herfs M, Fresnais M, Casadonte R, Delvenne P, De Pauw E, Longuespée R. Microproteomic profiling of high-grade squamous intraepithelial lesion of the cervix: Insight into biological mechanisms of dysplasia and new potential diagnostic markers. Proteomics Clin Appl 2019;13:e1800052.

Quinzler R, Freitag MH, Wiese B, Beyer M, Brenner H, Dahlhaus A, Döring A, Freund T, Heier M, Knopf H, Luppa M, Prokein J, Riedel-Heller S, Schäfer I, Scheidt-Nave C, Scherer M, Schöttker B, Szecsenyi J, Thürmann P, van den Bussche H, Gensichen J, Haefeli WE. A novel superior medication-based chronic disease score (medCDS) predicted all-cause mortality in independent geriatric cohorts. J Clin Epidemiol 2019;105:112-24.

Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia 2019;33:2924-33.

Rigalli JP, Scholz PN, Tocchetti GN, Ruiz ML, Weiss J. The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect. Eur J Nutr 2019;58:139-50.

Rigalli JP, Tocchetti GN, Weiss J. Modulation of ABC transporters by nuclear receptors. Physiological, pathological and pharmacological aspects. Curr Med Chem 2019;27:1-34.

Ruff C, Koukalova L, Haefeli WE, Meid AD. The role of adherence thresholds for development and performance aspects of a prediction model for direct oral anticoagulation adherence. Front Pharmacol 2019;10:113.

Russo A, Paret C, Alt F, Burhenne J, Fresnais M, Wagner W, Glaser M, Bender H, Huprich S, Harter PN, Filipski K, Lehmann N, Backes N, Roth L, Seidmann L, Sommer C, Brockmann MA, Pietsch T, Neu MA, Wingerter A, Faber J. Ceritinib-induced regression of an insulin-like growth factor-driven neuroepithelial brain tumor. Int J Mol Sci 2019;20:4267.

Sauter M, Uhl P, Foerster KI, Mohr I, Höne RT, Merle U, Burhenne J, Haefeli WE. An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma. J Pharm Biomed Anal 2019;174:633-8.

Sauter M, Uhl P, Majewsky M, Fresnais M, Haefeli WE, Burhenne J. An ultra-sensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs. Bioanalysis 2019;11:887-98.

Seidling HM*, Mahler C*, Straßner C, Strauß B, Bernhard G, Szecsenyi J, Haefeli WE, Wehrmann U. Use of medication lists: A population-based approach to increase the prevalence of medication lists within a region in Germany - A pre-post study. Int J Clin Pharmacol Ther 2019;57:375-83.

Schäfer J, Weiss J, Theile D. Bosentan enhances in vitro bortezomib’s antiproliferative potency against multiple myeloma by mechanisms going beyond endothelin receptor blockade. Brit J Haematol 2019;184:1011-55.

Schäfer J, Burhenne J, Weiss J, Theile D. Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. Naunyn-Schmiedebergs Arch Pharmacol 2019;392:461-6.

Theile D, Cho WC. Pharmacodynamic monitoring using biomarkers to individualize pharmacotherapy. Biomark Med 2019;13:393-408.

Uhl P, Grundmann C, Sauter M, Storck P, Tursch A, Özbek S, Leotta K, Roth R, Witzigmann D, Kulkarni JA, Fidelj V, Kleist C, Cullis PR, Fricker G, Mier W. Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide. Nanomedicine: Nanotechnology, Biology, and Medicine 2020;24:102132.

van Tilburg CM, Milde T, Witt R, Ecker J, Hielscher T, Seitz A, Schenk JP, Buhl JL, Riehl D, Frühwald MC, Pekrun A, Rossig C, Wieland R, Flotho C, Kordes U, Gruhn B, Simon T, Linderkamp C, Sahm F, Taylor L, Freitag A, Burhenne J, Foerster KI, Meid AD, Pfister SM, Karapanagiotou-Schenkel I, Witt O. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Clin Epigenet 2019:11:188.

Vay M, Foerster K, Mahmoudi M, Seessle J, Mikus G. No alteration of voriconazole concentration by plasmapheresis in a critically ill patient. Eur J Clin Pharmacol 2019;75:287-8.

Vay M, Sauter M, Mikus G, Burhenne J. Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. Bioanalysis 2019;11:1459-67.

Vay M, Skopp G, Mikus G, Burhenne J. Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma. Anal Methods 2019;11:5976-83.

Von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Munzinger J, Edler L, Efferth T, Schneeweiss A, Strowitzki T. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2). Phytomedicine 2019;54:140-8.

Walter V, Boakye D, Weberpals J, Jansen L, Haefeli WE, Martens UM, Knebel P, Chang-Claude J, Hoffmeister M, Brenner H. Decreasing use of chemotherapy in older stage III colon cancer patients irrespective of comorbidities. J Natl Compr Canc Netw 2019;17:1089-99.

Weiss J. Herb-drug interaction potential of anti-borreliae effective extracts from uncaria tomentosa (samento) and otoba parvifolia (banderol) assessed in vitro. Molecules 2019;24:137.

Weißenborn M, Schulz M, Kraft M, Haefeli WE, Seidling HM. [Potential benchmarks for successful interdisciplinary collaboration projects in Germany: A systematic review]. Gesundheitswesen 2019;81:1057-68.

Weißenborn M, Haefeli WE, Seidling HM. Wenn Arzt und Apotheker an einem Strang ziehen. UniDAZ 2019;2:38-9.

Ziesenitz VC, Mikus G. Methodological considerations on CYP2D6 phenoconversion due to drug-drug interaction. Clin Pharmacol Ther 2019;105:1076.

Zülke A, Luck T, Pabst A, Hoffmann W, Thyrian JR, Gensichen J, Kaduszkiewicz H, König H, Haefeli WE, Czock D, Wiese B, Frese T, Röhr S, Riedel-Heller SG. AgeWell.de – study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients. BMC Geriatrics 2019;19:203.

Buchbeiträge  

Czock D, Seidling HM. Dosisanpassung bei Niereninsuffizienz. Angewandte Pharmakotherapie, 2. Auflage, ISBN 978-3-8047-3736-5, S. 605-19.

2018

 

Algeelani S, Alam N, Hossain A, Mikus G, Greenblatt DJ. In vitro inhibition of human UGT isoforms by ritonavir and cobicistat. Xenobiotica 2018;48:764-9.

Bernhard G, Mahler C, Seidling HM, Stützle M, Ose D, Baudendistel I, Wensing M, Szecsenyi J. Developing a shared patient-centered, web-based medication platform for type 2 diabetes patients and their health care providers: qualitative study on user requirements. J Med Internet Res 2018;20:e105.

Blank A, Meier K, Urban S, Haefeli WE, Weiss J. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro. Antivir Ther 2018;23:267-75.

Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, van de Graaf S, Meyer MR, Maurer HH, Meier K, Weiss J, Bruckner T, Alexandrov A, Urban S, Mikus G, Haefeli WE. The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics. Clin Pharmacol Ther 2018;103:341-8.

Blassmann U, Morath B, Fischer A, Knoth H, Hoppe-Tichy T. Arzneimitteltherapie-sicherheit im Krankenhaus – Einbindung von Stationsapothekern zur Reduktion von arzneimittelbezogenen Problemen im stationären Medikationsprozess. Bundesgesundheitsblatt 2018;61(9):1103-10.

Czock D, Keller F. Polypharmazie bei Patienten mit Niereninsuffizienz. Nephro News 2018;20:11-3.

Czock D, Schwenger V, Kindgen-Milles D, Joannidis M, John S, Schmitz M, Jörres A, Zarbock A, Oppert M, Kielstein JT, Willam C. [Dose adjustment of anti-infective drugs in patients with renal failure and renal replacement therapy in intensive care medicine: Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI]. Med Klin Intensivmed Notfmed 2018;113:384-92.

Economou CJP, Kielstein JT, Czock D, Xie J, Field J, Richards B, Tallot M, Visser A, Koenig C, Hafer C, Schmidt JJ, Lipman J, Roberts JA. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. Int J Antimicrob Agents 2018;52:151-7.

Foerster KI, Huppertz A, Müller O, Rizos T, Tilemann L, Haefeli WE, Burhenne J. Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. J Pharm Biomed Anal 2018;148:238-44.

Foerster K, Huppertz A, Meid A, Müller OJ, Rizos T, Tilemann L, Haefeli WE, Burhenne J. Dried blood spot technique to monitor direct oral anticoagulants: Clinical validation of an UPLC/MS/MS based assay. Anal Chem 2018;90:9395-402. 

Frindert J, Zhang Y, Nübel G, Kahloon M, Kolmar L, Hotz-Wagenblatt A, Burhenne J, Haefeli WE, Jäschke A. Identification, biosynthesis, and decapping of NAD-capped RNAs in B. subtilis. Cell Rep 2018;24:1890-901

Gade C, Dalhoff K, Petersen TS, Riis T, Schmeltz C, Chabanova E,  Christensen HR, Mikus G, Burhenne J, Holm JC, Holst H. Higher chlorzoxazone clearance in obese children compared with nonobese peers. Br J Clin Pharmacol 2018;84:1738-47.

Geist MJP, Bardenheuer HJ, Burhenne J, Mikus G. In vivo CYP3A activity in palliative care patients: Study protocol for a single arm prospective trial. J Palliat Med 2018;21:686-8.

Haefeli WE, Meid AD. Pill-count and the arithmetic of risk: Evidence that polypharmacy is a health status marker rather than a predictive surrogate for the risk of ADEs. Int J Clin Pharmacol Ther 2018;DOI10.5414/CP203372.

Haefeli WE, Seidling HM. [Electronic decision support to promote medication safety]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018;61:271-7.

Hajek A, Bock JO, Saum KU, Matschinger H, Brenner H, Holleczek B, Haefeli WE, Heider D, König HH. Frailty and health care costs – Longitudinal results of a prospective cohort study. Age Ageing 2018;47:233-41.

Heider D, Matschinger H, Meid AD, Quinzler R, Adler J-B, Günster C, Haefeli WE, König HH. The impact of potentially inappropriate medication on the development of health care costs and its moderation by the number of prescribed substances. PLoS ONE 2018;13:e0198004.

Huppertz A, Werntz L, Meid AD, Foerster KI, Burhenne J, Czock D, Mikus G, Haefeli WE. Rivaroxaban and macitentan can be co-administered without dose adjustment but the combination of rivaroxaban and St. John's Wort should be avoided. Brit J Clin Pharmacol 2018;84:2903-13.

Joannidis M, Klein SJ, John S, Schmitz M, Czock D, Druml W, Jörres A, Kindgen-Milles D, Kielstein JT, Oppert M, Schwenger V, Willam C, Zarbock A. [Prevention of acute kidney injury in critically ill patients: Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI]. Med Klin Intensivmed Notfmed 2018;113:358-69.

Kitabi EN, Minzi OMS, Mugusi S, Sasi P, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E. Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. Sci Rep 2018;8:16316.

Kusch M, Haefeli WE, Seidling HM. How to answer patients’ individual needs for drug information – a scoping review. Patient Prefer Adherence 2018;12:2339-55.

Lampert A, Kessler J, Washington-Dorando P, Bardenheuer HJ, Bocek Eknes EM, Krisam J, Haefeli WE, Seidling HM. Patient experiences with handling of analgesic transdermal patches and challenges in correct drug administration: a pilot study on patient education. J Patient Saf 2018;14:97-101.

Mahmoudi M, Brenner T, Hatiboglu G, Burhenne J, Weiss J, Weigand MA, Haefeli WE. Reply to Truffot et al. Clin Infect Dis 2018;66:1644-6 (letter).

Majewsky M, Castel D, Le Dret L, Johann P, Jones DT, Pfister SM, Haefeli WE, Burhenne J. Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS. J Pharm Biomed Anal 2018;151:151-8.  

Meid AD, Groll A, Heider D, Mächler S, Adler J-B, Günster C, König H-H, Haefeli WE. Prediction of drug-related risks using clinical context information in longitudinal claims data. Value Health 2018;21:1390-8.

Meid A, Haefeli WE. Realitäts-Check in der Pharmakoepidemiologie. MMP 2018;41:81-6.

Morath B, Green K, Zaradzki M, Heid J, Karck M, Hoppe-Tichy T. Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report. Eur J Clin Pharmacol 2018;74:675-7.

Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. Eur J Clin Pharmacol 2018;74:1405-15.

Muhlack DC, Hoppe LK, Stock C, Haefeli WE, Brenner H, Schöttker B. The associations of geriatric syndromes and other patient characteristics with the current and future use of potentially inappropriate medications in a large cohort study. Eur J Clin Pharmacol 2018;74:1633-44.

Muth C, Uhlmann L, Haefeli WE, Rochon J, van den Akker M, Perera R, Güthlin C, Beyer M, Oswald F, Valderas JM, Knottnerus JA, Gerlach FM, Harder S. Effectiveness of a complex intervention 1 on PRIoritising Multimedication in Multimorbidity (PRIMUM) in primary care: results of a pragmatic cluster-randomised controlled trial. BMJ Open 2018;8:e017740.

Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, Gnant M, Bachleitner-Hofmann T, Scherer D, Ulrich CM, Stabuc B, Puntoni M, Coccia G, Petrera M, Haefeli WE, DeCensi A. High accumulation of metformin in colonic tissue of subjects with diabetes or metabolic syndrome. Gastroenterology 2018;154:1543-5 (letter).

Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mihajlovic Mislej E, Stabuc B, Gnant M, Bachleitner-Hofmann T, Roth W, Scherer D, Haefeli WE, Ulrich CM, De Censi A. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. BMC Cancer 2018;18:1210.

Pottier C, Kriegsmann M, Alberts D, Smargiasso N, Baiwir D, Mazzucchelli G, Herfs M, Fresnais M, Casadonte R, Delvenne P, De Pauw E, Longuespée R. Microproteomic profiling of high-grade squamous intraepithelial lesion of the cervix: insight into biological mechanisms of dysplasia and new potential diagnostic markers. Proteomics Clin Appl. 2018 Aug 10:e1800052.

Reber KC, König HH, Becker C, Rapp K, Büchele G, Mächler S, Lindlbauer I. Development of a risk assessment tool for osteoporotic fracture prevention: A claims data approach. Bone 2018;110:170-6.

Rigalli JP, Tocchetti GN, Weiss J. Modulation of ABC transporters by nuclear receptors. Physiological, pathological and pharmacological aspects. Curr Med Chem 2018;25:1-34.

Rigalli JP, Reichel M, Reuter T, Tocchetti GN, Dyckhoff G, Herold-Mende C, Theile D, Weiss J. The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma. Plos One 2018;10:1-17.

Rigalli JP, Reichel M, Tocchetti GN, Reuter T, Dyckhoff G, Herold-Mende C, Weiss J. Human papilloma virus (HPV) 18 proteins E6 and E7 up-regulate ABC transporters in oropharyngeal carcinoma. Involvement of the nonsense-mediated decay (NMD) pathway. Cancer Lett 2018;428:69-76.

Roesch S*, Lindner T*, Sauter M*, Loktev A, Flechsig P, Müller M, Mier W, Warta R, Dyckhoff G, Herold-Mende C, Haberkorn U, Altmann A. Comparative study of the RGD motif-containing ITG?v?6 binding peptides SFLAP3 and SFITGv6 for diagnostic application in HNSCC. J Nucl Med 2018;59:1679-85.

Rufener R, Ritler D, Zielinski J, Dick L, Teixeira da Silva E, da Silva Araujo A, Joekel DE, Czock D, Goepfert C, Marques Moraes A, Nora de Souza MV, Müller J, Mevissen M, Hemphill A, Lundström-Stadelmann A. Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis. Int J Parasitol Drugs Drug Resist 2018;8:331-40.

Schmitz M, Joannidis M, Czock D, John S, Jörres A, Klein SJ, Oppert M, Schwenger V, Kielstein J, Zarbock A, Kindgen-Milles D, Willam C. [Regional citrate anticoagulation in renal replacement therapy in the intensive care station: Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI]. Med Klin Intensivmed Notfmed 2018;113:377-83.

Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller A-V, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. A phase 1 trial extension to 1 assess immunologic efficacy and safety of prime – boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. Oncoimmunology 2018;7:e1303584 *equal contribution

Schwenger V, Kindgen-Milles D, Willam C, Jörres A, Druml W, Czock D, Klein SJ, Oppert M, Schmitz M, Kielstein JT, Zarbock A, Joannidis M, John S. [Extracorporeal renal replacement therapy in acute kidney injury: Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI]. Med Klin Intensivmed Notfmed 2018;113:370-6.

Seidling HM, Woltersdorf R. Verbesserung der Arzneimitteltherapie-sicherheit mit und für den Patienten. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018;61:1082-7.

Send AFJ, Bittmann J, Dyckhoff G, Haefeli WE, Seidling HM. What do laypeople consider "medication" and are they aware of modulators of a drug’s effects? Eur J Hosp Pharm 2018;25:218-21.

Strauß B, Seidling H, Wehrmann U, Szecsenyi J, Haefeli WE, Wensing M, Mahler C. Nutzen eines Medikationsplans aus Sicht der Bürger – eine qualitative Befragung. Gesundheitswesen 2018;80:700-7.

Theile D, Mikus G. Methadone against cancer: lost in translation. Int J Cancer 2018;143:1840-8.

Tikk K*, Czock D*, Haefeli WE, Kopp-Schneider A, Brenner H. Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms. BMC Cancer 2018;18:914-22.

Tocchetti GN, Dominguez CJ, Zecchinati F, Arana MR, Ruiz ML, Villanueva SSM, Mottino AD, Weiss J, Rigalli JP. Inhibition of multidrug resistance-associated protein 2 (MRP2) activity by the contraceptive nomegestrol acetate in HepG2 and Caco-2 cells. Eur J Pharm Sci 2018;122:205-13.

Tocchetti GN, Dominguez CJ, Zecchinati F, Arana MR, Ruiz ML, Villanueva SS, Weiss J, Mottino AD, Rigalli JP. Biphasic modulation of cAMP levels by the contraceptive nomegestrol acetate. Impact on P-glycoprotein expression and activity in hepatic cells. Biochem Pharmacol 2018;154:118-26.

Tocchetti GN, Arias A, Arana MR, Rigalli JP, Dominguez CJ, Zecchinati F, Ruiz ML, Villanueva SS, Mottino AD. Acute regulation of multidrug resistance-associated protein 2 localization and activity by cAMP and estradiol-17?-D-glucuronide in rat intestine and Caco-2 cells. Arch Toxicol 2018;92:777-88.

Vay M, Majewsky M, Mikus G. Isotopically labelled paroxetine standard allows for definite structure elucidation of the paroxetine MS/MS spectrum. Rapid Commun Mass Spectrom 2018;32:1311-2.

Vay M, Foerster K, Mahmoudi M, Seessle J, Mikus G. No alteration of voriconazole concentration by plasmapheresis in a critically ill patient. Eur J Clin Pharmacol 2018;75:287-8.

von Buedingen F, Hammer MS, Meid AD, Müller WE, Gerlach FM, Muth C. Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice. BMC Fam Pract 2018;19:1-11.

Wurmbach VS, Lampert A, Schmidt SJ, Bernard S, Thürmann PA, Seidling HM, Haefeli WE. [Simplifying complex drug therapies: Challenges and solutions]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018;61:1146-51.

Ziesenitz VC, Haefeli WE, van den Anker JN, Gorenflo M. No, we are not – we keep forgetting the right ventricle. Eur J Clin Pharmacol 2018;74:141-3.
 
Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of fentanyl and its derivatives in children: a comprehensive review. Clin Pharmacokinet 2018; 57: 125-49.

Buchbeiträge  

Czock D. Medikamentendosierung bei Niereninsuffizienz. Lehrbuch für Nieren- und Hochdruckkrankheiten 2018:339-44.

Weißenborn M, Seidling HM, Haefeli WE. Arzt und Apotheker im Dialog. Arbeitsbuch für eine erfolgreiche Zusammenarbeit. ISBN 978-3-7741-1408-1, S. 1-80.

In Press   

Ceballos MP, Rigalli JP, Cere LI, Semeniuk M, Catania VA, Ruiz ML. Regulation of ABC transporters and its association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem 2018 (review)

Geist MJP, Egerer G, Mikus G, Blank A, Hohmann N, Heinz W, Carls A. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions. Basic Clin Pharmacol Toxicol 2018.  

Kazdal D, Longuespée R, Dietz S, Casadonte R, Schwamborn K, Volckmar AL, Kriegsmann J, Kriegsmann K, Fresnais M, Stenzinger A, Sültmann H, Warth A, Kriegsmann M. Digital PCR After MALDI Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. Proteomics Clin Appl 2018;e1800034.

Kriegsmann K, Longuespée R, Hundemer M, Zgorzelski C, Casadonte R, Schwamborn K, Weichert W, Schirmacher P, Harms A, Kazdal D, Leichsenring J, Stenzinger A, Warth A, Fresnais M, Kriegsmann J, Kriegsmann M. Combined immunohistochemistry after mass spectrometry imaging for superior spatial information. Proteomics Clin Appl 2018;23:e1800035.

Lampert A, Haefeli WE, Seidling HM. Information gaps in package inserts cause insufficient patient information on correct handling of transdermal patches. Dtsch Med Wochenschr 2018.

Lampert A, Haefeli WE, Seidling HM. Reasons for drug administration problems and perceived needs for assistance of patients, family caregivers, and nurses: A qualitative study. J Patient Saf 2018. epub ahead of print.

Longuespée R, Kriegsmann K, Cremer M, Zgorzelski C, Casadonte R, Kazdal D, Kriegsmann J, Weichert W, Schwamborn K, Fresnais M, Schirmacher P, Kriegsmann M. In MALDI mass spectrometry imaging on formalin-fixed paraffin-embedded tissue specimen section thickness significantly influences m/z peak intensity. Proteomics Clin Appl 2018;e1800074.

Pottier C, Kriegsmann M, Alberts D, Smargiasso N, Baiwir D, Mazzucchelli G, Herfs M, Fresnais M, Casadonte R, Delvenne P, De Pauw E, Longuespée R. Microproteomic profiling of high-grade squamous intraepithelial lesion of the cervix: insight into biological mechanisms of dysplasia and new potential diagnostic markers. Proteomics Clin Appl 2018.e1800052.

Quinzler R, Freitag MH, Wiese B, Beyer M, Brenner H, Dahlhaus A, Döring A, Freund T, Heier M, Knopf H, Luppa M, Prokein J, Riedel-Heller S, Schäfer I, Scheidt-Nave C, Scherer M, Schöttker B, Szecsenyi J, Thürmann P, van den Bussche H, Gensichen J, Haefeli WE. A novel superior medication-based chronic disease score (medCDS) predicted all-cause mortality in independent geriatric cohorts. J Clin Epidemiol 2018.

Rigalli JP, Scholz PN, Tocchetti GN, Ruiz M, Weiss J. The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells. Potential chemosensitizing effect. Eur J Nutr 2018.

Schäfer J, Weiss J, Theile D. Bosentan enhances in vitro bortezomib’s antiproliferative potency against multiple myeloma by mechanisms going beyond endothelin receptor blockade. Br. J Haematol 2018 (letter).

2017

 

Amelung S, Meid AD, Nafe M, Thalheimer M, Hoppe-Tichy T, Haefeli WE, Seidling HM. Association of preventable adverse drug events with inpatients’ length of stay - a propensity-matched cohort study. Int J Clin Pract 2017;DOI:10.111/ijcp.12990.  

Arana MR, Tocchetti GN, Zecchinati F, Londero AS, Dominguez C, Perdomo V, Rigalli JP, Villanueva SSM, Mottino AD. Glucagon-like peptide 2 prevents down-regulation of intestinal multidrug resistance-associated protein 2 and P-glycoprotein in endotoxemic rats. Toxicology 2017;390:22-31.   

Arns W, Huppertz A, Rath T, Ziefle S, Rump LC, Hansen A, Budde K, Lehner LJ, Shipkova M, Baeumer D, Kroeger I, Sieder C, Klein T, Schenker P. Pharmacokinetics and clinical outcomes of generic tacrolimus (Hexal) versus branded tacrolimus in de novo kidney transplant patients: a multicenter, randomized trial. Transplantation 2017;101:2780-8.

Bajraktari G, Burhenne J, Bugert, P, Haefeli WE, Weiss J. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. Biochem Pharmacol 2017;145:54-63.

Bernhard G, Ose D, Baudendistel I, Seidling HM, Stützle M, Szecsenyi J, Wensing M, Mahler C. Understanding Challenges, Strategies, and the Role of Support Networks in Medication Self-management Among Patients With Type 2 Diabetes. Diabetes Educator 2017;43:190-205.

Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, van de Graaf SFJ, Meyer MR, Maurer HH, Meier K, Weiss J, Bruckner T, Alexandrov A, Urban S, Mikus G, Haefeli WE. The NTCP - inhibitor myrcludex B: pharmacodynamic effects on bile acids and its combination with tenofovir. Clin Pharmacol Ther 2017.

Blank A, Meier K, Urban S, Haefeli WE, Weiss J. Drug-drug interaction potential of the hepatitis B and hepatitis D virus entry inhibitor myrcludex B assessed in vitro. Antivir Ther 2017;DOI:10.3851/IMP3206.

Bock JO, Hajek A, Brenner H, Saum KU, Matschinger H, Haefeli WE, Quinzler R, Heider D, König HH. A longitudinal investigation of willingness to pay for health insurance in Germany. Health Serv Res 2017;52:1099-117.  

Brandt SD, Kavanagh PV, Dowling G, Talbot B, Westphal F, Meyer MR, Maurer HH, Halberstadt AL. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives. Drug Test Anal 2017;9:115-26.

Breithaupt-Groegler K, Coch C, Coenen M, Donath F, Erb-Zohar K, Francke K, Goehler K, Iovino M, Kammerer KP, Mikus G, Rengelshausen J, Sourgens H, Schinzel R, Sudhop T, Wensing G. Who is a ‘healthy subject’? – Consensus results on pivotal eligibility criteria for clinical trials. Eur J Clin Pharmacol 2017;73:409-16.

Burhenne J, Liu L, Heilig CE, Meid AD, Leisen M, Schmitt T, Kasper B, Haefeli WE, Mikus G, Egerer G. Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. Cancer Chemother Pharmacol 2017;80:433-9.

Clemens J, Welti L, Schäfer J, Seckinger A, Burhenne J, Theile D, Weiss J. Bortezomib, carfilzomib, and ixazomib do not mediate relevant transporter-based drug-drug interactions. Oncol Lett 2017;14:3185-92.

Doricakova A*, Theile D*, Weiss J^*, Vrzal R^*. Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4. Naunyn Schmiedebergs Arch Pharmacol 2017;390:49-59.

Enderle Y, Witt L, Wilkens H, Grünig E, Haefeli WE, Burhenne J. Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. J Pharm Biomed Anal 2017;143:291-8.

Faller CK, Lampert A, Haefeli WE, Seidling HM. Beitrag einer Servicestelle zur Sicherstellung der Rezeptqualität an einem Klinikum. Krankenhauspharmazie 2017;38:116.

Grünig E, Ohnesorge J, Benjamin N, Burhenne J, Enderle Y, Egenlauf B, Fischer C, Harutyunova S, Huppertz A, Klose H, Haefeli WE. Plasma drug-concentrations in patients with pulmonary arterial hypertension on combination treatment. Respiration 2017;94:26-37. 

Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS. Population pharmacokinetic model linking plasma and peripheral blood mononuclear cells (PBMCs) concentrations of efavirenz and its metabolite, 8-hydroxy-efavirenz in HIV patients. Antimicrob Agents Chemother 2017;61:e00207-17.

Hajek A, Bock JO, Brenner H, Saum KU, Matschinger H, Haefeli WE, Quinzler R, Heider D, König HH. Which factors affect out-of-pocket payments for health care services among elderly germans? Results of a longitudinal study. Gesundheitswesen 2017;79:e18-e25. 

Harnoss JM, Platzer LK, Burhenne J, Radhakrishnan P, Cai J, Strowitzki MJ, Weiss J, Ritter AS, Mollenhauer M, Schmidt T, Ulrich A, Haefeli WE, Schneider M. Prolyl hydroxylase inhibition enhances liver regeneration without induction of tumor growth. Ann Surg 2017;265:782-91.

Hassel JC, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, Halama N, Dimitrakopoulou-Strauss A, Haefeli WE, Jäger D, Enk A, Utikal J, Umansky V. Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). Oncoimmunology 2017;6:e1326440.

Heider D, Matschinger H, Meid AD, Quinzler R,  Adler JB, Günster C,  Haefeli WE, König HH. Health service use, costs and adverse events associated with potentially inappropriate medication in old age in Germany: retrospective matched cohort study. Drugs Aging 2017;34:278-301.

Hinderhofer K*, Mechler K*, Hoffmann GF, Lampert A, Mountford WK, Ries M. Critical appraisal of genotype assessment in molybdenum cofactor deficiency. Journal of Inherited Metabolic Disease 2017;40:801-11.

Högl B, Lohner H, Mikus G, Huff C: Acute and painful exacerbation of RLS and PLM induced by opioid interaction - withdrawal syndrome. Sleep Medicine 2017;36:186-7. 

Hohmann N, Kreuter R, Blank A, Weiss J, Burhenne J, Haefeli WE, Mikus G. Auto-inhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. Br J Clin Pharmacol 2017;83:1954-65.

Hossain A, Tran T, Chen T, Mikus G, Greenblatt DJ. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. J Pharm Pharmacol 2017;69:1786-93.

Kuhn C, Lehmann ML, Kress A, Truss MC, Hermes M, Blaszkewicz M, Hengstler JG, Golka K. Micro-brushing-based technique to gain fresh urothelial cells for gene expression analysis.J Toxicol Env Heal A 2017;80:411-6.

Lampert A, Haefeli WE, Seidling HM. Zu Risiken und Nebenwirkungen lesen Sie die Packungsbeilage UND fragen Sie Ihren Arzt oder Apotheker. Krankenhauspharmazie 2017;38:110.  

Londero AS, Arana MR, Perdomo VG, Tocchetti GN, Zecchinati F, Ghanem CI, Ruiz ML, Rigalli JP, Mottino AD, García F, Villanueva SSM. Intestinal multidrug resistance-associated protein 2 is down-regulated in fructose-fed rats. J Nutr Biochem 2017;40:178-86.

Mahmoudi M, Brenner T, Hatiboglu G, Burhenne J, Weiss J, Weigand MA, Haefeli WE. Substantial impairment of voriconazole clearance by high-dose meropenem in a patient with renal failure. Clin Infect Dis 2017;65:1033-6.

Mardal M, Kinyua J, Ramin P, Miserez B, Van Nuijs AL, Covaci A, Meyer MR. Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques. Drug Test Anal 2017;9:106-14.

Mayer T, Meid AD, Saum K-U, Brenner H, Schöttker B, Seidling HM, Haefeli WE. Comparison of nine instruments to calculate anticholinergic load in a large cohort of older outpatients: association with cognitive and functional decline, falls, and use of laxatives. Am J Geriatr Psychiatry 2017;25:531-40.    

Mayer T, Haefeli WE, Seidling HM. Vorgehen bei der Erkennung, Bewertung und Vermeidung anticholinerger Nebenwirkungen - eine Querschnittsbefragung unter Ärzten. Krankenhauspharmazie 2017;38:111. 

Medem AV, Seidling HM, Eichler H-G, Kaltschmidt J, Metzner M, Hubert CM, Czock D, Haefeli WE. Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics. Eur J Clin Pharmacol 2017;73:633-41.

Meid AD, von Medem A, Heider D, Adler J-B, Günster C, Seidling HM, Quinzler R, König HH, Haefeli WE. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf 2017;40:133-44. 

Meid AD, Groll A, Schieborr U, Walter J, Haefeli WE. How can we define and Analyse drug exposure more precisely to improve the prediction of hospitalizations in lonitudinal (claims) data? Eur J Clin Pharmacol 2017;73:373-80. 

Meid AD, Bighelli I, Mächler S, Mikus G, Carrà G, Castellazzi M, Lucii C, Martinotti G, Nosè M, Ostuzzi G, the STAR NETWORK INVESTIGATORS (full list in acknowledgment), Barbui C, Haefeli WE. Combinations of QTc-prolonging drugs: Towards disentangling pharmacokinetic and pharmacodynamic effects in their potential additivity. Ther Adv Psychopharmacol 2017;7:251-64.

Meid AD, Mächler S, Haefeli WE, Mikus G. Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies. Br J Clin Pharmacol 2017;83:2321-24. 

Meid AD, Haefeli WE. Refining estimates of prescription durations by using observed covariates in pharmacoepidemiologic databases: necessary refinements to stimulate alternative approaches. Pharmacoepidemiol Drug Saf 2017;26:1135-37.

Mikus G, Heinrich T, Bödigheimer J, Röder C, Matthee AK, Weiss J, Burhenne J, Haefeli WE. Semisimultaneous midazolam administration to evaluate the time course of CYP3A activation by a single oral dose of efavirenz. J Clin Pharmacol 2017;57:899-905. 

Mikus G, Foerster K. Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity. Transl Cancer Res 2017;6:1592-99.

Mikus G, Foerster K. Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity. Transl Cancer Res 2017;6:1592-99. 

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J 2017;19:298-312.  

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T. A physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemother Pharmacol 2017;80:1013-26

Morath B, Mayer T, Send A, Hoppe-Tichy T, Haefeli WE, Seidling HM. Pharmazeutisch beeinflussbare Risikofaktoren für Rehospitalisierungen oder unerwünschte Arzneimittelwirkungen nach Krankenhausentlassung - eine systematische Übersichtsarbeit. Krankenhauspharmazie 2017;38:111-12.   

Morath B, Mayer T, Send AFJ, Hoppe-Tichy T, Haefeli WE, Seidling HM. Risk factors of adverse health outcomes after hospital discharge modifiable by clinical pharmacist interventions - a review with a systematic approach. Br J Clin Pharmacol 2017;83:2163-78.   

O’Brien T, Wells JCD, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, Mikus G, Morlion BJ, Perez-Cajaraville J, Pogatzki-Zahn E, Varrassi G. European Pain Federation (EFIC) position paper on appropriate opioid use in chronic pain management. Eur J Pain 2017;21:3-19. 

Podszun MC, Jakobi M, Birringer M, Weiss J, Frank J. The long chain α–tocopherol metabolite α-13’-COOH and γ-tocotrienol induce P-glycoprotein expression and activity by activation of the pregnane X receptor in the intestinal cell line LS 180. Mol Nutr Food Res 2017;61(3):1600605.

Saronga HP, Duysburgh E, Massawe S, Dalaba MA, Wangwe P, Sukums F, Leshabari M, Blank A, Sauerborn R, Loukanova S. Cost-effectiveness of an electronic clinical decision support system for improving quality of antenatal and childbirth care in rural Tanzania: an intervention study. BMC Health Serv Res 2017;17:537.

Saum KU, Schöttker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, Brenner H. Is polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J Am Geriatr Soc 2017;65:e27-e32. 

Seidling HM, Send AF, Bittmann J, Renner K, Dewald B, Lange D, Bruckner T, Haefeli WE. Medication review in German community pharmacies - Post-hoc analysis of documented drug-related problems and subsequent interventions in the ATHINA-project. Res Social Adm Pharm 2017;13:1127-34.

Send AFJ, Peters-Klimm F, Bruckner T, Haefeli WE, Seidling HM. A randomized controlled trial to assess the effect of a medication plan containing drug administration recommendations on patient’s drug knowledge after 2 months. J Clin Pharm Ther 2017;42:69-74

Send AFJ, Ancker JS, Abramson E. Entwicklung einer Broschüre und eines Dosisrechners zur Unterstützung der Verabreichung von flüssigen Peroralia in der ambulanten pädiatrischen Versorgung in den USA. Krankenhauspharmazie 2017;38:113.

Slijepcevic D, Roscam Abbing RLP, Katafuchi T, Blank A, Donkers JM, van Hoppe S, de Waart DR, Tolenaars D, van der Meer J, Wildenberg M, Beuers U, Oude Elferink RPJ, Schinkel AH van de Graaf SFJ. Hepatic uptake of conjugated bile acids mediated by both NTCP and OATPs is modulated by intestinal sensing of plasma bile acid levels in mice. Hepatology 2017;66:1631-43.

Suzuki Y, Witt L, Mier W, Mikus G, Markert C, Haefeli WE, Burhenne J. Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal 2017;142:84-90. 

Schäfer J, Welti L, Seckinger A, Burhenne J, Theile D, Weiss J. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient. Cancer Chemother Pharmacol 2017;80:71-9.

Theile D, Hohmann N, Kiemel D, Gattuso G, Barreca D, Mikus G, Haefeli WE, Schwenger V, Weiss J. Clementine juice has the potential for drug interactions - in vitro comparison with grapefruit and mandarin juice. Eur J Pharm Sci 2017;97:247-56.

Theile D. Under-reported aspects of platinum drug pharmacology. Molecules 2017;22:2-8.   

Theile D*, Geng S*, Denny EC, Momand J, Kane SE. t-Darpp stimulates protein kinase a activity by forming a complex with its RI regulatory subunit. Cell Signal 2017;40:53-61.

Tocchetti GN, Arias A, Arana MR, Rigalli JP, Dominguez CJ, Zecchinati F, Ruiz ML, Villanueva SS, Mottino AD. Acute regulation of multidrug resistance-associated protein 2 localization and activity by cAMP and estradiol-17β-D-glucuronide in rat intestine and Caco-2 cells. Arch Toxicol 2017.

Vaughns JD, Ziesenitz VC, Williams EF, Mushtaq A, Bachmann R, Skopp G, Weiss J, Mikus G, van den Anker JN. Use of Fentanyl in adolescents with clinically severe obesity undergoing bariatric surgery - A pilot study. Paediatr Drugs 2017;19:251-7.

Volz AK, Krause A, Haefeli WE, Dingemanse J, Lehr T. A target-mediated drug disposition pharmacokinetic-pharmacodynamic model of bosentan and endothelin-1. Clin Pharmacokinet 201756:1499-511.

von Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Edler L, Munzinger J, Efferth T, Schneeweiss A, Strowitzki T. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast Cancer Res Treat 2017;164:359-69.

Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, van Herk-Sukel MPP, Vissers PAJ, Brenner H. Pre- and post-diagnostic beta blocker use and lung cancer survival: A comprehensive population-based cohort study. Sci Rep 2017;7:2911. 

Weinheimer M, Fricker G, Burhenne J, Mylius P, Schubert R. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - an in vitro and in vivo comparison. Eur J Pharm Sci 2017;108:13-22.

Weiss J, Kocher J, Mueller C. Rosenzweig R, Theile D. Impact of enzalutamide and ist main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug Transporters. Biopharm Drug Dispos 2017;38:517-25.   

Weißenborn M, Haefeli WE, Seidling HM. Entwicklung eines Handbuches zur Verbesserung der Zusammenarbeit zwischen Ärzten und Apothekern im ambulanten Bereich. Krankenhauspharmazie 2017;38:115.

Weißenborn M, Haefeli WE, Peters-Klimm F, Seidling HM. Interprofessional communication between community pharmacists and general practitioners: a qualitative study. Int J Clin Pharm 2017;39:495-506. 

Wolfert C, Merbach M, Stammler G, Emrich O, Meid AM, Burhenne J, Blank A, Mikus G. Chronisches Schmerzmanagement mit retardiertem Tilidin - Lebensqualität und Bedeutung der Komedikation auf den Tilidin Metabolismus. Der Schmerz 2017;31:516-23. 

Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of fentanyl and its derivatives in children: a comprehensive review. Clin Pharmacokinet 2017.

Buchbeiträge

Seidling HM, Walter-Sack I, Haefeli WE, Czock D, Ziesenitz V, Send AF, Blank A, Hohmann N, Mikus G, Lampert A. Allgemeinmedizin. Der Mentor für die Facharztprüfung und für die allgemeinmedizinische ambulante Versorgung. ISBN 978-3-13-240181-5. S. 272-288.

Theile D, Lenz G, Momand JA, Kane SE. Resistance to HER2-Targeted Therapy. Jenifer R. Prosperi (ed.), Resistance to Targeted Therapies in Breast Cancer. Springer International Publishing AG 2017. DOI 10.1007/978-3-319-70142-4_2.

2016

 

Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W, Reuter T, Meid A, Hoffmann MM, Weiss J. SLCO1B1 gene variations among Tanzanians, Ethiopians and Europeans: Relevance for African and worldwide precision medicine. OMICS 2016;20:538-45.

Arana MR, Tocchetti GN, Rigalli JP, Mottino AD, Villanueva SS. Physiological and pathophysiological factors affecting the expression and activity of the drug transporter MRP2 in intestine. Impact on its function as membrane barrier. Pharmacol Res 2016;109:32-44.

Becker JP, Clemens JR, Theile D, Weiss J. Bortezomib and ixazomib protect firefly luciferase from degradation and can flaw respective reporter gene assays. Anal Biochem 2016;509:124-9. 

Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. Myrcludex B: a first-in-human clinical study with a first-inclass hepatitis B and hepatitis D virus entry inhibitor. J Hepatol 2016;65:483-489.

Blank A, Eidam A, Lampert A, Pathil-Warth A, Mikus G. Arzneimitteltherapie in der Schwangerschaft: Risiken und Chancen im klinischen Alltag einschätzen (Drugs in pregnancy: risks and opportunities in prescribing). Gastroenterologe.2016;4:323-331.

Bock JO, Heider D, Matschinger H, Brenner H, Saum KU, Haefeli WE, König HH. Willingness to pay for health insurance among the elderly population in Germany. Eur J Health Econ 2016;17:149-58.    

Bock JO, König HH, Brenner H, Haefeli WE, Quinzler R, Matschinger H, Saum KU, Schöttker B, Heider D. Associations of frailty with health care costs - results of the ESTHER cohort study. BMC Health Serv Res 2016;16:128-38.     

Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Interim results of a Phase Ib/IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients. J Hepatol 2016;65:490-498

Dettmer S, Theile D, Schäfer J, Seckinger A, Burhenne J, Weiss J. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines. Naunyn Schmiedebergs Arch Pharmacol 2016;389:1091-1101. 

Doering JH*, Lampert A*, Hoffmann GF, Ries M. Thirty years of orphan drug legislation and the development of drugs to treat rare seizure conditions: a cross sectional analysis. PLoS One 2016, Aug 24;11(8):e0161660. doi: 10:1371/journal.pone.0161660.                                   

Duysburgh E, Temmerman M, Yé M, Williams A, Massawe S, Williams J, Mpembeni R, Loukanova S,  Haefeli WE, Blank A. Quality of antenatal and childbirth care in rural health facilities in Burkina Faso, Ghana and Tanzania: an intervention study.Trop Med Int Health 2016;21:70-83.  

Enderle Y, Foerster K, Burhenne J. Clinical feasibility of Dried Blood Spots: analytics, validation, and applications. J Pharm Biomed Anal 2016;130:234-43. 

Faller CK, Haefeli WE, Seidling HM. How to move an elephant. Qualität der Rezepte in einem Universitätsklinikum und Konsequenzen für die öffentliche Apotheke. DAZ 2016;38:56-61.

Gade C, Mikus G, Christensen HR, Dalhoff KP, Holm JC, Holst H. The CYTONOX trial. Dan Med J 2016;63:A5226. 

Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J. Long-term effect of rifampicin-based antiTB regimen co-administration on the pharmacokinetic parameters of efavirenz and 8-hydroxy-efavirenz in HIV infected and TB-HIV co-infected Ethopian patients. J Clin Pharmacol 2016;56:1538-49.

Hohmann, N, Maus A, Carls A, Haefeli WE, Mikus G:  St. John's Wort treatment in women bears risks beyond pharmacokinetic drug interactions. Arch Toxicol 2016;90:1013-1015.  

Hohmann N, Haefeli WE, Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol 2016;12:479-97.

Hohmann N, Reinhard R, Schnaidt S, Witt L, Carls A, Burhenne J, Mikus G, Haefeli WE. Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans. J Antimicrob Chemother 201;71(8):2241-7.

Hohmann N, Xia N, Steinkamp-Fenske K, Förstermann U, Li H. Estrogen receptor signaling and the PI3K/Akt pathway are involved in betulinic acid-induced eNOS activation. Molecules 2016;21:973.

Hohmann N, Kocheise F, Carls A, Burhenne J, Weiss J, Haefeli WE, Mikus G. Dose-dependent bioavailability and CYP3A-inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet 2016;55:1535-45.

König M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Sertel S. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother Pharmacol 2016;77:413-27. 

Lampert A, Hoffmann GF, Ries M. Ten Years after the International Committee of Medical Journal Editors' Clinical Trial Registration Initiative, One Quarter of Phase 3 Pediatric Epilepsy Clinical Trials Still Remain Unpublished: A Cross Sectional Analysis. PLoS One 2016;11:e0144973.

Lampert A, Wien K, Haefeli WE, Seidling HM. Guidance on how to develop comprehensible patient information leaflets in four steps. Int J Qual Health Care 2016;28:634-638.

Londero AS, Arana MR, Perdomo VG, Tocchetti GN, Zecchinati F, Ghanem CI, Ruiz ML, Rigalli JP, Mottino AD, Garcia F, Villanueva SSM. Intestinal multidrug resistance-associated protein 2 is down-regulated in fructose-fed rats. J Nutr Biochem 2016;40:178-86.

Lutz T, Lampert A, Hoffmann GF, Ries M. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US Orphan Drug Act. Orphanet J Rare Dis. equal contribution.

Mächler S, Meid AD, Send AFJ, Quinzler R, Freigofas J, Haefeli WE. Vor dem Essen - zum Essen - nach dem Essen? Welche Rolle spielen Essenshinweise auf Medikationsplänen? DAZ 2016;22:58-65. 

Mächler S, Meid AD, Quinzler R, Haefeli WE. Ist mangelhafte Qualität von Medikationsplänen mit arzneimittelbezogenen Problemen assoziiert? Eine Pilotstudie. eHealth Journal 2016;1:26-31.

Mardal M, Miserez B, Bade R, Portolés T, Bischoff M, Hernández F, Meyer MR. 3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques. J Pharm Biomed Anal 2016;128:485-95. 

Maurer HH, Meyer MR. High-resolution mass spectrometry in toxicology: current status and future perspectives. Arch Toxicol 2016;90:2161-72. 

Mayer T, Kopitz J, Plaschke K, Weiss J, Seidling HM, Haefeli WE. Limitations of the anticholinergic activity assay and consequences for its clinical application. Am J Geriatr Psychiatry 2016;12:1182-8.

Meid AD, Haefeli WE. Age-dependent impact of medication underuse and strategies for improvement. Gerontology 2016;62:491-9.

Meid AD, Quinzler R, Groll A, Wild B, Saum K-U, Schöttker B, Heider D, König H-H, Brenner H, Haefeli WE. Longitudinal evaluation of medication underuse in older outpatients and its association with quality of life. Eur J Clin Pharmacol 2016 Mar 29 epub ahead of print.

Meid AD, Heider D, Adler J-B, Quinzler R, Brenner H, Günster C, König H-H, Haefeli WE. Comparative evaluation of methods approximating drug prescription durations in claims data: Modeling, simulation, and application to real data. Pharmacoepidemiol Drug Saf 2016;25:1434-42.

Meyer GM, Maurer HH, Meyer MR. Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology. Bioanalysis 2016;8:457-81.

Meyer MR. New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. Arch Toxicol 2016;90:2421-44.  

Meyer MR, Maurer HH. Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices - Where do we stand today? Anal Chim Acta 2016;927:13-20.   

Meyer MR, Bergstrand MP, Helander A, Beck O. Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Anal Bioanal Chem 2016;408:3571-91.

Meyer MR, Hübschmann HJ. Handbook of GC-MS: fundamentals and applications, 3rd ed. Anal Bioanal Chem 2016;408:1535-6.

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New insights into drug-drug interactions and co-medication regimens. AAPS J 2016.

Muth C, Harder S, Uhlmann L, Rochon J, Fullerton B, Güthlin C, Erler A, Beyer M, van den Akker M, Perera R, Knottnerus A, Valderas JM, Gerlach FM, Haefeli WE. Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot). BMJ Open 2016;6:e011613. 

Nylén H, Habtewold A, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study. Medicine (Baltimore). 2016 Aug;95(34):e4631.

Outeiro N, Hohmann N, Mikus G. No increased risk of ketoconazole toxicity in drug-drug interaction studies. J Clin Pharmacol 2016;56:1203-1211.

Perdomo VG, Rigalli JP, Luquita MG, Pellegrino JM, Ruiz ML, Catania VA. Up-regulation of ATP-binding cassette transporters in the human macrophagic cell line THP-1 by the antichagasic benznidazole. Mem Inst Oswaldo Cruz 2016;111:707-11.

Richter LH, Kaminski YR, Noor F, Meyer MR, Maurer HH. Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Anal Bioanal Chem 2016;408:6283-94.

Rigalli JP, Tocchetti GN, Arana RM, Villanueva SSM, Catania VA, Theile D, Ruiz ML, Weiss J. The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Letters 2016, epub ahead of print

Rigalli JP, Perdomo VG, Ciriaci N, Frances DE, Ronco MT, Bataille AM, Ghanem CI, Ruiz ML, Manautou JE, Catania VA. The tripanocidal Benznidazole promotes adaptive response to oxidative injury. Involvement of the nuclear factor-erythroid 2-related factor-2 (Nrf2) and multidrug resistance associated protein 2 (MRP2). Toxicol Appl Pharmacol 2016;304:90-8.

Rigalli JP, Ciriaci N, Mottino AD, Catania VA, Ruiz ML. Modulation of expression and activity of ABC transporters by the phytoestrogen genistein. Impact on drug disposition. Curr Med Chem 2016;23:1370-89.

Saum K-U, Schöttker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, Brenner H. Is polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J AM Geriatr Soc 2016 Dec 26. doi:10/111/jgs.14718. epub ahead of print.  

Seidling HM, Faller CK, Thalheimer M, Bruckner T, Haefeli WE. Formal prescribing errors are substantially reduced in electronic prescribing and after teaching sessions. Dtsch Med Wochenschr 2016;141:e1-7. 

Seidling MH, Stützle M, Hoppe-Tichy T, Allenet B, Bedouch P, Bonnabry P, Coleman JJ, Fernandez-Llimos F, Lovis C, Rei MJ, Störzinger D, Taylor LA, Pontefract SK, van den Bemt PMLA, van der Sijs H, Haefeli WE. Best practice strategies to safeguard drug prescribing and drug administration – an anthology of expert views and opinions. Int J Clin Pharm 2016;38:362-73. 

Schmitt T, Mayer-Steinacker R, Mayer F, Grünwald V, Schütte J, Hartmann JT, Kasper B, Hüsing J, Hajda J, Ottawa G, Mechtersheimer G, Mikus G, Burhenne J, Lehmann L, Heilig C, Ho AD, Egerer G: Vorinostat in refractory soft tissue sarcomas - results of a multi-center phase II trial of the German Soft Tissue Sarcoma and Bone Tumor Working Group (AIO). Eur J Cancer 2016;64:74-82.

Stockklausner C*, Lampert A*,  Hoffmann GF, Ries M. Novel Treatments for Rare Cancers: The US Orphan Drug Act is Delivering. A Cross-Sectional Analysis. Oncologist 2016 Apr;21(4):487-93.

Theile D, Kos M. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs. Toxicol Lett 2016;242:47-52.   

Tocchetti GN, Rigalli JP, Arana MR, Villanueva SS, Mottino AD. Modulation of expression and activity of intestinal multidrug resistance-associated protein 2 by xenobiotics. Toxicol Appl Pharmacol 2016;303:45-57.

Wagmann L, Meyer MR, Maurer HH. What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett 2016;258:55-70.  

Weiss J, Gajek T, Köhler B, Haefeli WE. Venetoclax (ABT-199) might act as a perpetrator in pharmacokinetic drug-drug interactions. Pharmaceutics 2016;8:5. 

Witt L, Suzuki Y, Hohmann N, Mikus G, Haefeli WE, Burhenne J. Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1027:207-13.

2015

 

Boehlen F, Herzog W, Quinzler R, Haefeli WE, Maatouk I, Niehoff D, Saum KU, Brenner H, Wild B. Loneliness in the elderly is associated with the use of psychotropic drugs. Int J Geriatr Psychiatry 2015;30:957-64.

Campos B, Weisang S, Osswald F, Ali R, Sedlmeier G, Bageritz J, Mallm JP, Hartmann C, von Deimling A, Popanda O, Goidts V, Plass C, Unterberg A, Schmezer P, Burhenne J, Herold-Mende C. Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia 2015;63:1850-9.

Clemens J, Seckinger A, Hose D, Theile D, Longo M, Haefeli WE, Burhenne J, Weiss J. Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemother Pharmacol 2015;75:281-91.

Czock D, Konias M, Seidling HM, Kaltschmidt J, Schwenger V, Zeier M, Haefeli WE. Tailoring of alerts substantially reduces the alert burden in computerized clinical decision support for drugs that should be avoided in patients with renal disease. J Am Med Inform Assoc 2015;22:881-7.

Czock D, Sommerer C. Niedermolekulare Heparine bei Niereninsuffizienz - Was ist bei der Anwendung zu beachten? Dialyse aktuell 2015;19:78-85.

Czock D, Spitaletta M, Keller F. Suboptimal antimicrobial drug exposure in patients with renal impairment. Int J Clin Pharm 2015;37(5):906-16.

Dettmer S*, Theile D*, Seckinger A, Burhenne J, Weiss J. Fetal calf sera can distort cell-based luminescent proteasome assays through heat-resistant chymotrypsin-like activity. Anal Biochem 2015;471:23-5.
*Equal contribution

Eichbaum C, Mathes K, Burhenne J, Markert C, Blank A, Mikus G. Pre-systemic Elimination of Tilidine: Localization and Consequences for the Formation of the Active Metabolite Nortilidine. Basic Clin Pharmacol Toxicol 2015;116:129-33.

Freigofas J, Seidling HM, Quinzler R, Schöttker B, Saum KU, Brenner H, Haefeli WE. Characteristics of medication schedules used by elderly ambulatory patients. Eur J Clin Pharmacol 2015;71:1109-20.

Haag M, Hofmann U, Mürdter TE, Heinkele G, Leuthold P, Blank A, Haefeli WE, Alexandrov A, Urban S, Schwab M. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na⁺-taurocholate cotransporting polypeptide inhibitor. Anal Bioanal Chem 2015; 407:6815-25.

Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Pharmacogenomics 2015;16:1047-64.

Haefeli WE. Arzneimitteltherapie bei betagten Patienten. Atemwegs- und Lungenkrankheiten 2015;1:21-6.

Hohmann N, Haefeli WE, Mikus G. Use of Microdose Phenotyping to Individualise Dosing of Patients. Clin Pharmacokinet 2015;54:893-900.

Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol 2015;79:278-285.

Keller F, Czock D. NephroPharmacology coming of age. Clin Nephrol 2015;84:127-9.

Keller F, Ludwig U, Czock D. Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. Expert Opin Drug Metab Toxicol 2015;11:139-47.

König HH, Lehnert T, Brenner H, Schöttker B, Quinzler R, Haefeli WE, Matschinger H, Heider D. Health service use and costs associated with excess weight in older adults in Germany. Age Ageing 2015;44:616-23.

Lohmann K, Ferber J, Haefeli M, Störzinger D, Schwald M, Haefeli WE, Seidling HM. Knowledge and training needs of nurses and physicians on unsuitable drugs for patients with dysphagia or feeding tubes. J Clin Nurs 2015;24:3016-9.

Lohmann K, Freigofas J, Leichsenring J, Wallenwein CM, Haefeli WE, Seidling HM. Development and evaluation of an algorithm to facilitate drug prescription for inpatients with feeding tubes. Eur J Clin Pharmacol 2015;71:489-97.

Lohmann K, Gartner D, Kurze R, Schösler T, Schwald M, Störzinger D, Hoppe-Tichy T, Haefeli WE, Seidling HM. More than just crushing: a prospective pre-post intervention study to reduce drug preparation errors in patients with feeding tubes. J Clin Pharm Ther 2015;40:220-5.

Markert C, Kastner IM, Hellwig R, Kalafut P, Schweizer Y, Hoffmann MM, Burhenne J, Weiss J, Mikus G, Haefeli WE. The Effect of Induction of CYP3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of known CYP2C19 Genotype. Basic Clin Pharmacol Toxicol 2015;116:423-8.

Mayer T, Haefeli WE, Seidling HM. Different methods, different results - how do available methods link a patient's anticholinergic load with adverse outcomes? Eur J Clin Pharmacol 2015;71:1299-314.

Meid AD, Lampert A, Burnett A, Seidling HM, Haefeli WE. The impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysis. Br J Clin Pharmacol 2015;80:768-76.

Meid AD, Quinzler R, Freigofas J, Saum KU, Schöttker B, Holleczek B, Heider D, König HH, Brenner H, Haefeli WE. Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study. PLoS One 2015;10:e0136339.

Mensah N, Sukums F, Awine T, Meid A, Williams J, Akweongo P, Kaltschmidt J, Haefeli WE, Blank A. Impact of an electronic clinical decision support system on workflow in antenatal care: the QUALMAT eCDSS in rural health care facilities in Ghana and Tanzania. Glob Health Action 2015;8:25756.

Mikus G. Urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions? J Anal Toxicol 2015;39:81-2.

Mikus G, Klimas R. Relative contribution of morphine and morphine-6-glucuronide to the analgesic effect after morphine administration. Br J Anaesth 2015;114:1007.

Niemann D, Bertsche A, Meyrath D, Koepf ED, Traiser C, Seebald K, Schmitt CP, Hoffmann GF, Haefeli WE, Bertsche T. A prospective three-step intervention study to prevent medication errors in drug handling in paediatric care. J Clin Nurs 2015;24:101-14.

Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, Kopp-Schneider A, Fabian J, Schober A, Fernekorn U, von Deimling A, Deubzer HE, Milde T, Witt O, Oehme I. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis 2015;6:e1657.

Reuter T, Warta R, Theile D, Meid AD, Rigalli JP, Mogler C, Herpel E, Grabe N, Lahrmann B, Plinkert PK, Herold-Mende C, Dyckhoff G, Haefeli WE, Weiss J. Role of NR1l2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology 2015;388:1141-50.

Schiele JT, Penner H, Schneider H, Quinzler R, Reich G, Wezler N, Micol W, Oster P, Haefeli WE. Swallowing tablets and capsules increases the risk of penetration and aspiration in patients with stroke-induced dysphagia. Dysphagia 2015;30:571-82.

Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology 2015;4:e1001217.

Sukums F, Mensah N, Mpembeni R, Massawe S, Duysburgh E, Williams A, Kaltschmidt J, Loukanova S, Haefeli WE, Blank A. Promising adoption of an electronic clinical decision support system for antenatal and intrapartum care in rural primary healthcare facilities in sub-Saharan Africa: The QUALMAT experience. Int J Med Inform 2015;84:647-57.

Theile D, Allendorf D, Köhler BC, Jassowicz A, Weiss J. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in MDR cell lines. J Pharm Pharmacol 2015;67:1575-84.

Theile D, Haefeli WE, Weiss J. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. Endocrine 2015;49:842-53.

Theile D, Weiss J. Comment on "Sweat but no gain": Inhibiting proliferation of multidrug resistant cancer cells with "Ersatzdroges". Int J Cancer 2015;136:2241-2.

Weiss J, Baumann S, Theile D, Haefeli WE. Desmethyl bosentan displays a similar in vitro interaction profile as bosentan. Pulm Pharmacol Ther 2015;30C:80-86.

Weiss J, Haefeli WE. Comment on: Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. J Antimicrob Chemother 2015;70:322-3.

Ziesenitz VC, König SK, Mahlke N, Skopp G, Haefeli WE, Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol 2015; 55: 708-717.

Book Chapters

Czock D, Keller F. Arzneimittelinduzierte Nephrotoxizität. In: Haase M, Haase-Fielitz A (Hrsg). Akute Nierenschädigung. 1. Auflage. Heidelberg: Springer; 2015. S. 117-31.

Czock D, Seidling S. Dosisanpassung bei Niereninsuffizienz. In: Rose O, Friedland K (Hrsg). Angewandte Pharmakotherapie. 1. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2015. S. 465-78.

Haefeli, WE. Arzneimittel-Interaktionen in der pulmonalen arteriellen Hypertonie:Mechanismen, Ausmaß und Prävention.1. Auflage.Stuttgart:Verlag für Klinik und Praxis;2015

Seidling HM, Stuetzle M, Haefeli WE. Aufgaben des Medikamentenmanagements. In: Euteneier A (Hrsg). Handbuch Klinisches Risikomanagement. 1. Auflage. Heidelberg: Springer; 2015. S. 185-93.

Seidling HM, Stuetzle M, Haefeli WE. Aufgaben des Medikamentenmanagements. In: Euteneier A (Hrsg). Handbuch Klinisches Risikomanagement. 1. Auflage. Heidelberg: Springer; 2015. S. 516-20.

2014

 

Albarmawi A*, Czock D*, Gauss A, Ehehalt R, Lorenzo Bermejo J, Burhenne J, Ganten TM, Sauer P, Haefeli WE. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and Model for End-Stage Liver Disease (MELD) scores. Br J Clin Pharmacol. 2014;77:160-9.
*Equal contribution

Ammenwerth E, Aly AF, Bürkle T, Christ P, Dormann H, Friesdorf W, Haas C, Haefeli WE, Jeske M, Kaltschmidt J, Menges K, Möller H, Neubert A, Rascher W, Reichert H, Schuler J, Schreier G, Schulz S, Seidling HM, Stühlinger W, Criegee-Rieck M. Zum Einsatz von Informationstechnologie zur Verbesserung der Arzneimitteltherapiesicherheit (Memorandum AMTS-IT). GMS Med Inform Biom Epidemiol. 2014;10(1):Doc03.

Ammenwerth E, Aly AF, Bürkle T, Christ P, Dormann H, Friesdorf W, Haas C, Haefeli WE, Jeske M, Kaltschmidt J, Menges K, Möller H, Neubert A, Rascher W, Reichert H, Schuler J, Schreier G, Schulz S, Seidling HM, Stühlinger W, Criegee-Rieck M. Memorandum on the use of information technology to improve medication safety. Methods Inf Med 2014;53:336-43.

Ammenwerth E, Aly AF, Criegee-Rieck M, Haefeli WE, Neubert A. Memorandum zum Einsatz von Informationstechnologie in der Arzneimitteltherapie: Herausforderungen und Empfehlungen. Z Evid Fortbild Qual Gesundhwes 2014;108:242-3.

Becker JP, Weiss J, Theile D. Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation. Toxicol Lett 2014;225:43-7.

Bock JO, Matschinger H, Brenner H, Wild B, Haefeli WE, Quinzler R, Saum KU, Heider D, König HH. Inequalities in out-of-pocket payments for health care services among elderly Germans - results of a population-based cross-sectional study. Int J Equity Health 2014;13:3.

Birgersson S, Ericsson T, Blank A, Hagens Cv, Ashton M, Hoffmann KJ. A high-throughput LC-MS/MS assay for quantification of artesunate and its metabolite dihydroartemisinin in human plasma and saliva. Bioanalysis 2014;6:2357-69.

Carls A, Jedamzik J, Witt L, Hohmann N, Burhenne J, Mikus G. Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. Br J Clin Pharmacol 2014;78:1433-1440.

Carls A, Winter J, Enderle Y, Burhenne J, Gorenflo M, Haefeli WE. Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports. J Med Case Rep 2014;8:171.

Clemens J, Longo M, Seckinger A, Hose D, Haefeli WE, Weiss J*, Burhenne J*. Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr A 2014;1345:128-38.
* Equal contribution

Czock D. Antidiabetika bei Patienten mit Niereninsuffizienz. Der Nephrologe 2014;9:433-41.

Czock D, Keller F. Antibiotikadosierung bei Dialysepatienten. Der Nephrologe 2014;9:477-87.

Dalaba MA, Akweongo P, Williams J, Saronga HP, Tonchev P, Sauerborn R, Mensah N, Blank A, Kaltschmidt J, Loukanova S. Costs associated with implementation of computer-assisted clinical decision support system for antenatal and delivery care: case study of kassena-nankana district of northern ghana. PLoS One 2014;9:e106416.

Deppe S, Ripperger A, Weiss J, Ergün S, Benndorf RA. Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan. Biochem Biophys Res Commun 2014;443:1211-7.

Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother 2014;69:1633-41.

Ericsson T, Blank A, von Hagens C, Ashton M, Abelö A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol 2014;70:1453-63.

Faller CK, Seidling HM, Haefeli WE. Gute Verordnungspraxis im ambulanten Sektor – Qualitätsanforderungen an die Rezeptschreibung in Deutschland. Ther Umsch 2014;71:317-23.

Freigofas J, Haefeli WE, Schöttker B, Brenner H, Quinzler R. Indirect evidence for proton pump inhibitor failure in patients taking them independent of meals. Pharmacoepidemiol Drug Saf 2014;23:768-72.<//span>

Freytag A*, Quinzler R*, Freitag M, Bickel H, Fuchs A, Hansen H, Hoefels S, König H-H, Mergenthal K, Riedel-Heller SG, Schön G, Weyerer S, Wegscheider K, Scherer M, van den Bussche H, Haefeli WE, Gensichen J,  für die MultiCare Study Group. Gebrauch und potenzielle Risiken durch nicht verschreibungspflichtige Schmerzmittel - Ergebnisse einer Beobachtungsstudie in der Primärversorgung. Schmerz 2014; 28:175-82.
* Equal contribution

Haefeli WE. Asthma und COPD im Alter - Das richtige Inhalieren muss trainiert werden. Der Allgemeinarzt 2014;10:34-6.

Haefeli WE. Polypharmazie und Arzneimitteltherapie im Alter. Eine Balance zwischen Einsetzen, Anpassen und Absetzen von Medikamenten. Klinikarzt 2014;43:404-9.

Haefeli WE, Carls A. Drug interactions with phytotherapeutics in oncology. Expert Opin Drug Metab Toxicol 2014;10:359-77.

Heider D, Matschinger H, Müller H, Saum KU, Quinzler R, Haefeli WE, Wild B, Lehnert T, Brenner H, König HH. Health care costs in the elderly in Germany: an analysis applying Andersen's behavioral model of health care utilization. BMC Health Serv Res 2014;14:71.

Hohmann N, Halama B, Siller N, Mikus G, Haefeli WE. Response to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam. Clin Pharmacol Ther 2014;95:490-1.

Hohmann N, Mikus G, Czock D. Wirkungen und Risiken neuartiger psychoaktiver Substanzen: Fehldeklaration und Verkauf als „Badesalze“, „Spice“ und Forschungschemikalien“. Dtsch Ärzteblatt 2014;111:139-147.

Keller F, Hartmann B, Czock D. Time of effect duration and administration interval for sitagliptin in patients with kidney failure. Eur J Drug Metab Pharmacokinet 2014;39:77-85.

Klimas R, Mikus G. Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth 2014;113:935-44.

Lampert A, Haefeli WE, Seidling HM. Do you have any questions about your medication? Patient Educ Couns 2014;97:434.

Lampert A, Seiberth J, Haefeli WE, Seidling HM. A systematic review of medication administration errors with transdermal patches. Expert Opin Drug Saf 2014;13:1101-14.

Lampert A, Tesarz J, Volkert A, Wesche D, Wild B, Schwab M, Haefeli WE. An N-of-1 trial as an individualized withdrawal treatment approach for psychological methylphenidate dependence. Psychother Psychosom 2014;83:379-81.

Liu L, Detering J-C, Milde T, Witt O, Haefeli WE, Burhenne J. Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. J Chromatogr B 2014;964:212-21.

Lohmann K, Ferber J, Send AF, Haefeli WE, Seidling HM. Inappropriate crushing information on ward lists: cytotoxic drugs, capsules, and modified release formulations are gravely neglected. Eur J Clin Pharmacol 2014;70:565-73.

Loukanova S, Prytherch H, Blank A, Duysburgh E, Tomson G, Gustafsson LL, Sié A, Williams J, Leshabari M, Haefeli WE, Sauerborn R, Fonn S. Nesting doctoral students in collaborative North-South partnerships for health systems research. Glob Health Action 2014;7:24070.

Mahler C, Freund T, Baldauf A, Jank S, Ludt S, Peters-Klimm F, Haefeli WE, Szecsenyi J. Das strukturierte Medikamentenmanagement in der Hausarztpraxis - ein Beitrag zur Förderung der Arzneimitteltherapiesicherheit. Z Evid Fortbild Qual Gesundhwes 2014;108:258-69.

Mahlke NS, Ziesenitz V, Mikus G, Skopp G. Quantitative low-volume assay for simultaneous determination of fentanyl, norfentanyl, and minor metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Int J Legal Med 2014;128:771-8.

Markert C, Burhenne J, Weiss J, Mikus G, Haefeli W. CYP2C9 Polymorphism is not a major determinant of bosentan exposure in healthy volunteers. Clin Pharmacol Ther 2014;95:250-1.

Markert C, Ngui P, Hellwig R, Wirsching T, Kastner IM, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. Influence of St. John's wort on the steadystate pharmacokinetics and metabolism of bosentan. Int J Clin Pharmacol Ther 2014;52:328-36.

Markert C, Schweizer Y, Hellwig R, Wirsching T, Riedel K-D, Burhenne J, Weiss J, Mikus G, Haefeli WE. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. Br J Clin Pharmacol 2014;77:141-8.

Markert C, Wirsching T, Hellwig R, Burhenne J, Weiss J, Riedel KD, Mikus G, Haefeli WE. Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. Int J Clin Pharmacol Ther 2014;52:957-64.

Mikus G, Klimas R. Contribution of oxycodone and its metabolites to the analgesic effect. Br J Anaesth 2014;112:944-5.

Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel KD, Suda A, Ueda N, Bakari M, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E, Diczfalusy U. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. J Antimicrob Chemother 2014;69:3311-9.

Niemann D, Bertsche A, Meyrath D, Oelsner S, Ewen AL, Pickardt B, Henhapl T, Hoffmann G, Meyburg J, Bertsche T. Drug Handling in a Paediatric Intensive Care Unit - Can Errors be Prevented by a Three-Step Intervention? Klin Padiatr 2014;226:62-67.

Phansalkar S, Zachariah M, Seidling HM, Mendes C, Volk L, Bates DW. Evaluation of Medication Alerts in Electronic Health Records for Compliance with Human Factors Principles. J Am Med Inform Assoc 2014;21:e332-40.

Rickert V, Haefeli WE, Weiss J. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro. Pulm Pharmacol Ther 2014;28:130-7.

Roggelin L, Pelletier D, Hill JN, Feldt T, Hoffmann S, Ansong D, Sylverken J, Burhenne J, Fischer-Herr J, Mehrfar P, Thiel C, Burchard GD, Nguah SB, Cramer JP. Disease-associated QT-shortage versus quinine associated QT-prolongation: age dependent ECG-effects in Ghanaian children with severe malaria. Malar J 2014;13:219.

Roos K, Gotthardt D, Giese T, Schnitzler P, Stremmel W, Czock D, Eisenbach C. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. Liver Transpl 2014;20:1106-17.

Schiele JT, Schneider H, Quinzler R, Reich G, Haefeli WE. Two techniques to make swallowing pills easier. Ann Fam Med 2014;12:550-2.

Schmitt T, Goldschmidt H, Neben K, Freiberger A, Hüsing J, Gronkowski M, Thalheimer M, Pelzl le H, Mikus G, Burhenne J, Ho AD, Egerer G. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 2014;32:3413-20.

Seidling HM, Haefeli WE. Gute Verordnungspraxis. Ther Umsch 2014;71:313-6.

Seidling HM, Klein U, Schaier M, Czock D, Theile D, Pruszydlo MG, Kaltschmidt J, Mikus G, Haefeli WE. What, if all alerts were specific – estimating the potential impact on alert burden. Int J Med Inform 2014;83:285-91.

Seidling H, Lenssen R. Empfehlungen zur Arzneimitteltherapiesicherheit im Krankenhaus. Z Evid Fortbild Qual Gesundhwes 2014;108:44-8.

Send AFJ, Schwab M, Gauss A, Rudofsky G, Haefeli WE, Seidling HM. Pilot study to assess the influence of an enhanced medication plan on patient knowledge at hospital discharge. Eur J Clin Pharmacol 2014;70:1243-50.

Seyffart G. Nephropharmakologie. Viele Daten ohne Sinn. Der Nephrologe 2014;9:427-32.

Siller N, Egerer G, Bochtler T, Hohmann N, Mikus G. Normal CYP3A activity during arsenic trioxide therapy. Ann Hematol 2014;93:1941-2.

Siller N, Egerer G, Weiss J, Mikus G. Prolonged sedation of lorazepam due to absent UGT2B4/2B7 glucuronidation. Arch Toxicol 2014;88:179-80.

Sukums F, Mensah N, Mpembeni R, Kaltschmidt J, Haefeli WE, Blank A. Health workers' knowledge of and attitudes towards computer applications in rural African health facilities. Global Health Action 2014;7:24534.

Theile D, Gal Z, Warta R, Rigalli JP, Lahrmann B, Grabe N, Herold-Mende C, Dyckhoff G, Weiss J. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. Cancer Biol Ther 2014;15:436-42.

Theile D, Mikus G. Deceptive argumentation against diagnostic microdosing of anticancer drugs. Int J Cancer 2014;135:1753-4.

Warta R*, Theile D*, Mogler C, Herpel E, Grabe N, Lahrmann B, Plinkert PK, Herold-Mende C, Weiss J, Dyckhoff G. Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma. PLoS One 2014;9:e108908.
* Equal contribution

Weiss J, Becker JP, Haefeli WE. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but no PXR activator in vitro. Int J Antimicrob Agents 2014;43:184-8.

Weiss J, Theile D, Dvorak Z, Haefeli WE. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro. Pharmaceutics 2014;6:632-50.

Book Chapters

Freigofas J, Quinzler R, Kaltschmidt J, Haefeli WE, Saum KU. Medikationspläne im Alltag: Anforderungen, Nutzen und das ernüchternde Abbild in der Realität. In: Duesberg, F. Hellmann G (Hrsg). e-Health 2014: Solingen; S. 66-74.

Seidling HM, Haefeli WE. Erhöhung der Medikationssicherheit im Krankenhaus durch elektronische Verordnungsunterstützung. In:  Burgard G, Baberg HT, Popken G (Hrsg). Patientensicherheit GemeinsamSicher. 1. Aufllage. Berlin: MWV Medizinisch Wissenschaftliche Verlagsgesellschaft mbH & Co. KG; 2014. S. 91-7.

Stracke S, Czock D. Systematik des Nierenversagens. In: Hautmann R (Hrsg). Urologie. 5. Auflage. Heidelberg: Springer Medizin Verlag; 2014. S. 438-57.

Stützle M, Send AFJ, Mahler C, Längst G, Seidling HM, Haefeli WE. Nutzergruppen-spezifische Anforderungen an Struktur und Inhalt von Medikationsplänen. In: Duesberg, F. Hellmann G (Hrsg). e-Health 2014: Solingen; S. 24-9.

2013

 

Bates DW, Baysari MT, Dugas M, Haefeli WE, Kushniruk AW, Lehmann CU, Liu J, Mantas J, Margolis A, Miyo K, Nohr C, Peleg M, de Quirós FGB, Slight SP, Starmer J, Takabayashi K, Westbrook JI. Discussion of "Attitude of physicians towards automatic alerting in computerzied physician order entry systems". Methods Inf Med 2013;52:109-27.

Blank A, Prytherch H, Katschmidt J, Krings A, Sukums F, Mensah N, Zakane A, Loukanova S, Gustafsson LL, Sauerborn R, Haefeli WE. "Quality of prenatal and maternal care: bridging the know-do gap" (QUALMAT study): an electronic clinical decision support system for rural Sub-Saharan Africa. BMC Med Inform Decis Mak 2013;13:44.

Böhnke E, Dietz L, Heinrich T, Aderjan R, Skopp G, Mikus G. Disposition and enterohepatic circulation of intravenously administered 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol in serum and urine in healthy human subjects. J Forensic Toxicol Pharmacol 2013;2:2-6.

Carli-Ghabarou D, Seidling HM, Bonnabry P, Lovis C. A survey-based inventory of clinical decision support systems in computerized provider order entry in Swiss hospitals. Swiss Med Week 2013;143:w13894.

Clemens KE, Faust M, Jaspers B, Mikus G. Pharmacological treatment of constipation in palliative care: A review. Curr Opin Support Palliat Care 2013;7:183-91.

Coleman JJ, van der Sijs H, Haefeli WE, Slight SP, McDowell SE, Seidling HM, Eiermann B, Aarts J, Ammenwerth E, Slee A, Ferner RE. On the alert: future priorities for alerts in clinical decision support for computerized physician order entry identified from a European workshop.  BMC Med Inform Decis Mak 2013;13:111.

Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G. Concentration-effect relationship of  CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol 2013; Jun 9, 2013;69:1795-800.

Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, Mikus G. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol 2013;69:507-13.

Geist MJP, Egerer G, Burhenne J, Riedel K-D, Weiss J, Mikus G. Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother 2013;68:2592-9.

Grün B, Kiessling, MK, Burhenne J, Riedel KD, Weiss J, Rauch G, Haefeli WE, Czock D. Trimpethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1. Br J Clin Pharmacol 2013;76:787-96.

Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J 2013;13:484-9.

Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. A nonogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther 2013;93:564-71.

Hof H, Mikus G. Candida-Infektionen im hohen Alter. Z Gerontol Geriatr 2013;46:64-70.

Keller F, Hartmann B, Czock D. Time of effect duration and administration interval for sitagliptin in patients with kidney failure.  Eur J Drug Metab Pharmacokinet 2014;39:77-85.

Klimas R, Witticke D, El Fallah S, Mikus G. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration. Expert Opin Drug Metab Toxicol 2013;9:517-28.

Mahler C, Freund T, Baldauf A, Jank S, Ludt S, Peters-Klimm F, Haefeli WE, Szecsenyi J. Strukturiertes Medikamentenmanagement in der Hausarztpraxis - ein Beitrag zur Förderung der Arzneimitteltherapiesicherheit. Z Evid Fortbild Qual Gesundhwes 2013.

Markert C, Burhenne J, Weiss J, Mikus G, Haefeli WE. CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers. Clin Pharmacol Ther 2014;95:250-1.

Markert C, Hellwig R, Burhenne J, Hoffmann MM, Weiss J, Mikus G, Haefeli WE. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Eur J Clin Pharmacol 2013;69:1785-93.

Müller O, Mockenhaupt FP, Marks B, Meissner P, Coulibaly B, Kuhnert R, Buchner H, Schirmer RH, Walter-Sack I, Sié A, Mansmann U. Haemolysis risk in methyleine blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Pharmacoepidemiol Drug Saf 2013;22:376-85.

Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Akillu E, Burhenne J. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two Sub-Saharan Africa populations. Plos One 2013;8:e67946

Rigalli JP, Reuter T, Herold-Mende C, Dyckhoff G, Haefeli WE, Weiss J, Theile D. Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro. Cancer Chemother Pharmacol 2013;1335-43.

Schiele JT, Quinzler R, Klimm H-D, Pruszydlo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol 2013;69:937-48.

Seidling HM, Kaltschmidt J, Ammenwerth E, Haefeli WE. Medication safety through e-health technology: can we close the gaps?. Br J Clin Pharmacol 2013;76 Suppl S1:i-iv.

Seidling HM, Lampert A, Lohmann K, Schiele JT, Send AFJ, Witticke D, Haefeli WE. Safeguarding the process of drug administration with an emphasis on electronic support tools. Br J Clin Pharmacol 2013;76 Suppl 1:25-36.

Send A, Al-Ayyash A, Schecher S, Rudofsky G, Klein U, Schaier M, Pruszydlo MG, Witticke D, Lohmann K, Kaltschmidt J, Haefeli WE, Seidling HM. Development of a standardized knowledge base to generate individualized medication plans automatically with drug administration recommendations. Br J Clin Pharmacol 2013;76 Suppl 1:37-46.

Skopp G, Mikus G. An in vitro experiment on the interaction of charcoal or wheat bran with 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol and its glucuronide. Anal Bioanal Chem 2013;405:9449-53.

Stoll F, Burhenne J, Lausecker B, Weiss J, Thomsen T, Haefeli WE, Mikus G. Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. J Clin Pharmacol 2013;53:1199-1204.

Theile D, Schmidt TT, Haefeli WE, Weiss J. In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins.  J Pharm Pharmacol 2013;65:1518-25.

Theile D, Spalwisz A, Weiss J. Watch out for reporter gene assays with renilla luciferase and paclitaxel. Anal Biochem 2013;15:109-10.

Theile D, Haefeli WE, Seitz HK, Millonig G, Weiss J, Mueller S. Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res 2013;37 Suppl 1:E17-22.

van Erp R, Czock D, Keller F. Pharmakotherapie bei Niereninsuffizienz – Fokus Chemotherapie, neue Antikoagulanzien, neue Antidiabetika. Klinikarzt 2013;42:518-523.

Weiss J, Haefeli WE. Potential of the novel antiretroviral drug rilpivirine to modulate expression and function of drug transporters and drug metabolising enzymes in vitro. Int J Antimicrob Agents 2013;41:484-7.

Weiss J, Theile D, Rüppell MA, Speck T, Spalwisz A, Haefeli WE. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol 2013;15:168-75.

Weiss J, Theile D, Spalwisz A, Burhenne J, Riedel K-D, Haefeli WE. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochem Pharmacol 2013;85:265-73.

Witticke D, Seidling HM, Lohmann K, Send AFJ, Haefeli WE. Opportunities to reduce medication regimen complexity: A retrospective analysis of 500 patients discharged from a university hospital in Germany. Drug Saf 2013;36:31-41.

Zembruski N, Nguyen C, Theile D, Ali R, Herzog M, Hofhaus G, Heintz U, Burhenne J, Haefeli WE, Weiss J. Liposomal sphingomyelin influences the cellular lipid profile of human lymphoblastic leukaemia cells without effect of P-glycoprotein activity. Mol Pharm 2013;10:1020-34.

Ziesenitz VC, König SK, Mahlke N, Jantos R, Skopp G, Weiß J, Haefeli WE, Mikus G. Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings. Basic Clin Pharmco Toxicol 2013;113:43-8.

Ziesenitz VC, van den Anker JN. Impact of CYP3A and ABCB1 polymorphisms on the pharmacokinetics and pharmacodynamics of fentanyl. Int J Clin Pharmacol Ther 2013;51:991-2.

Ziesenitz VC, Weiss J, Haefeli WE, Mikus G. Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphisms. Clin Pharmacol Ther 2013;93:388.

Editorial Activities

Haefeli WE, Quinzler R, Seidling H, editors. Arzneimittel richtig anwenden. Stuttgart: Georg Thieme; 2013.

2012

 

Ali R, Campos B, Dyckhoff G, Haefeli WE, Herold-Mende C, Burhenne J. Quantification of retinoid concentrations in human serum and brain tumor tissues. Anal Chim Acta 2012;725:57-66.

Baker U, Tomson G, Somé M, Kouyaté B, Williams J, Mpembeni R, Massawe S, Blank A, Gustafsson LL, Eriksen J. 'How to know what you need to do’: a cross-country comparison of maternal health guidelines in Burkina Faso, Ghana and Tanzania. Implement Sci 2012;7:31:1-13.

Bertsche T, Nachbar M, Fiederling J, Schmitt SPW, Kaltschmidt J, Seidling HM, Haefeli WE. Assessment of a computerised decision support system for allergic rhino-conjunctivitis counselling in German pharmacy. Int J Clin Pharm 2012;34:17-22. 

Billing H, Sommerer C, Giese T, Zeier M, Meuer S, Czock D, Tönshoff B. Increased cyclosporin A sensitivity in vivo in pediatric renal transplant recipients compared to adults. Ther Drug Monit 2012;34:554-60.

Burhenne J. Bioanalytical Method Validation. J Anal Bioanal Techniques 2012;3:e111. Editorial.

Burhenne J, Scope A. Evaluation of the influence of formulation, food intake, and species on voriconazole plasma concentration in birds. Vet Med Austria 2012;99:157-62.

Burhenne J, Halama B, Maurer M, Riedel K-D, Hohmann N, Mikus G, Haefeli WE. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal  Chem 2012;402:2439-50.

Carow F, Rieger K, Walter-Sack I, Meyer MR, Peters FT, Maurer HH, Haefeli WE. Objective assessment of nonadherence and unknown co-medication in hospitalized patients. Eur J Clin Pharmacol 2012;68:1191-9.

zock D, Keller F, Seidling H. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol 2012;74:66-74.

Erler A, Beyer M, Petersen JJ, Saal K, Rath T, Rochon J, Haefeli WE, Gerlach FM. How to improve drug dosing for patients with renal impairment in primary care - a cluster-randomized controlled trial. BMC Fam Pract 2012;13:91.

Grün B, Merkel U, Riedel KD, Weiss J, Mikus G. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. Br J Clin Pharmacol 2012;74:854-63.

Haefeli WE. Polypharmazie: Therapien durchführbar machen und regelmäßig prüfen. Druckpunkt 2012;1:20-23.

Keubler A, Weiss J, Haefeli WE, Mikus G, Burhenne J. Drug interaction of efavirenz and midazolam: Efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro. Drug Metab Dispos 2012;40:1178-82.

Kleber CJ, Spiess A, Kleber JB, Hinz U, Holland-Cunz S, Weiss J. Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy. Eur J Pediatr 2012;171:941-6.

Mahler C, Hermann K, Janke S. Haefeli WE, Szecsenyi J. Can a feedback report and training on medication counseling for general practitioners improve patient satisfaction with information on medicines? Patient Prefer Adherence 2012;6:179-86.

Mahler C, Hermann K, Horne R, Jank S, Haefeli WE, Szecsenyi J. Patients' beliefs about medicines in a primary care setting in Germany. J Eval Clin Pract 2012;18:409-13.

Maxwell S, Eichler H-G, Busics A, Haefeli WE, Gustafsson LL. e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. Br J Clin Pharmacol 2012;73:12-5.

Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, Burhenne J, Lindquist L, Mugusi F, Sandstrom E, Eklillu E. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PloS One 2012;7:e40180.

Niethammer AG, Lubenau H, Mikus G, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, Grenacher L, Buchler MW, Koch M, Weitz J, Haefeli WE, Schmitz-Winnenthal FH. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012;12:361.

Pruszydlo MG, Walk-Fritz SU, Hoppe-Tichy T, Kaltschmidt J, Haefeli WE. Development and evaluation of a computerised clinical decision support system for switching drugs at the interface between primary and tertiary care. BMC Med Inform Decis Mak 2012;12:137.

Rigalli JP, Perdomo VG, Luquita MG, Villanueva SSM, Arias A, Theile D, Weiss J, Mottino AD, Ruiz ML, Catania VA. Regulation of Biotransformation Systems and ABC Transporters by Benznidazole in HepG2 Cells: Involvement of Pregnane X-Receptor. Plos Negl Trop Dis 2012;6:e1951.

Rother A, Glander P, Vitt E, Czock D, von Ahsen N, Armstrong VW, Oellerich M, Budde K, Feneberg R, Tönshoff B, Weber LT. Iosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. Eur J Clin Pharmacol 2012;68:913-22.

Theile D, Detering J-C, Herold-Mende C, Dyckhoff G, Haefeli WE. Weiss J, Burhenne J. Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry. J Pharmacol Exp Ther 2012; J Pharmacol Exp Ther 2012;341:51-8.

Weiss J, Theile D, Haefeli WE. Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data. Naunyn-Schmiedebergs Arch Pharmacol 2012;385:1025-34

Weiss J, Fränkl SA, Flammer J, Grieshaber MC, Hollo G, Teuchner B, Haefeli WE. No difference in genotype frequencies of polymorphisms of the nitric oxide pathway between Caucasian normal and high tension glaucoma patients. Mol Vis 2012;18:2174-81.

Witticke D, Seidling HM, Klimm HD, Haefeli WE. Do we prescribe what patients prefer? A pilot study to assess patients' preferences for medication regimen characteristics. Patient Prefer Adherence 2012;6:679-84.

Wustrow I, Riedel K-D, Mikus G, Weiss J. In vitro identification of the cytochrome P450 isozymes involved in the N-demethylation of the active opiod metabolite nortilidine to bisnortilidine. Naunyn-Schmiedebergs Arch Pharmacol 2012;385:633-9.

Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, Worku A, Haefeli WE, Burhenne J, Aderaye G, Lindquist L, Aklillu E. High plasma efavirenz level and CYP2B*6 are associated with efavirenz-based HAART-induced liver injury in treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2012;12:499-506.

Zembruski NCL, Stache V, Haefeli WE, Weiss J. 7-Aminoactinomycin D for apoptosis staining in flow cytometry. Anal Biochem 2012;429:79-81.

Book Chapters

Konias M, Kaltschmidt J, Green K, Seidling HM, Haefeli WE. Entscheidungsunterstützung bei der medikamentösen Therapie älterer Patienten. In: Duesberg F, editor. e-Health 2012. Solingen: medical future verlag; 2012.

Blank A, Kaltschmidt J, Krings A,  Loukanova S,  Sauerborn R, Haefeli WE. e-Health in Afrika: Chancen eines Clinical Decision Support Systems in der medizinischen Grundversorgung im ländlichen Afrika. In: Duesberg F, editor. e-Health 2013. Solingen: medical future verlag; 2013.

2011

 

Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, König S, Ziesenitz V, Mikus G, Haefeli WE, Weiss J. Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol 2011;67:1139-45.

Aly A-F, Menges K, Haas CH, Zimmermann L, Kaltschmidt J, Criegee-Rieck M. Voraussetzungen für elektronische Systeme zur Prüfung auf Arzneimitteltherapiesicherheit (AMTS). BGesBl 2011;54:1170-8.

Bertsche T, Mikus G. Unerwünschte Wirkungen und Wechselwirkungen in der Analgetikatherapie. Ther Umsch 2011;68:19-26.

Campos B, Centner F-S, Bermejo JL, Ali R, Dorsch K, Wan F, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, Unterberg A, Burhenne J, Herold-Mende C. Aberrant expression of retinoic acid signalling molecules influences patient survival in astrocytic gliomas. Am J Pathol 2011;178:1953-64.

Czock D, Keller F. Arzneimittelinteraktionen und Nephrotoxizität. Ther Umsch 2011;68:11-8. 

Ding R, Frei E, Fardanesh M, Schrenk H-H, Kremer P, Haefeli WE. Pharmacokinetics of 5-aminofluorescein-albumin, a novel fluorescence marker of brain tumors during surgery. J Clin Pharmacol 2011;51:672-8. 

Eichbaum C, Haefeli WE. Nomenklatur und Einteilung von Biologicals. Ther Umsch 2011;68:593-601.

Fetzner L, Burhenne J, Weiss J, Völker M, Unger M, Mikus G, Haefeli WE. Daily honey consumption does not change CYP3A activity in humans. J Clin Pharmacol 2011;51:1223-32. 

Genovese S, Epifano F, Curini M, Menger D, Zembruski NCL, Weiss J. In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression. Phytomedicine 2011;18:586-91.

Ghofrani HA, Distler O, Gerhardt F, Gorenflo M, Grünig E, Haefeli WE, Hoeper MM, Kähler CM, Haemmer H, Klose H, Köllner V, Kopp B, Mebus S, Meyer A, Miera O, Pittrow D, Riemekasten G, Rosenkranz S, Schranz D, Voswinckel R, Olschewski H. Treatment of pulmonary arterial hypertension (PAH): Updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011;152S:S20-S33.

Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel K-D, Ueda N, Worku A, Haefeli WE, Lindquist L, Aderaye G, Burhenne J, Aklillu E. Long-term effect of efavirenz autoinduction on plasma/PBMC drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotype among HIV patients. J Antimicrob Chemother 2011;66:2350-1.

Haefeli WE, Reinhart WH. Proteine als Therapeutika. Ther Umsch 2011;68:591.

Haefeli WE. Polypharmazie. Schweiz Med Forum 2011;11:847-52.

Haefeli WE, Quinzler R. Arzneimittelexposition bei älteren Patienten: modifizierende Faktoren und die Rolle von Gebrechlichkeit, Multimorbidität, psychosozialen Charakteristika und psychiatrischer Komorbidität. Z Gerontol Geriatr 2011;44(Suppl.2):36-7.   

Hafner-Blumenstiel V. Phytopharmaka als Ursache von unerwünschten Arzneimittelwirkungen. Ther Umsch 2011;68:54-7.

Hassan A, Burhenne J, Riedel K-D, Weiss J, Mikus G, Haefeli WE, Czock D. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit 2011;33:86-93.  

Herzog M, Storch CH, Gut P, Kotlyar D, Füllekrug J, Ehehalt R, Haefeli WE, Weiss J. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn-Schmiedebergs Arch Pharmacol 2011;383:1-11. 

Kaan HYK, Weiss J, Menger D, Ulaganathan V, Tkocz K, Laggner C, Popowycz F, Joseph B, Kozielski F. Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5. J Med Chem 2011;54:1576-86.

Katzenmaier S, Markert C, Riedel K-D, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 2011;90:666-73.

Kaufmann-Kolle P, Szecsenyi J, Broge B, Haefeli WE, Schneider A. Führt die Implementierung von offenem Benchmarking in datengestützten Qualitätszirkeln zur Verbesserung der hausärztlichen Versorgung bei Arzneimittelinteraktion und  Asthma bronchiale? Z Evid Fortbild Qual Gesundhwes 2011;105:389-95.

Kellner S, Seidu-Larry S, Burhenne J, Motorin Y, Helm M. A multifunctional bioconjugate module for versatile photoaffinity labeling and click chemistry of RNA. Nucleic Acids Res 2011;39:7348-60.

Mahler C, Jank S, Pruszydlo MG, Hermann K, Gärtner H, Kaltschmidt J, Ludt S, Bertsche T, Haefeli WE, Szecsenyi J. Heicare®: ein Projekt zur Verbesserung der sektorenübergreifenden Arzneimittelkommunikation. Dtsch Med Wochenschr 2011;136:2239-44.

Mikus G. Unerwünschte Arzneimittelwirkungen (UAW) und Arzneimittel-Interaktionen – Definition und Einteilung. Ther Umsch 2011;68:3-9.

Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011;12:861-72.

Motorin Y, Burhenne J, Teimer R, Koynov K, Willnow S, Weinhold E, Helm M. Expanding the chemical scope of RNA: methyltransferases to site-specific alkynylation of RNA for click labeling. Nucleic Acids Res 2011;39:1943-52.

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel K-D, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WEH, Bertilsson L, Burhenne J, Aklillu E. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with and without tuberulosis. Clin Pharmacol Ther 2011;90:406-13.

Schmitt T, Mikus G, Egerer G. Leitliniengerechte Therapie von Übelkeit und Erbrechen. J Gastroenterol Hepatol Erkr 2011;9:18-24. 

Seidling HM, Phansalkar S, Seger DL, Paterno MD, Shaykevich S, Haefeli WE, Bates DW. Factors influencing alert acceptance: a novel approach for predicting success of clinical decision support. JAMIA 2011;18:479-84.

Senger C, Seidling HM, Quinzler R, Leser U, Haefeli WE. Design and evaluation of an ontology-based drug application database. Methods Inf Med 2011;50:273-84.

Sommerer C, Zeier M, Czock D, Schnitzler P, Meuer S, Giese T. Pharmacogynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 2011;33:373-9.

Theile D, Ketabi-Kiyanvash N, Herold-Mende C, Dyckhoff G, Efferth T, Bertholet V, Haefeli WE, Weiss J. Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head & Neck 2011;33:959-68.

Volodina A, Bertsche T, Kostev K, Winkler V, Haefeli WE, Becher H. Drug utilization patterns and reported health status in ethnic German migrants (Aussiedler) in Germany: a cross-sectional study. BMC Public Health 2011;11:509.

Weiss J, Haefeli WE. Interaction potential of the endothelin-A receptor antagonist atrasental with drug transporters and drug metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol 2011;68:1093-8.

Weiss J, Herzog M, Haefeli WE. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol 2011;660:298-304.

Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011;6:e27810.

Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, Kuppe H, Kuebler WM. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail 2011;4:198-206.

Zachariah M, Phansalkar S, Seidling H, Neri PM, Cresswell KM, Duke J, Bloomrosen M, Volk LA, Btes DW. Development and validation of an instrument assessing implementation of human-factors principles medication-related decision-support systems - I-MeDeSa. J Am Med Inform Assoc 2011;18Suppl1:i62-72.

Zembruski NCL, Büchel G, Jödicke L, Herzog M, Haefeli WE, Weiss J. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 2011;66:802-12.

Zembruski NCL, Haefeli WE, Weiss J. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother 2011;55:1282-4.

2010

 

Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010;5:314-27. 

Bertsche T, Bertsche A, Krieg EM, Kunz N, Bergmann K, Hanke G, Hoppe-Tichy T, Ebinger F, Haefeli WE. Prospective pilot intervention study to prevent medication errors in drugs administered to children by mouth or gastric tube: A program for nurses, physicians and parents. Qual Saf Health Care 2010;19:e26.

Bertsche T, Pfaff J, Schiller P, Kaltschmidt J, Pruszydlo MG, Stremmel W, Walter-Sack I, Haefeli WE, Encke J. Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med 2010;36:665-72. 

Bertsche T, Veith C, Stahl A, Hoppe-Tichy T, Meyer FJ, Katus HA, Haefeli WE. A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities. Pharm World Sci 2010;32:663-9. 

Bertsche T, Pfaff J, Haefeli WE, Encke J. Interaktionsmanagement vermeidet Interaktionen. Pharm Ztg 2010;12:27-30.

Bountogo M, Zoungrana A, Coulibaly B, Klose C, Mansmann U, Mockenhaupt FP, Burhenne J, Mikus G, Walter-Sack I, Schirmer RH, Sié A, Meissner P, Müller O. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop Med Int Health 2010;15:713-7.

Burhenne J, Matthee AK, Pasakova I, Röder C, Heinrich T, Haefeli WE, Mikus G, Weiss J. No evidence for induction of ABC-transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother 2010;54:4185-91.

Burkhardt O, Thon S, Burhenne J, Welte T, Kielstein JT. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int J Antimicrob Agents 2010;36:93-4.

Deppe S, Böger RH, Weiss J, Benndorf R. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 2010;6:863-71. 

Egerer G, Eisenlohr K, Gronkowski M, Riedel K-D, Burhenne J, Mikus G. The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 2010;70:903-7.

Ghofrani HA, Distler O, Gerhardt F, Gorenflo M, Grünig E, Haefeli WE, Held M, Hoeper MM, Kähler C-M, Kaemmerer H, Klose H, Köllner V, Kopp B, Mebus S, Meyer A, Miera O, Pittrow D, Riemekasten G, Rosenkranz S, Schranz D, Voswinckel R, Olschewski H. Therapie der pulmonal arteriellen Hypertonie (PAH): Empfehlungen der Kölner Konsensus Konferenz 2010. Dtsch Med Wochenschr 2010;135:S87-101.

Hafner V, Czock D, Burhenne J, Riedel K-D, Bommer J, Mikus G, Machleidt C, Weinreich T, Haefeli WE. Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodialfiltration. Antimicrob Agents Chemother 2010;54:2596-602.

Hafner V, Grün B, Markert C, Czock D, Mikus G, Haefeli WE. Arzneimittelinteraktionen. Internist 2010;51:359-70.

Hafner V, Haefeli WE. Simvastatin und Atorvastatin: Interaktionen mit CYP3A4 Hemmern. AVP 2010;37:15-6.

Hafner, V, Jäger M, Mattée A-K, Ding R, Burhenne J, Haefeli WE, Mikus G. Effect of simultaneous induction and inhibition of CYP3A by St. John's wort and ritonavir on CYP3A activity. Clin Pharmacol Ther 2010;87:191-6.

Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Ärztebl Int 2010;107:647-55.                                                                                                                              

Hassan A, Haefeli WE. Appropriateness of timing of drug administration in elctronic prescriptions. Pharm World Sci 2010;32:162-71.

Katzenmaier S, Markert C, Mikus G. Proposal of a new limited sampling strategy to predict CYP3A4 activity using a partial AUC of midazolam. Eur J Clin Pharmacol 2010;66:1137-41. 

Kellner S, Burhenne J, Helm M. Detection of RNA modifications. RNA Biol 2010;7:237-47.

König S, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010;65:2319-28.

Mahler C, Hermann K, Horne R, Ludth S, Haefeli WE, Szecsenyi J, Jank S. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract 2010;16:574-9. 

Maus S, Holch C, Czock D, Thalhammer F, Keller F, Hartmann B. Umfrage zur Arzneimitteldosierung bei Niereninsuffizienz unter nephrologisch tätigen Ärzten. Wien Klin Wochenschr 2010;122:479-85.

Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010;88:676-84.

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzmann D, Guenther S, Winnenburg R, Schroeder M, Preissner R. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010;38:D237-43.

Seidling HM, Paterno MD, Haefeli WE, Bates DW. Coded entry versus free-text and alert overrides: What you get depends on how you ask. Int J Med Inform 2010;79:792-6.

Seidling HM, Schmitt SPW, Bruckner T, Kaltschmidt J, Pruzydlo M, Senger C, Bertsche T, Walter-Sack I, Haefeli WE. Patient-specific electronic decision support reduces prescription of excessive doses. Qual Saf Health Care 2010;19:e15.

Senger C, Kaltschmidt J, Schmitt SPW, Pruszydlo MG, Haefeli WE. Misspellings in drug information system queries: Characteristics of drug name spelling errors and straegies for their prevention. Int J Med Inform 2010;79:832-9. 

Sertel S, Eichhorn T, Sieber S, Sauer A, Weiss J, Plinkert PK, Efferth T. Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem-Biol Interact 2010;185:42-52.

Sommerer C, Müller-Krebs S, Schaier M, Glander P, Budde K, Schwenger V, Mikus G, Zeier M. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010; 69:346-57.

Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269-74.

Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010;66:291-8.

Theile D, Staffen B, Weiss J. ATP-binding cassette transporters as pitfalls in selection of transgenic cells. Anal Biochem 2010;399:246-50. 

Weiss J, Haefeli WE. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol 2010;280:219-79.

Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Böger RH, Haefeli WE, Benndorf RA. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010;31:150-61.

Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Stürmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf 2010;19:1248-55.   

Book chapters 

Bertsche T, Kaltschmidt J, Bardenheuer HJ, Haefeli WE. Verbesserte Schmerzbehandlung bei Tumorpatienten durch elektronische Unterstützung. In: Duesberg F, editor. e-Health 2010. Solingen: POINT63 Media- und Verlagsservice; 2010.

Haefeli WE. Therapie-Monitoring, Probleme der Compliance (Adherence) und Noncompliance. In: Lemmer B, Brune K, editors. Pharmakotherapie. Klinische Pharmakologie. 14th ed. Heidelberg: Springer; 2010.

Stracke S, Czock D. Systematik des Nierenversagens. In: Hautmann R, editor. Urologie. 4th ed. Heidelberg: Springer Medizin Verlag; 2010.

2009

 

Benkhaial A, Kaltschmidt J, Weisshaar E, Diepgen TL, Haefeli WE. Prescribing errors in patients with documented drug allergies: Comparison of ICD-10 coding and written patient notes. Pharm World Sci 2009;31:464-72.

Bertsche T, Askoxylakis V, Habl G, Laidig F, Kaltschmidt J, Schmitt SPW, Ghaderi H, Zabel-du Bois A, Milker-Zabel S, Debus J, Bardenheuer HJ, Haefeli WE. Multidisciplinary pain management based on computerized clinical decision support system in cancer pain patients. Pain 2009;147:20-8.

Bertsche T, Kaltschmidt J, Haefeli WE. Patientensicherheit durch computerbasierte Arzneimittelinformation - Der Patient im elektronischen Check-up. Der Internist 2009;50:748-56.

Bertsche T, Münk L, Mayer Y, Stahl R, Hoppe-Tichy T, Encke J, Haefeli WE. One-year follow-up on procedure to prevent i.v. drug incompatibilites in an intensive care unit.  Am J Health Sys Pharm 2009;66:1250,1253.

Bertsche T, Fleischer M, Pfaff J, Encke J, Czock D, Haefeli WE. Pro-active provision of drug information as a technique to address overdosing in intensive care patients with renal insufficiency. Eur J Clin Pharmacol 2009;65:823-9.

Bertsche T, Schulz M, Schubert-Zsilavecz M. Klinische Pharmazeuten verbessern die Sicherheit der Arzneimitteltherapie. Dt Apoth Ztg 2009;149:3032-3.

Bertsche T, Schwalbe O, Högger P. Klinische Pharmazie: Eine Bestandsaufnahme an deutschen Universitäten. Pharm Ztg 2009;48:154:60-4.

Blank A, Hellstern V, Schuster D, Hartmann M, Matthée A-K, Burhenne J, Haefeli WE, Mikus G. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clin Infect Dis 2009;48:1787-9.

Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 2009;50:143-54.

Czock D, Bertsche T, Haefeli WE. Drug dose adjustment in patients with renal impairment. Am J Kidn Dis 2009;54:983-4. (letter)

Czock D, Keller F, Hameister J, Tiefenbach B, Mitzner S. Levomethadone is poorly removed by the molecular adsorbents recirculating system. J Clin Psychopharm 2009;29:622-4. (letter)

Czock D, Markert C, Hartman B, Keller F. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol 2009;5:475-87.

Czock D, Rasche FM, Boesler B, Shipkova M, Keller F. Irinotecan in cancer patients with end-stage renal failure. Ann Pharmacother 2009;43:363-9.

Grün B, Haefeli WE. Die richtige Rekrutierung von Studienteilnehmern. Bundesgesundheitsbl 2009;52:402-9.

Grün B, Krautter S, Riedel K-D, Mikus G. Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole. Br J Clin Pharmacol 2009;68:712-20.

Jank S, Bertsche T, Schellberg D, Herzog W, Haefeli WE. The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. Pharm World Sci 2009;31:426-31.

Keller F, Hartmann B, Czock D. Mean residence time as estimated from cropped and truncated moments. Arzneimittelforschung 2009;59:377-81.

Keller F, Hartmann B, Czock D. Explicit solution of integrated 1 - exp equation for predicting accumulation and decline of concentrations for drugs obeying nonlinear saturation kinetics. Ther Drug Monit 2009;31:783-5.

Kremer P, Mahmoudreza F, Ding R, Pritsch M, Zoubaa S, Frei E. Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery 2009;63(Suppl 3):53-61. 

Mahler C, Jank S, Hermann K, Haefeli WE, Szecsenyi J. Informationen zur Medikation - wie bewerten chronisch kranke Patienten das Medikamentengespräch in der Arztpraxis? Dtsch Med Wochenschr 2009; 134:1620-4.

Mahler C, Jank S, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J. Psychometric properties of a German version of the "Satisfaction with Information about Medicine Scale" (SIMS-D). Value Health 2009;12:1176-9. 

Peters FT, Drvarov O, Lottner S, Spellmeier A, Rieger K, Haefeli WE, Maurer HH. A systematic comparison of four different workup procedures for systematic toxicological analysis of urine samples using gas chromatography-mass spectrometry. Anal Bioanal Chem 2009;393:735-45.

Quinzler R, Schmitt SP, Pritsch M, Kaltschmidt J, Haefeli W. Substantial reduction of inappropriate tablet splitting with computerised decision support: a prospective intervention study assessing potential benefit and harm. BMC Med Inform Decis Mak 2009;9:30.

Reimer K, Hopp M, Zenz M, Maier C, Holzer P, Mikus G, Bosse B, Smith K, Buschmann-Kramm C, Leyendecker P. Meeting the challenge of opioid-induced constipation in chronic pain management - A novel approach. Pharmacology 2009;83:10-7.

Schless B, Yildirim S, Beha D, Keller F, Czock D. Rituximab in two casses of Goodpasture's syndrome. NDT plus 2009;2:225-7.

Scholz I, Oberwittler H, Riedel K-D, Burhenne J, Weiss J, Haefeli WE, Mikus G. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009;68:906-15.

Schwalbe O, Keiner D, Bertsche T. Der geriatrische Patient. Dt Apoth Ztg 2009;149:5748-9.

Seidling HM, Storch CH, Bertsche T, Senger C, Kaltschmidt J, Walter-Sack I, Haefeli WE. Successful strategy to improve the specificity of electronic statin-drug interation alerts. Eur J Clin Pharmacol 2009;65:1149-57. 

Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 2009;78:1366-73.

Walk SU, Fritz S, Pruszydlo MG, Hartwig W, Haefeli WE, Hoppe-Tichy T. Pharmazeutische Beratung zu Medikationsumstellungen an der Schnittstelle von ambulanter zu stationärer Versorgung. Krankenhauspharmazie 2009;30:218-21.

Walter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O, Meissner P, Mikus G. High absolute bioavailability of methylene blue given as an aqueous oral formulation.Eur J Clin Pharmacol 2009;65:179-89.

Warth A, Goeppert B, Bopp C, Schirmacher P, Flechtenmacher C, Burhenne J. Turquoise to dark green organs at autopsy. Virchows Arch 2009;454:341-4.

Weiss J, ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009;49:196-204.

Weiss J, Herzog, Koenig S, Storch CH, Ketabi-Kiyanvash N, Haefeli WE. Induction of multiple drug transporters by efavirenz. J Clin Pharmacol Sci 2009;109:242-50.

Weiss J, Sauer A, Herzog M, Böger RH, Haefeli WE, Benndorf RA. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology 2009;84:264-70.

Bookchapters

Czock D, Aymanns C. Pharmakokinetik und Dosisanpassung bei Patienten mit Niereninsuffizienz. In: Keller F, Ketteler M, Schindler R, Heemann U, Wolf G, editors. Manuale nephrologicum. 2nd ed. München-Orlando: Dustri Verlag Dr. Karl Feistle; 2009.

2008

 

Bertsche T, Mayer Y, Stahl R, Hoppe-Tichy T, Encke J, Haefeli WE. Prevention of intravenous drug incompatabilities in an intensive care unit. Am J Health Syst Pharm 2008;65:1834-40.

Bertsche T, Hoppe-Tichy T, Haefeli WE. Arzneimittelbezogene Probleme erkennen und lösen - Wechselwirkung  zwischen Digoxin und Clarithromycin. Cosmas 2008;1:22-4.

Bertsche T, Niemann D, Mayer Y, Ingram K, Hoppe-Tichy T, Haefeli WE. Prioritising the prevention of medication handling errors. Pharm World Sci 2008;30:907-15.

Bertsche T, Walk SU, Pruszydlo MG, Kaltschmidt J, Hoppe-Tichy T, Haefeli WE. Arzneimitteltherapie an intersektoralen Schnittstellen - Lösungsstrategien zur Qualitätssicherung. Krankenhauspharmazie 2008;29:163-6.

Burhenne J, Haefeli WE, Hess M, Scope A. Pharmacokinetics, tissue concentratons, and safety of the antifungal voriconazole in chickens. J Avian Med Surg 2008;22:199-207.

Burhenne J, Riedel K-D, Rengelshausen J, Meissner P, Müller O, Mikus G, Haefeli WE, Walter-Sack I. Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry. J Chromatogr B 2008;863:273-82.

Czock D, Keller F, Paar WD, Thalhammer F. Nierenersatztherapie beim kritisch Kranken. Soll man Antibiotika bei kontinuierlicher Hämofiltration anders dosieren? Intensiv- und Notfallbehandlung 2008;33:169-83.

Gut F, Schiek W, Haefeli WE, Walter-Sack I, Burhenne J. Cation exchange resins as pharmaceutical carriers fo rmethylene blue: Binding and release. Eur J Pharm Biopharm 2008;69:582-7.

Haefeli WE. Erwiderung zu: Medizinische Probleme und Risiken bei der rabattvertragsrechtlichen Umstellung von Inhalatoren in Deutschland. Dtsch Med Wochenschr 2008;133:1857-8. (letter)

Haefeli WE, Walter-Sack I. Dosierungseinheiten am Anfang und Ende einer Therapie. Ther Umsch 2008;65:573-5.

Hafner V, Albermann N, Haefeli WE, Ebinger F. Inhibition of voriconazole metabolism by chlorampehnicol in an adolescent with Central Nervous System aspergillosis.Antimibrob Agents Chemother 2008;52:4172-4.

Hafner V, Rutsch C, Ding R, Heinrich T, Diedrichs L, Schmidt-Gayk H, Walter-Sack I, Bommer J, Mikus G. Calcium balance during calcitriol and paracalcitol administration in healthy humans. Int J Clin Pharmacol Ther 2008;46:131-5.

Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss J. Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 2008;64:555-63.

Harenberg J, Weiss C, Mikus G, Jörg I, Vukojevic Y. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 2008;6:890-2.

Heinrich T, Heidt H, Hafner V, Schmidt-Gayk H, Jenetky E, Walter-Sack I, Mikus G, Bommer J. Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. Nephrol Dial Transplant 2008;23:2861-7. 

Hilbel T, Helms TM, Mikus G, Katus HA, Zugck C. Telemetrie - Szenarien im klinischen Umfeld. Herzschr Elektrophys 2008;19:146-54.

Jank S, Bertsche T, Herzog W, Haefeli WE. Patient knowledge on oral anticoagulants: results of a questionnaire survey in Germany and comparison with the literature. Int J Clin Pharmacol Ther 2008;46:280-8.

Kaltschmidt J, Schmitt SPW, Pruszydlo MG, Haefeli WE. Characteristics of effective electronic mail messages distributed to healthcare professionals in a hospital setting.JAMIA 2008;15:235-9.

Meissner PE, Mandi G, Mockenhaupt FP, Witte S, Coulibaly B, Mansmann U, Frey C, Merkle H, Burhenne J, Walter-Sack I, Müller O. Marked differences in the prevalence of chloroquine resistance between urban and rural communities in Burkika Faso. Acta Trop 2008;105:81-6.

Pfeiffer K, Some F, Müller O, Sie A, Kouyaté B, Haefeli WE, Zoungrana A, Gustafsson LL, Tomson G, Sauerborn R. Clinical diagnosis of malaria and the risk of chloroquine self-medication in rural health centres in Burkina Faso. Trop Med Int Health 2008;13:418-26.

Pruszydlo MG, Quinzler R, Kaltschmidt J, Haefeli WE. Medizinische Probleme und Risiken bei der rabattvertragsgerechten Umstellung von Medikationen in Deutschland. Dtsch Med Wochenschr 2008;133:1423-8.

Quinzler R, Bertsche T, Szecsenyi J, Haefeli WE. Teilung von Tabletten: welchen Einfluss haben die Rabattverträge auf die Verordnungsqualität? Med Klin 2008;103:569-74.

Rittner C, Taupitz J, Walter-Sack I, Wessler I. Die neuen Musterbedingungen für die Probandenversicherung als Pflichtversicherung (AVB-Prob/AMG-JV) und für die nicht der Versicherungspflicht unterliegende klinische Prüfung (AVB-Prob/NV-Objekt) - ein Fortschritt für die Versicherten. VersR 2008;4:18-63.

Schneider A, Wensing M, Biessecker K, Quinzler R, Kaufmann-Kolle P, Szecsenyi J. Impact of quality cirlces for improvement of asthma care: results of a randomized controlled trial. J Eva. Clin Pract 2008;14:185-90.

Steiner T, Walter-Sack I, Taupitz J, Hacke W, Strowitzki T. Ethische und juristische Aspekte beim Einschluss nicht einwilligungsfähiger Patienten in Akuttherapie-Studien. Dtsch Med Wschr 2008;133:787-92.

Storch CH, Nikendei C, Schild S, Haefeli WE, Weiss J, Herzog W. Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls. Int J Eat Disord 2008;41:432-8.

Walk SU, Bertsche T, Kaltschmidt J, Pruszydlo MG, Hoppe-Tichy T, Walter-Sack I, Haefeli WE. Rule-based standardised switching of drugs at the interface between primary and tertiary care. Eur J Clin Pharmacol 2008;64:319-27.

Weiss J, Sawa E, Riedel K-D, Haefeli WE, Mikus G. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.Naunyn-Schmiedebergs Arch Pharmacol 2008;378:275-82.

Weiss J, Weis N, Ketabi-Kiyanvash N, Storch CH, Haefeli WE. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 2008;579:104-9.

Zoungrana A, Coulibaly B, Sié A, Walter-Sack I, Mockenhaupt FP, Kouyaté B, Schirmer H, Klose C, Mansmann U, Meissner P, Müller O. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: A randomized controlled trial from Burkina Faso. PLoS ONE 2008;3, Epub e1630, Feb. 20.

Buchbeiträge

Haefeli WE. Arzneimittelverabreichung in der Notfallmedizin. In: Schoenenberger RA, Haefeli WE, Schifferli J, editors. Internistische Notfälle. 8th ed.. Stuttgart New York: Georg Thieme; 2008.

Haefeli WE. Pharmakaverzeichnis. In: Schoenenberger RA, Haefeli WE, Schifferli J, editors. Internistische Notfälle. 8th ed.. Stuttgart New York: Georg Thieme; 2008.

Kaltschmidt J, Haefeli WE. Essenzielle Charakteristika eines Arzneimittel-Informationssystems am Beispiel der Eigentwicklung AiDKlinik des Universitätsklinikums Heidelberg. In: Jäckel A, editor. Telemedizinführer Deutschland, 8th ed.. Bad Nauheim; 2008.

Editorial activities

Schoenenberger RA, Haefeli WE, Schifferli J, editors. Internistische Notfälle. 8th ed. Stuttgart New York: Georg Thieme; 2008.  

2007

 

Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, Nagel D, Uppenkamp M. Renal safety and pharmacokineticsof ibandronate in multiple myeloma patients with our without impaired renal function. J Clin Pharmacol 2007;47:942-50.

Bertsche T, Haemmerlein A, Schulz M. German national drug information service: user satisfaction and potential positive patient outcomes. Pharm World Sci 2007;29:167-72.

Derendorf H, Huebner M, Drewelow B, Fuhr U, Gleiter C, Lemmer B, Mikus G, Roots I, Ziegler A, Ukena D. Ciclesonid - Pharmakokinetische und pharmakodynamische Eigenschaften. Arzneimitteltherapie 2007;25:89-94.

Dietz L, Glaz-Sandberg A, Nguyen H, Skopp G, Mikus G, Aderjan R. The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. Ther Drug Monit 2007;29:368-72.

Ehrhardt M, Moeck M, Haefeli WE, Mikus G, Burhenne J. Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. J Chromatogr B 2007;850:249-258.

Gehrig AK, Mikus G, Haefeli WE, Burhenne J. Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plaslma. Rapid Commun Mass Spectrom 2007;21:2704-16.

Geist MJP, Egerer G, Burhenne J, Riedel K-D, Mikus G. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia - importance of interdisciplinary communication to prevent treatment errors with complex medications.Antimicrob Agents Chemother 2007;51:3455-6.

Glaz-Sandberg A, Dietz L, Nguyen H, Oberwittler H, Aderjan R, Mikus G. Pharmacokinetics of 11-nor-carboxy-delta-9-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clin Pharmacol Ther 2007;82:63-9. 

Haefeli WE. Drug-drug interactions with levodopa modulating treatment responses in Parkinson's disease. J Neurol 2007;254(Suppl 4):IV/29-36.

Haefeli WE. Riskante Teilung. Pharm. Ztg. 2007;152(3):178.

Indermitte J, Erba L, Beutler M, Bruppacher R, Haefeli WE, Hersberger KE. Managment of potential drug interactions in community pharmacies: A questionnaire-based survey in Switzerland. Eur J Clin Pharmacol 2007;63:297-305.

Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson LL, Haefeli WE, Bertilsson L. CYP3A5 genotypes has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 2007;81:708-12.

Kaltschmidt J, Haefeli WE. Mittel zum Zweck. Special IT-Systeme. Krankenhaus - Technik + Management, Okt. 2007, S.38-41.

Ketabi-Kiyanvash N, Herold-Mende C, Kashfi F, Caldeira S, Tommasino M, Haefeli WE, Weiss J. NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics. Cell Tissue Res 2007;238:19-29.

Oberwittler H, Hirschfeld-Warneken A, Wesch R, Willerich H, Teichert L, Lehr K-H, Ding R, Haefeli WE, Mikus G. Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol 2007;47:70-7.

Quinzler R, Schmitt SPW, Szecsenyi J, Haefeli WE. Optimizing informatíon on drug exposure by collection of package code information in questionnaire surveys.Pharmacoepidemiol Drug Saf 2007;16:1024-30.

Quinzler R, Szecsenyi J, Haefeli WE. Tablet splitting: patients and physicians need better support. (letter) Eur J Clin Pharmacol 2007;63:1203-4.

Rengelshausen J, Goeggelmann C, Burhenne J, Riedel K-D, Mikus G, Walter-Sack I, Haefeli WE.  Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. Int J Clin Pharmacol Ther 2007;45:431-7. 

Roeder C, Heinrich T, Gehrig A-K, Mikus G. Misleading results of illicit drugs during efavirenz treatment. AIDS 2007;21:1390-1.

Schneider A, Wensing M, Quinzler R, Bieber Ch, Szecsenyi J. Higher preference for participation in treatment decisions is associated with lower medication adherence in asthma patients. Patient Educ Couns 2007;67:57-62.

Schneider A, Biessecker K, Quinzler R, Kaufmann-Kolle P, Meyer FJ, Wensing M, Szecsenyi J. Asthma patients with low perceived burden of illness: a challange for guideline adherence. J Eval Clin Pract 2007;13:846-52.

Seidling HM, Al Barmawi A, Kaltschmidt J, Bertsche T, Pruszydlo MG, Haefeli WE. Detection and prevention of prescriptions with excessive doses in elektronic prescribing systems. Eur J Clin Pharmacol 2007;63:1185-92.

Stiefel M, Reiss T, Staege M, Rengelshausen J, Burhenne W, Wawer A, Foell JL. Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. Pediatr Blood Cancer 2007;49:203-7.

Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007;73:1573-81.

Storch CH, Klimm H-D, Heinrich T, Haefeli WE, Weiss J. Plasma LDL cholesterol has no impact in p-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn-Schmiedeberg's Arch Pharmacol 2007;376:135-43.

Storch CH, Ehehalt R, Haefeli WE, Weiss J. Localisation of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 2007;323:257-64.

Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007;51:239-44.

Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007;59:238-45. 

Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 200735:340-4.

Book chapters

Haefeli WE, Klotz U. Interindividuelle Variabilität der Arzneimittelwirkung. In: Estler CJ, Schmidt H, editors. Pharmakologie und Toxikologie. 6th ed. Stuttgart New York: Schattauer; 2007; p.1049-54.

Haefeli WE. Therapie-Monitoring, Probleme der Compliance (Adherence) and Noncompliance. In: Lemmer B, Brune K, editors. Pharmakotherapie. Klinische Pharmakologie. 13th ed. Heidelberg: Springer Medizin Verlag; 2007; p.25-33.

Walter-Sack I, Bertsche T. Immunsuppressive Arzneimittel - mögliche Wechselwirkungen. In: Beimler J, Schmidt J, Büchler M, Zeier M, Herausgeber. Heidelberger Manual der Nieren- und Pankreastransplantation, 2. Aufl. Universitätsklinikum Heidelberg, Abteilung für Allgemeine, Viszerale- und Transplantationschirurgie, Nierenzentrum Heidelberg, Sektion Nephrologie, Medizinische Universitätsklinik Heidelberg; 2007; p.134-67.

2006

 

Bergner R, Hoffmann M, Riedel KD, Mikus G, Heinrich DM, Haefeli WE, Uppenkamp M, Walter-Sack I. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg independent of filtration rate. Nephrol Dial Transplant 2006;21:1019-23.

Bertsche T, Bardenheuer HJ. Arzneimittelanwendung in der Therapie chronischer Schmerzen. Ther Umsch 2006;63:391-7.

Bertsche T, Ghaderi H, Bardenheuer HJ, Haefeli WE. Schmerzpflaster - Reden vor dem Kleben. Pharm Ztg 2006;151:1878-84.

Bertsche T, Haas M, Oberwittler H, Haefeli WE, Walter-Sack I. Arzneimittel in Schwangerschaft und Stillzeit: Neue Risikofaktoren - dargestellt am Beispiel von Antibiotika. Dtsch Med Wochenschr 2006;131:1016-22.

Bertsche T, Haefeli WE. Maßgeschneiderte Arzneimitteltherapie bei Niereninsuffizienz. CHAZ 2006;7:77-82.

Bertsche T, Haefeli WE. Maßgeschneiderte Arzneimitteltherapie bei Interaktionen. CHAZ 2006;7:281-6.

Bertsche T, Haefeli WE. Klinische Pharmazie: Individualisierte Arzneimitteltherapie bei Patienten mit Niereninsuffizienz. Pharm Ztg 2006;151:717-23.

Bertsche T, Kaltschmidt J, Haefeli WE. Elektronische Arzneimittelinformationsmedien - Chancen (v)erkannt? Dtsch Arztebl 2006;103:A1438-42.

Busse D, Templin S, Mikus G, Schwab M, Hofmann U, Eichelbaum M, Kivistö KT. Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. Eur J Clin Pharmacol 2006;62:613-9.

Elter T, Sieniawski M, Gossmann A, Wickenhauser C, Schroder U, Seifert H, Kuchta J, Burhenne J, Riedel KD, Fatkenheuer G, Cornely OA. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents 2006;28:262-5.

Geist M, Egerer G, Burhenne J, Mikus G. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother 2006;50:3227-8.

Haefeli WE. Verabreichungsfehler - welche Informationen braucht ein Patient um seine Arzneimittel-Therapie sicher durchzuführen? Ther Umsch 2006;63:363-5.

Haefeli WE. Individualisierung der Evidenz: Single Case Randomized Trial. Therap Umschau 2006;63:777-81.

Hartge F, Wetter T. Haefeli WE. A similarity measure for case based reasoning modeling with temporal abstraction based on cross-correlation. Comput Meth Prog Bio 2006;81:41-8.

Hesse C, Luntz SP, Siedler H, Unnebrink K, Mikus G, de Bruijn M, Zondag E, de Vries M, Seibert-Grafe M, Haefeli WE. Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. Br J Clin Pharmacol 2006;61:414-9.

Kees F, Bucher M, Schweda F, Gschaidmeier H, Burhenne J, Mikus J. Comparative bioavailability of the microemulsion formulation of cyclosporine (neoral) with a generic dispersion formulation (cicloral) in young healthy volunteers. Ther Drug Monit 2006;28:312-20.

Knaup P, Pilz J, Kaltschmidt J, Ludt S, Szecsenyi J, Haefeli WE. Standardized documentaion of drug recommendations in discharge letters: A contribution to quality management in cooperative care. Methods Inf Med 2006;45:336-42.

Mach von MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006;6:6.

Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer HR, Kouyate B, Mueller O. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malaria J 2006;5:84.

Mikus G, Schöwel V, Drzewinska M. Rengelshausen J, Ding R, Riedel K-D, Burhenne J, Weiss J, Thomsen T, Haefeli WE: Potent CYP2C19 genotype related interaction between voriconazole and the CYP3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-35.

Möller M, Weiss J, Wink M. Reduction of cytotoxicity of the alkaloid emetine through P-glycoprotein (MDR1/ABCB1) in human Caco-2 cells and leukemia cell lines. Planta Med 2006;12:1121-6.

Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006;60:707-15.

Peters T, Lindenmaier H, Haefeli WE, Weiss J. Interaction of th mitotic kinesin Eg5 inhibitor monastrol with p-glycoprotein. Naunyn-Schmiederberg's Arch Pharmacol 2006;372:291-9.

Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 2006;62:1065-73.

Quinzler R, Haefeli WE. Tabletten teilen. Ther Umsch2006;63:441-7.

Rengelshausen J, Beedgen B, Tsamouranis K, Mikus G, Walter-Sack I, Haefeli WE, Linderkamp O. Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age. Eur J Clin Pharmacol 2006;62:773-7.

Weiss J, Haefeli WE. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2-values. Drug Metab Dispos 2006;34:203-7.

2005

 

Akoachere M, Buchholz K, Fischer E, Burhenne J, Haefeli WE, Schirmer H, Becker K. In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother 2005;49:4592-7.

Albermann N, Schmitz-Winnenthal FH, Z'graggen K. Volk C, Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005;70:949-58.

Berger MM, Hesse C, Dehnert C, Siedler H, Kleinbongard P, Bardenheuer HJ, Kelm M, Bärtsch P, Haefeli WE. Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. Am J Respir Crit Care Med 2005;172:763-7.

Bergk V, Gasse C, Schnell R, Haefeli WE. Mail surveys - Obsolescent model or valuable instrument in general practice research? Swiss Med Wkly 2005;135:189-91.

Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence deom the literature. Eur J Clin Pharmacol 2005;61:327-35.

Bertsche T, Haefeli WE. Klinisch-pharmazeutische Kurzbewertung: Schlafmedikation auf den Patienten abstimmen. Pharm Ztg 2005;150:1700-4.

Bertsche T, Haefeli WE. Klinisch-pharmazeutische Kurzbewertung: Mögliche Interaktionen identifizieren. Pharm Ztg 2005;150:3552-5.

Bertsche T, Fritz R, Sauer P. Encke J. Haefeli WE, Walter-Sack I. Off-Label-Use in der Langzeitantikoagulation nach Lebertransplantation wegen phenprocoumoninduzierten Leberversagens. Med Klin 2005;100:820-4.

Borwitzky H, Haefeli WE, Burhenne J. Analysis of methylene blue in human urine by capillary electrophoresis. J Chromatogr B 2005;826:244-51.

Eckhardt M, Bertsche T, Schulz M, Jaehde U. Seamless Care in der Pharmazie. 1. Entwicklung und internationaler Vergleich. Med Monatsschr Pharm 2005;28:150-7.

Eckhardt M, Reinecke MF, Bertsche T, Schulz M, Jaehde U. Seamless Care in der Pharmazie. 2. Befragung von Apothekern und Patienten in Deutschland. Med Monatsschr Pharm 2005;28:315-20.

Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005;94-537-43.

Groebner W, Walter-Sack I. Therapie der Hyperurikämie und Gicht. Med Monatsschr Pharm 2005;28:159-64.

Hesse C, Siedler H, Burhenne J, Riedel K-D, Haefeli WE. Fluvoxamine affects sildenafil kinetics and dynamics. J Clin Psychopharmacol 2005;25:589-92.

Hesse C, Siedler H, Luntz SP, Arendt BM, Goerlich R, Fricker R, Heer M, Haefeli WE. Modulation of endothelial and smooth muscle function by bed rest and hypoenergetic, low-fat nutrition. J Appl Physiol 2005;99-2196-203.

Lindenmaier H, Becker M, Haefeli WE, Weiss J. Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos 2005;33:1576-9.

Mandi G, Witte S, Meissner P, Boubacar C, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Wuest K, Walter-Sack I, Mikus G, Burhenne J, Riedel K-D, Schirmer H, Kouyate B, Mueller O. Safetey of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health 2005;10:32-8.

Martin-Facklam M, Rengelshausen J, Tayrouz Y, Ketabi-Kiyanvash N, Lindenmaier H, Schneider V, Bergk V, Haefeli WE. Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol 2005;60:807-11.

Meissner P, Mandi G, Witte S, Coulibaly B, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Tapsoba T, Walter-Sack I, Mikus G, Burhenne J, Riedel K-D, Schirmer H, Kouyaté B, Mueller O. Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso. Malar J 2005;4:45.

Mikus G, Weiss J. Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. Current Pharmacogenomics 2005;3:43-52.

Nikendei C, Zipfel S, Kraus B, Friedrich HC, Faber R, Löwe B, Müller-Tasch T, Schwab M, Mikus G, Bobbert M, Herzog W, Jünger J. Integrierte Psychosomatik: Implementierung und Evaluation eines Unterrichtsmoduls für StudentInnen der Inneren Medizin. GMS Z Med Ausbildung 2005; 22:Doc 213.

Parlar H, Burhenne J, Coelhan M, Vetter W. Structure of the toxaphene compound 2,5-endo, 6-exo, 8, 9, 9, 10, 10-octachlorobornene-2: A temperature-dependent formation of two rotamers. Environ Sci Technol 2005;39:1736-40.

Rengelshausen J, Banfield M, Riedel K-D, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005;78:25-33.

Streit M, Goeggelmann C, Dehnert C, Burhenne J, Riedel K-D, Menold E, Mikus G, Bärtsch P, Haefeli WE. Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4500 meters). Eur J Clin Pharmacol 2005;61:39-46.

Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. FORST (kava-kava) inhibit p-glycoprotein in vitro. Drug Metab Dispos 2005;33:1580-3.

2004

 

Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole induced QT interval prolongation and ventricular tachycardia. A non-concentration dependent adverse effect. Clin Infect Dis 2004;39:e50-2.

Bähring S, Rauch A, Toka O, Schroeder Ch, Hesse Ch, Siedler H, Fesüs G, Haefeli WE, Busjahn A, Aydin A, Neuenfeld Y, Mühl A, Toka HR, Gollasch M, Jordan J, Luft FC. Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12. Hypertension 2004;43[part2]:671-6.

Bergk V, Gasse C, Schnell R, Haefeli WE. Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 2004;60:595-602.

Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: Impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004;76:85-96.

Ding R, Tayrouz Y, Riedel K-D, Burhenne J, Weiss J, Mikus G, Haefeli WE. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004;76:73-84.

Döring A, Fröhlich M, Löwel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004;172:281-6.

Ehrhardt M, Lindenmaier H, Burhenne J, Haefeli WE, Weiss J. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol 2004;67:285-92.

Fricker R, Hesse C, Weiss J, Tayrouz Y, Hoffmann MM, Unnebrink K, Mansmann U, Haefeli WE. Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation. Br J Clin Pharmacol 2004;58:169-77.

Friederich HC, Michaelsen J, Hesse C, Schellberg D, Schwab M. Herzog W. Treatment of recurrent cardioinhibitory neurocardiogenic syncope with Ipratropiumbromide. Z Kardiol 2004;93:479-85.

Fröhlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, Weiss J. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 2004;68:2409-16.

Fröhlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, Haefeli WE. Assocation of CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. (letter) Br J Clin Pharmacol 2004;58:443-4.

Fröhlich M, Burhenne J, Martin-Facklam M, Weiss J, von Wolff M, Strowitzki T, Walter-Sack I, Haefeli WE. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004;57:244-52.

Hauser ER, Crossman DC, Granger CG, Haines JL, Johnes CJ, Mooser V, McAdam B, Winkelmann BR, Wiseman AH, Muhlestein JB, Bartel AG, Dennis CA, Dowdy E, Estabrooks S, Eggleston K, Francis S, Roche K, Clevenger PW, Huang L, Pedersen B, Shah S, Schmidt S, Haynes C, West S, Asper D, Booze M, Sharma S, Sundseth S, Middleton K, Roses AD, Hauser MA, Vance JM, MA Pericak-Vance, Kraus WE. A genomewide scan for early-onset coronary artery disease in 438 families: The GENECARD study. Am J Hum Genet 2004;75:436-47.

März W, Boehm BO, Winkelmann BR, Hoffmann MM. The P1A1/A2 polymorphism of platelet glycoprotein IIIa is not associated with the risk of type 2 diabetes. The Ludwigshafen risk and cardiovascular health study. Diabetologia 2004;47:1969-73.

März W, Nauck M, Hoffmann MM, Nagel D, Boehm BO, Koenig W, Rothenbacher D, Winkelmann BR. G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease adn type 2 diabetes mellitus. Circulation 2004;109:2844-9.

März W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J 2004;25:2109-19.

März W, Scharnagl H, Winkler K, Tiran A, Nauck M, Boehm BO, Winkelmann BR. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen risk and cardiovascular study. Circulation 2004;9:3068-74.

Martin P, Haefeli WE, Martin-Facklam M. A drug database model as a central element for computer-supported dose adjustment within a CPOE system. JAMIA 2004;11:427-32.

Martin-Facklam M, Rieger K, Riedel K-D, Burhenne J, Walter-Sack I, Haefeli WE. Undeclared exposure to St. John's Wort in hospitalized patient. Br J Clin Pharmacol 2004;58:437-41.

Martin-Facklam M, Kostrzewa M, Martin P, Haefeli WE. Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality. An intervention study on pages about sildenafil. Br J Clin Pharmacol 2004;57:80-5.

Mikus G, Schmidt L, Burhenne J, Ding R, Riedel K-D, Tayrouz Y, Weiss J, Haefeli WE. Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet 2004;43:1015-24.

Rengelshausen J, Burhenne J, Fröhlich M, Tayrouz Y, Singh SK, Riedel K-D, Müller O, Hoppe-Tichy T, Haefeli WE, Mikus G, Walter-Sack I. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol 2004;60:709-15.

Rengelshausen J, Lindenmaier H, Cihlar T, Walter-Sack I, Haefeli WE, Weiss J. Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine. Biochem Biophys Res Commun 2004;320:90-4.

Renner W, Grammer T, Hoffmann MM, Nauck MS, Winkelmann BR, Boehm BO, März W. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 2004;22:2398-400.

Riedel K-D, Rieger K, Martin-Facklman M, Mikus G, Haefeli WE, Burhenne J. Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatography-tandem mass spectrometry. J Chromatogr B 2004;813:27-33.

Rieger K, Scholer A, Arnet I, Peters FT, Maurer HH, Walter-Sack I, Haefeli WE, Martin-Facklam M. High prevalence of unknown co-medication in hospitalised patients. Eur J Clin Pharmacol 2004;60:363-8.

Romerio SC, Linder L, Nyfeler J, Wenk M, Litynski P, Asmis R, Haefeli WE. Acute hyperhomocysteinemia decreases NO bioavailability in healthy adults. Atherosclerosis 2004;176:337-44.

Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz JR, Kappenberger L, März W, Vassalli G. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J 2004;25:1438-46.

Simeoni E, Hoffmann MM, Winkelmann BR, Ruiz J, Fleury S, Boehm BO, März W, Vassalli G. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and type 2 diabetes mellitus. Diabetology 2004;47:1574-80.

Troost J, Lindenmaier H, Haefeli WE, Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol 2004;66:132-9.

Troost J, Albermann N, Haefeli WE, Weiss J. Cholersterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. Biochem Biophys Res Comm 2004;316:705-11.

Vassalli G, Winkelmann BR. Molecular genetics of myocardial infarction: many genes, more questions than answers. Eur Heart J. 2004;25:451-3.

Walter-Sack I, Clanget Ch, Ding R, Göggelmann Ch, Hinke V, Lang M, Pfeilschifter J, Tayrouz Y, Wegscheider K. Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures. Clin Pharmacokinet 2004;43:1037-53.

Weiss J, Haefeli WE. Genotyping of the A6986G polymorphism of CYP3A5. (letter) Br J Clin Pharmacol 2004;57:663-4.

Winkelmann BR. American heart association scientific sessions. Expert Opin Investig Drugs. 2004;13:435-45.

2003

 

Bugert P, Hoffmann MM, Winkelmann BR, Vosberg M, Jahn J, Entelmann M et al. The variable number of tandem repeat polymorphism in the P-selectin glycoprotein ligand-1 gene is not associated with coronary heart disease. J Mol Med 2003;81:495-501.

Burhenne J, Riedel K-D, Martin-Facklam M, Mikus G, Haefeli WE. Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry. J Chromatography B 2003;784:233-42.

Fröhlich M, Mühlberger N, Hanke H, Imhof A, Döring A, Pepys MB, Koenig W. Markers of inflammation in women on different hormone replacement therapies. Ann Med 2003;35:353-61.

Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003;24:1365-72.

Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine, and paramethoxyamphetamine. Addict Biol 2003;8:413-8.

Rengelshausen J, Göggelmann C, Burhenne J, Riedel KD, Ludwig J, Weiss J, Mikus G, Walter-Sack I, Haefeli WE. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003;56:32-8.

Schneider V, Henschel V, Tadjalli Mehr K, Mansmann U, Haefeli WE. Impact of serum creatinine measurement error on dose adjustment in renal failure. Clin Pharmacol Ther 2003;74:458-67.

Tayrouz Y, Ding R, Burhenne J, Riedel K-D, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. Pharmacokinetic and pharmaceutic interaction between digoxin and cremophor RH40. Clin Pharmacol Ther 2003;73:397-405.

Vrtic F, Haefeli WE, Drewe J, Krähenbühl S, Wenk M. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. Br J Clin Pharmacol 2003;55:191-8. 

Walter-Sack I, Rittner Ch. Probandenversicherung nach dem Gefährdungsprinzip auch bei Forschungsvorhaben am Menschen ohne bisherige Versicherungspflicht - Vorschläge für eine Risikobewertung. VersR 2003;10:432-5.

Weiss J, Albermann N. Quantification of mRNA levels with reverse transcription-polymerase chain reaction (letter). Biochem Biophys Res Commun 2003;311:561-2.

Weiss J, Kerpen CJ, Lindenmaier H, Dormann S-MG, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 2003;307:262-7.

Weiss J, Haefeli WE, Gasse C, Hoffmann MM, Weymann J, Gibbs S, Mansmann U, Bärtsch P. Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway. High Alt Med Biol 2003;4:355-66.

Weiss J, Hesse C, Haefeli WE. Rapid and reliable genotyping of the C181T polymorphism in the bradykinin B2 receptor gene. Clin Chem Lab Med 2003;41:281-3.

Weiss J, Dormann S-MG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197-204.

Winkelmann BR. Pharmacogenomics, genetic testing and ethnic variablity: tackling the ethical questions. Pharmacogenomics 2003;4:531-5.

Winkelmann BR, Hoffmann MM, Nauck M, Kumar AM, Nandabalan K, Judson Boehm BO, Tall AR, Ruano G, Marz W. Hyplotypes of the cholesteryl ester transfer protein gene predict lipd-modifying response to statin therapy. Pharmacogenomics J 2003;3:284-96.

Book chapters

Haefeli WE. Arzneimittelverabreichung in der Notfallmedizin. In: Gyr NE, Schoenenberger RA, Haefeli WE, editors. Internistische Notfälle. 7th ed. Stuttgart New York: Georg Thieme Verlag; 2003.

Editorial activities

Gyr NE, Schoenenberger RA, Haefeli WE, editors. Internistische Notfälle. 7th ed. Stuttgart New York: Georg Thieme Verlag; 2003.

2002

 

Ammon S, Marx C, Behrens C, Hofmann U, Mürdter T, Griese EU, Mikus G. Diclofenac does not interact with codeine metabolism in vivo: A study in healthy volunteers. BMC Clinical Pharmacology 2002;2:2.

Gröbner W, Walter-Sack I. Hyperurikämie und Gicht - Diagnostik / Der konkrete Fall / Therapie. Dtsch Med Wochenschr 2002;127:207-13.

März W, Winkelmann BR. Akutes Koronarsyndrom - früher Einsatz von Statinen. Cardiovas 2002;1:68-9.

März W, Winkelmann BR. HMG-CoA reductase inhibition in the treatment of atherosclerosis: effects beyond lipid lowering. J Kardiol 2002;9:284-94.

Mansmann U, Winkelmann BR. Classification and prediction in pharmacogenetics - context, construction and validation. Pharmacogenomics 2002;3:157-60.

Martin-Facklam M, Burhenne J, Ding R, Fricker R, Mikus G, Walter-Sack I, Haefeli WE. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophore EL. Br J Clin Pharmacol 2002;53:576-81.

Martin-Facklam M, Kostrzewa M, Schubert F, Gasse C, Haefeli WE. Quality markers of drug information on the internet. An evaluation of sites on St. John's Wort. Am J Med 2002;113:740-5.

Meineke I, Freudenthaler S, Hofmann U, Schaeffeler E, Mikus G, Schwab M, Prange HW, Gleiter Ch, Brockmöller J. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002;54:592-603.

Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med 2002;80:507-13.

Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen risk and cardiovascular health (LURIC) study. Am J Cardiol 2002;90:1249-52.

Oettel M, Hübler D, Winkelmann BR. Über das therapeutische Potential von Estrogenen beim Mann. J Menopause 2002;2:39-51.

Ranjith N. Verho NK, Verhoe M, Winkelmann BR. Acute myocardial infarction in a young South African Indian-based population. patient characteristics on admission and gender-specific risk factor prevalance. Curr Med Res Opin 2002;18:242-8.

Rengelshausen J, Hull WE, Schwenger V, Göggelmann Ch, Walter-Sack I, Bommer J. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis 2002;39:E10.

Schwenger V, Mündlein E, Dagrosa EE, Fahr AM, Zeier M, Mikus G, Andrassy K. Treatment of life-threatening multiresistant staphyloccocal and enterococcal infections in patients with end-stage renal failure with Quinupristin/Dalfopristin: prelimiary report. Infection 2002;30:257-61.

Walter-Sack I. Unsicherheiten bei pädiatrischen Studien und Konflikte des Prüfarztes. DZKF 2002;3/4:6.

Walter-Sack I, Haefeli WE. Rahmenbedingungen ärztlicher Forschung beim Menschen - Algorithmen zu Planung und Organisation. Dtsch Med Wochenschr 2002;127:627-33.

Weiss J, Burhenne J, Riedel KD, Haefeli WE. Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. AIDS 2002;16:674-6.

Weiss J, Fricker R, Haefeli WE. Rapid detection of polymorphisms of the nitric oxide cascade. Clin Chem Lab Med 2002;40:341-4.

Winkelmann BR, Hoffmann MM, Lindenmaier H. Molekularbiologische Terminologie. Medizin im Dialog 2002;2:26-31.

2001

Falconnier AD, Haefeli WE, Schoenenberger RA, Surber Ch, Martin-Facklam M. Drug Dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med 2001;16:369-375.

Ganßmann B, Klingmann A, Burhenne J, Tayrouz Y, Aderjan R, Mikus G. Simultaneous determination of loperamide and its demethylated metabolites in plasma and urine by high pressure liquid chromatography - atmospheric-pressure ionization mass spectrometry. Chromatographia 2001;53:656-60.

Gasse C, Hense H-W, Stieber J, Döring A, Liese AD, Keil U. Assessing hypertension management in the community: trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertension 2001;15:27-36.

Khanlari B, Linder L, Haefeli WE. Local effect of transdermal isosorbide dinitrate (SDN) ointment on hand vein diameter. Eur J Clin Pharmacol 2001;57:701-4.

Loehrer FMT, Tschöpl M, Angst CP, Litynski P, Jäger K, Fowler B, Haefeli WE. Disturbed ratio of erythrocyte and plasma S-adenosylmethionine / S-adenosylhomocysteine in peripheral arterial occlusive disease. Atherosclerosis 2001;154:147-54.

Mikus G, Kees F. Die Substanz Buprenorphin aus pharmakologischer Sicht. Onkologie Service aktuell 2001;3:8-9.

Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med 2001;161:2021-6.

Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli WE, Mikus G. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 2001;70:405-14. Walter-Sack I, Haefeli WE. Arzneimittelsicherheit auch für Kinder. Deutsches Ärzteblatt 2001;98:A447-9.

Webb JA, Rostami-Hodjegan A, Abdul-Manap R, Hofmann U, Mikus G, Kamali F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br J Clin Pharmacol 2001;52:35-44.

Winkelmann BR, Boehm BO, Nauck M, Kleist P, März W, Verho NK, Ranjith N, Kneissl G. Cigarette smoking is independently associated with markers of endothelial dysfunction and hyperinsulinaemia in non-diabetic individuals with coronary artery disease. Curr Med Res Opin 2001;17:132-141.

2000

 

Ammon S, Richter von O, Hofmann U, Thon K-P, Eichelbaum M, Mikus G. In vitro interaction of codeine and diclofenac. Drug Metab Disp 2000;28:1149-52.

Arnet I, Haefeli WE. Merkmale der offensichtlichen Non-Complier im Spital. Managed Care 2000;6:26–28.

Arnet I, Haefeli WE. Overconsumption detected by electronic drug monitoring requires subtle interpretation. Clin Pharmacol Ther 2000;67:44-7.

Drewe J, Ball HA, Beglinger C, Peng B, Kemmler A, Schächinger H, Haefeli WE. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Brit J Clin Pharmacol 2000;50:237-46.

Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 2000;20(6):629-34.

Gross AS, Eichelbaum M, Mörike K, Mikus G. Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. Br J Clin Pharmacol 2000;49:132-8.

Haefeli WE. Individualisierte Arzneimitteltherapie - es gibt etwas zu verbessern. Therapeutische Umschau 2000;57:545-6.

Hotz MA, Ritz R, Linder L, Scollo-Lavizzari G, Haefeli WE. Auditory and electroencephalographic effects of midazolam and ·-hydroxy-midazolam in healthy subjects. Br J Clin Pharmacol 2000;49:72-9.

Li S, Schänzle G, Hofmann U, Mikus G: Determination of morphine-3-glucuronide and morphine-6-glucuronide in human serum and urine using high-performance liquid chromatography with ultraviolet and eletrochemical detection. Analytical Pharmacology 2000;1:65-70.

Martin-Facklam M, Drewe J, Haefeli WE. Arzneimittel-Interaktion am Cytochrom-P450-System. Deutsch Med Wschr 2000;125:63-7.

Martin-Facklam M, Haefeli WE. Unerwünschte, klinisch relevante Arzneimittelinteraktionen. Therapeutische Umschau 2000;57:579-83.

Martin-Facklam M. Individualisierung der Arzneimitteltherapie bei Nieren- und Leberinsuffizienz. Therapeutische Umschau 2000;57:568-72.

Mikus G. Klinische Relevanz von Polymorphismen des Arzneimittelstoffwechsels. Therapeutische Umschau 2000;57:573-8.

Müller-Schweinitzer E, Brett W, Zerkowski H-R, Haefeli WE. The mechanism of cryoinjury: In vitro studies on human internal mammary arteries. Br J Pharmacol 2000;130:636-40.

Rittner Ch, Kratz EJ, Walter-Sack I. Zur Angemessenheit des Probandenschutzes nach § 40 Abs. 1 Nr. 8 AMG. - Bericht der Arbeitsgruppe "Probandenversicherung" des Arbeitskreises Medizinischer Ethikkommissionen. VersR 2000;16:688-94.

Romerio SC, Linder L, Flammer J, Haefeli WE. Correlation between apoliprotein B and endothelin-1-induced vasoconstriction in humans. Peptides 2000;21:871-4.

Salbach PB, Brückmann M, Turovets O, Kreuzer J, Kübler W & Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Brit J Clin Pharmacol 2000;50:221-6.

Schwaninger M, Ringleb P, Annecke A, Winter R, Kohl B, Werle E, Fiehn W, Rieser PA, Walter-Sack I. Elevated plasma concentrations of lipoprotein (a) in medicated epileptic patients. J Neurol 2000;247:687-90.

Schwarz S, Knauth Michael, Schwab S, Walter-Sack I, Bonmann E, Storch-Hargenlocher B. Acute disseminated encephalomyelitis after parenteral therapy with herbal extracts: a report of two cases. J Neurol Neurosurg Psychiatry 2000;69:516-8.

Walter-Sack I, Haefeli WE. Berücksichtigung der Arzneimittelabsorption in der Individualisierung der Arzneimitteltherapie. Therapeutische Umschau 2000;57:557-62.

Walter-Sack I, Haefeli WE. Qualitätssicherung der pädiatrischen Arzneimittel–Therapie durch klinische Studien - ethische und rechtliche Rahmenbedingungen unter Berücksichtigung der spezifischen Bedürfnisse von Kindern. MedR 2000;10:454-3.